var title_f34_27_35248="Sulfacetamide: Pediatric drug information";
var content_f34_27_35248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfacetamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/13/18643?source=see_link\">",
"       Sulfacetamide (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/16/38147?source=see_link\">",
"       Sulfacetamide (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12813 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35248=[""].join("\n");
var outline_f34_27_35248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/13/18643?source=related_link\">",
"      Sulfacetamide (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/16/38147?source=related_link\">",
"      Sulfacetamide (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35249="AP forearm technique";
var content_f34_27_35249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anteroposterior (AP) forearm radiograph technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Technique for neutral rotation AP radiograph with wrist neutral, forearm pronated, elbow flexed 90 degrees, and shoulder abducted 90 degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35249=[""].join("\n");
var outline_f34_27_35249=null;
var title_f34_27_35250="Patient information: Food allergy (The Basics)";
var content_f34_27_35250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15337\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/41/7824\">",
"         Hives",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/24/42370\">",
"         Patient information: Allergy skin testing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/35/17971\">",
"         Patient information: Peanut allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/57/15250\">",
"         Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/14/41186\">",
"         Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/47/29429\">",
"         Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/35/35379\">",
"         Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Food allergy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/food-allergy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H212701358\">",
"      <span class=\"h1\">",
"       What is a food allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A food allergy is when a person&rsquo;s immune system responds as if a certain food is harmful to the body. If a person eats, touches, or breathes in that food, he or she can have an allergic reaction. Most allergic reactions happen within 5 minutes to 1 hour after eating or touching the food.",
"     </p>",
"     <p>",
"      The most common foods that people are allergic to are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Milk and foods that contain milk, such as ice cream or butter (called dairy foods)",
"       </li>",
"       <li>",
"        Eggs",
"       </li>",
"       <li>",
"        Wheat",
"       </li>",
"       <li>",
"        Soy",
"       </li>",
"       <li>",
"        Peanuts",
"       </li>",
"       <li>",
"        Tree nuts, such as almonds or cashews",
"       </li>",
"       <li>",
"        Fish",
"       </li>",
"       <li>",
"        Shellfish, such as shrimp or oysters",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People can have an allergy to one or more foods. Sometimes it is hard to tell if you really have a food allergy or not. People can feel sick after eating some foods for other reasons. For example, people can get heartburn after eating spicy foods. But that is not the same as a food allergy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212701365\">",
"      <span class=\"h1\">",
"       What are the symptoms of a food allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of a food allergy can range from mild to severe. Mild symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hives &ndash; raised, red patches of skin that are very itchy (",
"        <a class=\"graphic graphic_picture graphicRef79242 \" href=\"mobipreview.htm?7/41/7824\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Red or swollen skin",
"       </li>",
"       <li>",
"        Itchy, watery, or swollen eyes",
"       </li>",
"       <li>",
"        Runny nose or sneezing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Severe symptoms are also called &ldquo;anaphylaxis.&rdquo; They can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling of the throat, or coughing a lot",
"       </li>",
"       <li>",
"        Wheezing or trouble breathing",
"       </li>",
"       <li>",
"        Throwing up or having diarrhea",
"       </li>",
"       <li>",
"        Feeling dizzy or passing out",
"       </li>",
"       <li>",
"        Death",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms can differ from person to person. Also, a person can have different symptoms each time he or she has an allergic reaction.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212701372\">",
"      <span class=\"h1\">",
"       Is there a test for food allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can use two types of tests to tell if you have a food allergy. You and your doctor will decide which is best for you.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Skin test",
"        </strong>",
"        &ndash; For a skin test, the doctor will put a drop of the food you might be allergic to on your skin and make a tiny prick in the skin. Then, he or she will watch your skin to see if you get a red, itchy bump, like a mosquito bite.",
"       </li>",
"       <li>",
"        <strong>",
"         Blood test",
"        </strong>",
"        &ndash; Blood tests for food allergies look for antibodies (proteins) called &ldquo;IgEs&rdquo; that the body makes when it is having an allergic response.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse will also do an exam and talk with you. Sometimes it can be hard to figure out what food you are allergic to. Keeping a record of the foods you eat and the symptoms you have is helpful.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212701379\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have severe allergic symptoms,",
"      <strong>",
"       call 9-1-1 for an ambulance",
"      </strong>",
"      . Do not try to get yourself to the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212701386\">",
"      <span class=\"h1\">",
"       How is a food allergy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The best treatment for a severe reaction is a medicine called &ldquo;epinephrine.&rdquo; At the hospital, doctors can give you epinephrine and other medicines to treat your symptoms. Doctors will also watch to make sure your symptoms don&rsquo;t get worse.",
"     </p>",
"     <p>",
"      If you have had severe reactions to foods before, your doctor might have prescribed a device called an &ldquo;auto-injector.&rdquo; This device has one or two shots of epinephrine that you can give yourself. Many people get an auto-injector called an &ldquo;EpiPen.&rdquo; You should keep your auto-injector with you at all times. Use it right away if you think you are having a severe allergic reaction.",
"     </p>",
"     <p>",
"      If you have mild food allergy symptoms, your doctor may prescribe medicine to help stop your itching and hives.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212701393\">",
"      <span class=\"h1\">",
"       Can allergic reactions be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can prevent an allergic reaction by not eating the food you are allergic to. Even a tiny bite of food can cause a big reaction. You and your doctor can make a food allergy plan that includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Knowing how to avoid the food you are allergic to by reading food labels",
"       </li>",
"       <li>",
"        Telling restaurants about your food allergy if you eat out",
"       </li>",
"       <li>",
"        Knowing when to get help for a reaction",
"       </li>",
"       <li>",
"        Having an epinephrine auto-injector with you at all times",
"       </li>",
"       <li>",
"        Wearing a medical bracelet to let others know about your allergy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212701400\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with a food allergy are able to live normal lives. But you may need to make some changes in your life. You will need to follow your food allergy plan.",
"     </p>",
"     <p>",
"      You can have food allergies for your whole life. But people sometimes outgrow them. Talk with your doctor about how to tell if you have outgrown a food allergy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212701407\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42370?source=see_link\">",
"       Patient information: Allergy skin testing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/35/17971?source=see_link\">",
"       Patient information: Peanut allergy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"       Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=see_link\">",
"       Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=see_link\">",
"       Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/27/35250?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15337 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35250=[""].join("\n");
var outline_f34_27_35250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701358\">",
"      What is a food allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701365\">",
"      What are the symptoms of a food allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701372\">",
"      Is there a test for food allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701379\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701386\">",
"      How is a food allergy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701393\">",
"      Can allergic reactions be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701400\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212701407\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/41/7824\">",
"      Hives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42370?source=related_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/35/17971?source=related_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35251="Anterior anatomy of knee";
var content_f34_27_35251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Anterior anatomy of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing represents an anterior view of the knee with the patella removed and demonstrates the relationship between the bones, menisci, and major ligaments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35251=[""].join("\n");
var outline_f34_27_35251=null;
var title_f34_27_35252="Alopecia areata beard";
var content_f34_27_35252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This man's alopecia areata is limited to his beard.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35252=[""].join("\n");
var outline_f34_27_35252=null;
var title_f34_27_35253="Cetirizine and pseudoephedrine: Drug information";
var content_f34_27_35253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetirizine and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/46/13029?source=see_link\">",
"    see \"Cetirizine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ZyrTEC-D&reg; Allergy &amp; Congestion [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Reactine&reg; Allergy and Sinus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F148898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F148884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seasonal/perennial allergic rhinitis: Oral: 1 tablet twice daily (maximum: 2 tablets/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F148893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in children &lt;12 years; see adult dosing for children &ge;12 years",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F148885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjust dose according to renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F148886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     11-31 mL/minute or if patient is on hemodialysis: Oral: 1 tablet once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F148887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 1 tablet once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release: Cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ZyrTEC-D&reg; Allergy &amp; Congestion: Cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F148866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Tablet should be swallowed whole; do not break, crush, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F148865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptoms of seasonal or perennial allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC&reg; may be confused with Lipitor&reg;, Serax, Xanax&reg;, Zantac&reg;, Zocor&reg;, Zyprexa&reg;, Zyrtec-D&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC-D&reg; may be confused with ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F148896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported with combination product. Additional adverse effects reported; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (4%), fatigue (2%), somnolence (2%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (2%), epistaxis (1%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F148869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyzine, adrenergic agents, cetirizine, pseudoephedrine, or any component of the formulation; MAO inhibitor therapy or use within 14 days of discontinuing MAO inhibitor therapy; narrow-angle glaucoma; urinary retention; severe hypertension; severe coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F148856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F148894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F148877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Cetirizine's absorption and maximal concentration are reduced when taken with food; may be taken without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ephedra, yohimbe (may cause hypertension). Avoid valerian, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F148871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Cetirizine-Pseudoephedrine ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-120 mg (24): $17.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (KLS Aller-Tec D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-120 mg (24): $17.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (ZyrTEC-D Allergy &amp; Congestion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-120 mg (12): $13.08",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F148872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acidrine-D (CO);",
"     </li>",
"     <li>",
"      Actifedduo LP Rhinite Allergique (FR);",
"     </li>",
"     <li>",
"      Alercet-D (EC, PE);",
"     </li>",
"     <li>",
"      Cetirax D (CO);",
"     </li>",
"     <li>",
"      Cetirivax-D (VE);",
"     </li>",
"     <li>",
"      Cetirrinol D (CO);",
"     </li>",
"     <li>",
"      Ceton (TW);",
"     </li>",
"     <li>",
"      Cetriler-D (AR);",
"     </li>",
"     <li>",
"      Cipan (AR, BO, BR, BZ, CN, CO, CR, DO, EC, GT, HN, MX, NI, PE, PY, SV, UY, VE);",
"     </li>",
"     <li>",
"      Cirrus (AT, BE, EE, FI, ID, MY, PL, TR);",
"     </li>",
"     <li>",
"      Lergium Plus (PE);",
"     </li>",
"     <li>",
"      Nosetec (TW);",
"     </li>",
"     <li>",
"      Reactine (IT);",
"     </li>",
"     <li>",
"      Remitex-D (CN);",
"     </li>",
"     <li>",
"      Virlix D (MX);",
"     </li>",
"     <li>",
"      Zetaler D (PE);",
"     </li>",
"     <li>",
"      Zirtraler-D (GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Zyrtec Plus (KP);",
"     </li>",
"     <li>",
"      Zyrtec-D (AR, BB, BG, BM, BR, BS, CN, CR, DO, EC, GT, GY, HK, HN, IN, JM, MX, NI, NL, PA, PE, PR, SG, SR, SV, TH, TT, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F148855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cetirizine is an antihistamine; exhibits selective inhibition of H",
"     <sub>",
"      1",
"     </sub>",
"     receptors. Pseudoephedrine is a sympathomimetic and exerts a decongestant action on nasal mucosa.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F148868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Cetirizine: 7.9 hours; Pseudoephedrine: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Cetirizine: 2.2 hours; Pseudoephedrine: 4.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70%); feces (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8621 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-82E6EA8F2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35253=[""].join("\n");
var outline_f34_27_35253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148880\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148881\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148898\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148884\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148893\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148885\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148886\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148887\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148864\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148852\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148866\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148865\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148905\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148896\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148869\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148856\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148894\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148860\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148877\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148871\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323054\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148872\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148855\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148868\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8621|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/46/13029?source=related_link\">",
"      Cetirizine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35254="Acetaminophen, dextromethorphan, and doxylamine: Drug information";
var content_f34_27_35254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen, dextromethorphan, and doxylamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/54/5989?source=see_link\">",
"    see \"Acetaminophen, dextromethorphan, and doxylamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7676299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      All-Nite Multi-Symptom Cold/Flu Relief [OTC];",
"     </li>",
"     <li>",
"      Night Time Multi-Symptom Cold/Flu Relief [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Cold &amp; Cough Nighttime [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Cough &amp; Sore Throat Nighttime [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cold &amp; Flu Nighttime Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; NyQuil&reg; Cold &amp; Flu Multi-Symptom [OTC] [DSC];",
"     </li>",
"     <li>",
"      Vicks&reg; NyQuil&reg; Cold &amp; Flu Nighttime Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7676303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7677055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of cold and flu symptoms:",
"     </b>",
"     Oral: Two capsules",
"     <b>",
"      or",
"     </b>",
"     30 mL every 6 hours (maximum: 8 capsules",
"     <b>",
"      or",
"     </b>",
"     120 mL/24 hours [Vicks&reg; NyQuil&reg; Cold &amp; Flu, Vicks&reg; Nature Fusion&trade; Cold &amp; Flu, All-Nite]",
"     <b>",
"      or",
"     </b>",
"     240 mL/24 hours [Tylenol&reg; Cold and Cough])",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7677054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of cold and flu symptoms:",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7677075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7677079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, liquid filled, oral: Acetaminophen 325 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Night Time Multi-Symptom Cold/Flu Relief: Acetaminophen 325 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; NyQuil&reg; Cold &amp; Flu Nighttime Relief: Acetaminophen 325 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     All-Nite Multi-Symptom Cold/Flu Relief: Acetaminophen 500 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg per 15 mL (177 mL) [contains ethanol 10 %, propylene glycol, and sodium 18 mg/15 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     All-Nite Multi-Symptom Cold/Flu Relief: Acetaminophen 500 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg per 15 mL (177 mL) [contains ethanol 10%, propylene glycol, and sodium 18 mg/15 mL; original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Cold &amp; Cough Nighttime: Acetaminophen 500 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg per 15 mL (240 mL) [ethanol free; contains propylene glycol, sodium 11 mg/15 mL, sodium benzoate; Cool Burst&reg; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Cough &amp; Sore Throat Nighttime: Acetaminophen 500 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg per 15 mL (240 mL) [contains sodium 11 mg/15 mL, propylene glycol, sodium benzoate; Cool Burst&trade; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Cough &amp; Sore Throat Nighttime: Acetaminophen 500 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg per 15 mL (240 mL) [contains sodium 11 mg/15 mL, propylene glycol, sodium benzoate; honey lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; Nature Fusion&trade; Cold &amp; Flu Nighttime Relief: Acetaminophen 650 mg, dextromethorphan hydrobromide 30 mg, and doxylamine succinate 7.5 mg per 30 mL (236 mL) [dye free, ethanol free, gluten free; contains propylene glycol, sodium 36 mg/30 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; NyQuil&reg; Cold &amp; Flu Multi-Symptom: Acetaminophen 500 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg per 15 mL (180 mL, 300 mL, 360 mL) [contains sodium 18 mg/15 mL, ethanol, propylene glycol; original flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; NyQuil&reg; Cold &amp; Flu Multi-Symptom: Acetaminophen 500 mg, dextromethorphan hydrobromide 15 mg, and doxylamine succinate 6.25 mg per 15 mL (180 mL, 300 mL, 360 mL) [contains sodium 19 mg/15 mL, ethanol, propylene glycol; cherry flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; NyQuil&reg; Cold &amp; Flu Nighttime Relief: Acetaminophen 650 mg, dextromethorphan hydrobromide 30 mg, and doxylamine succinate 12.5 mg per 30 mL (360 mL) [contains ethanol 10%, propylene glycol, sodium benzoate, sodium 44 mg/30 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; NyQuil&reg; Cold &amp; Flu Nighttime Relief: Acetaminophen 650 mg, dextromethorphan hydrobromide 30 mg, and doxylamine succinate 12.5 mg per 30 mL (240 mL, 360 mL) [contains ethanol 10%, propylene glycol, sodium benzoate, sodium 43 mg/30 mL; original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; NyQuil&reg; Cold &amp; Flu Nighttime Relief: Acetaminophen 650 mg, dextromethorphan hydrobromide 30 mg, and doxylamine succinate 12.5 mg per 30 mL (360 mL) [contains ethanol 10%, propylene glycol, sodium benzoate, sodium 44 mg/30 mL; vanilla cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7676301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7677077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liquid: Only use enclosed dosing cup or tablespoon to administer; do not use other devices.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7677035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of common cold and flu symptoms (eg, minor aches and pain, fever, cough, runny nose, sneezing, sore throat)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7676298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7677040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7677036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of MAO inhibitors within 14 days; concurrent use with other products containing acetaminophen; pediatric sedation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7677037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with hepatic impairment; acetaminophen may cause severe hepatic toxicity with acute overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Use with caution in children; may cause excitability. Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient&rsquo;s age, the product should",
"     <b>",
"      not",
"     </b>",
"     be administered without the guidance of a physician. Do not use in children &lt;4 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sodium: Some products may contain sodium; use with caution in sodium-restricted patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dosage limit: Limit acetaminophen dose to &lt;4 g/day (adults) or &lt;2.6 g/day (children &lt;12 years of age).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Patients with glaucoma or prostatic hyperplasia should consult a physician prior to use. Patients with chronic cough (associated with COPD or smoking) and/or productive cough (eg, copious amounts of phlegm) should be evaluated by a healthcare provider prior to use. Products containing acetaminophen are not recommended in patients consuming &ge;3 alcoholic beverages/day; consult a physician. If pain or cough increases in severity or persists &gt;7 days during use, consult a physician. If redness, swelling, or rash occurs or if fever worsens or persists &gt;3 days during therapy, consult a physician. If sore throat is severe, accompanied by fever, nausea/vomiting, headache, swelling or rash, or last &gt;2 days, discontinue use and consult healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7710326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7677049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7677076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Night Time Cold/Flu Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-325 mg (16): $5.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Robitussin Cold+Flu Nighttime Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-325 mg (20): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vicks NyQuil Cold &amp; Flu Night Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-325 mg (16): $6.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Contac Cold+Flu Night Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-500 mg/15 mL (240 mL): $7.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Coricidin HBP Nighttime Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-325 mg/15 mL (355 mL): $5.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-500 mg/15 mL (296 mL): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Delsym Night Time Cough/Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-500 mg/15 mL (120 mL): $8.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Delsym Night Time Multi-Sympt Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-325 mg/15 mL (120 mL): $8.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks Nature Fusion Cold &amp; Flu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-7.5-650 mg/30 mL (236 mL): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks NyQuil Cold &amp; Flu Night Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-6.25-325 mg/15 mL (354 mL): $7.88",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35254/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8933 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35254=[""].join("\n");
var outline_f34_27_35254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676299\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676303\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677055\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677054\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677075\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677079\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676301\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677077\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677035\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676298\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677040\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677036\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677037\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298658\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710326\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677049\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677076\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321924\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/54/5989?source=related_link\">",
"      Acetaminophen, dextromethorphan, and doxylamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35255="Ticlopidine: Drug information";
var content_f34_27_35255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ticlopidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/34/4645?source=see_link\">",
"    see \"Ticlopidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F227763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ticlopidine&reg;;",
"     </li>",
"     <li>",
"      Dom-Ticlopidine;",
"     </li>",
"     <li>",
"      Gen-Ticlopidine;",
"     </li>",
"     <li>",
"      Mylan-Ticlopidine;",
"     </li>",
"     <li>",
"      Novo-Ticlopidine;",
"     </li>",
"     <li>",
"      Nu-Ticlopidine;",
"     </li>",
"     <li>",
"      PMS-Ticlopidine;",
"     </li>",
"     <li>",
"      Sandoz-Ticlopidine;",
"     </li>",
"     <li>",
"      Teva-Ticlopidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent;",
"     </li>",
"     <li>",
"      Antiplatelet Agent, Thienopyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stroke prevention:",
"     </b>",
"     Oral: 250 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coronary artery stenting (initiate after successful implantation):",
"     </b>",
"     Oral: 250 mg twice daily (in combination with antiplatelet doses of aspirin). If initiated prior to percutaneous coronary intervention, a loading dose of 500 mg may be administered (Berger, 1999). May continue treatment for up to 30 days per the manufacturer; however, in general, duration of therapy may extend up to 12 months in patients with drug-eluting stents or those with stent implantation (bare metal or drug eluting) for acute coronary syndrome (Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Overall, the use of ticlopidine has largely been replaced by newer P2Y",
"     <sub>",
"      12",
"     </sub>",
"     inhibitors (ie, clopidogrel, prasugrel, ticagrelor).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     250 mg twice daily with food; dosage in older patients has not been determined; however, in two large clinical trials, the average age of subjects was 63 and 66 years. A dosage decrease may be necessary if bleeding develops.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6759555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6759556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific guidelines for patients with hepatic impairment; use with caution. Use is contraindicated with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F227747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet aggregation inhibitor that reduces the risk of thrombotic stroke in patients who have had a stroke or stroke precursors (",
"     <b>",
"      Note:",
"     </b>",
"     Due to its association with life-threatening hematologic disorders, ticlopidine should be reserved for patients who are intolerant to aspirin, or who have failed aspirin therapy); adjunctive therapy (with aspirin) following successful coronary stent implantation to reduce the incidence of subacute stent thrombosis.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F227800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protection of aortocoronary bypass grafts, diabetic microangiopathy, ischemic heart disease, prevention of postoperative DVT, reduction of graft loss following renal transplant",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9961827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is associated with ticlopidine. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the use of multiple agents which alter hemostasis and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Total cholesterol increased (increases of ~8% to 10% within 1 month of therapy), triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5%), purpura (2%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7%), dyspepsia (7%), gastrointestinal pain (4%), vomiting (2%), flatulence (2%), anorexia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (&gt;2 x upper limit of normal; 8%), abnormal liver function test (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anaphylaxis, angioedema, aplastic anemia, arthropathy, bilirubin increased, bone marrow suppression, bronchiolitis obliterans-organized pneumonia, chronic diarrhea, conjunctival bleeding, eosinophilia, erythema multiforme, erythema nodosum, exfoliative dermatitis, gastrointestinal bleeding, hematuria, hemolytic anemia, hepatic necrosis, hepatitis, hyponatremia, intracranial bleeding (rare), jaundice, maculopapular rash, menorrhagia, myositis, nephrotic syndrome, pancytopenia, peptic ulcer, peripheral neuropathy, pneumonitis (allergic), positive ANA, renal failure, sepsis, serum creatinine increased, serum sickness, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombocytopenia (immune), thrombocytosis, thrombotic thrombocytopenic purpura, urticaria, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ticlopidine or any component of the formulation; active pathological bleeding such as peptic ulcer bleeding or intracranial hemorrhage; severe liver impairment; hematopoietic disorders (neutropenia, thrombocytopenia, or a past history of TTP or aplastic anemia)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause life-threatening hematologic reactions, including neutropenia, agranulocytosis, thrombotic thrombocytopenia purpura (TTP), and aplastic anemia.",
"     </b>",
"     Routine monitoring is required (see Monitoring Parameters). Monitor for signs and symptoms of neutropenia including WBC count. Discontinue if the absolute neutrophil count falls to &lt;1200/mm",
"     <sup>",
"      3",
"     </sup>",
"     or if the platelet count falls to &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thienopyridine hypersensitivity: Because of structural similarities, cross-reactivity is possible among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with previous thienopyridine hypersensitivity. Use of ticlopidine is contraindicated in patients with hypersensitivity to ticlopidine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet disorders, bleeding disorders and/or at increased risk for bleeding (eg, PUD, trauma, or surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment. Use is contraindicated with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal impairment (experience is limited); bleeding times may be significantly prolonged and the risk of hematologic adverse events (eg, neutropenia) may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants and platelet aggregation inhibitors: Use with caution in patients receiving either anticoagulants (eg, heparin, warfarin) or other platelet aggregation inhibitors; bleeding risk is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in the elderly due to availability of safer alternative agents (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery stents: In patients who have received bare-metal or drug-eluting stents (sirolimus or paclitaxel), premature interruption of antiplatelet therapy may result in stent thrombosis with subsequent fatal and nonfatal myocardial infarction. If ticlopidine is used, duration of therapy, in general, is determined by the type of stent placed (bare metal or drug eluting) and whether an ACS event was ongoing at the time of placement (Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elective surgery: Consider discontinuing 10-14 days before elective surgery  (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy; patient-specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (moderate), CYP2C19 (strong), CYP2C9 (weak), CYP2D6 (moderate), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Ticlopidine may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Ticlopidine may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Ticlopidine may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F227759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Ticlopidine bioavailability may be increased (20%) if taken with food. High-fat meals increase absorption, antacids decrease absorption. May cause upset stomach. Management: Take with food to reduce stomach upset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications have additional antiplatelet activity. Management: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, chamomile, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American), ginseng (Panax), ginseng (Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, and white willow.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13459612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies; a case report has demonstrated the safe use of ticlopidine in pregnant women (Ueno, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F227772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F227753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food to reduce stomach upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F227752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ticlopidine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (60): $111.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F227742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of bleeding; CBC with differential every 2 weeks starting the second week through the third month of treatment; more frequent monitoring is recommended for patients whose absolute neutrophil counts have been consistently declining or are 30% less than baseline values. The peak incidence of TTP occurs between 3-4 weeks, the peak incidence of neutropenia occurs at approximately 4-6 weeks, and the incidence of aplastic anemia peaks after 4-8 weeks of therapy. Few cases have been reported after 3 months of treatment. Liver function tests (alkaline phosphatase and transaminases) should be performed in the first 4 months of therapy if liver dysfunction is suspected.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F227754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anagregal (IT);",
"     </li>",
"     <li>",
"      Antigreg (MY, SG);",
"     </li>",
"     <li>",
"      Aplaket (MY, SG, TH);",
"     </li>",
"     <li>",
"      Ban Su (CL);",
"     </li>",
"     <li>",
"      Cartrilet (ID);",
"     </li>",
"     <li>",
"      Cenpidine (TH);",
"     </li>",
"     <li>",
"      Clid (KP);",
"     </li>",
"     <li>",
"      Declot (TW);",
"     </li>",
"     <li>",
"      Desitic (DE);",
"     </li>",
"     <li>",
"      Ipaton (HU);",
"     </li>",
"     <li>",
"      Licodin (TW);",
"     </li>",
"     <li>",
"      Nichistate (TW);",
"     </li>",
"     <li>",
"      Panaldine (JP);",
"     </li>",
"     <li>",
"      Piclodin (ID);",
"     </li>",
"     <li>",
"      Strokan FC (MY);",
"     </li>",
"     <li>",
"      Tagren (EE, HR);",
"     </li>",
"     <li>",
"      Ticard (TH);",
"     </li>",
"     <li>",
"      Ticlid (AE, AR, BB, BE, BH, BM, BO, BR, BS, BZ, CN, CO, CR, CY, CZ, DO, EC, EG, FR, GB, GR, GT, GY, HK, HN, HU, IQ, IR, JM, JO, KW, LB, LU, LY, MX, MY, NI, NL, NO, OM, PA, PE, PK, PL, PR, PY, QA, SA, SE, SR, SV, SY, TH, TR, TT, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Ticlidil (IL);",
"     </li>",
"     <li>",
"      Ticlo (RU);",
"     </li>",
"     <li>",
"      Ticlodix (PT);",
"     </li>",
"     <li>",
"      Ticlodone (GR, IT, KP);",
"     </li>",
"     <li>",
"      Ticlopid (BG);",
"     </li>",
"     <li>",
"      Ticlopine (TH);",
"     </li>",
"     <li>",
"      Ticuring (ID);",
"     </li>",
"     <li>",
"      Tikleen (IN);",
"     </li>",
"     <li>",
"      Tiklid (AT, ES, IT);",
"     </li>",
"     <li>",
"      Tiklyd (DE);",
"     </li>",
"     <li>",
"      Tikpid (PH);",
"     </li>",
"     <li>",
"      Tilodene (AU);",
"     </li>",
"     <li>",
"      Tiodin (SG);",
"     </li>",
"     <li>",
"      Tipidin (HK, MY, SG);",
"     </li>",
"     <li>",
"      Tipidine (TH);",
"     </li>",
"     <li>",
"      Tyklid (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ticlopidine requires",
"     <i>",
"      in vivo",
"     </i>",
"     biotransformation to an unidentified active metabolite. This active metabolite irreversibly blocks the P2Y12 component of ADP receptors, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Platelets blocked by ticlopidine are affected for the remainder of their lifespan.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F227749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 3-5 days; serum levels do not correlate with clinical antiplatelet activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Parent drug: 98%; &lt;15% bound to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; has at least 1 active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60%); feces (23%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albiero R, Hall P, Itoh A, et al, &ldquo;Results of a Consecutive Series of Patients Receiving Only Antiplatelet Therapy After Optimized Stent Implantation. Comparison of Aspirin Alone Versus Combined Ticlopidine and Aspirin Therapy,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(5):1145-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9054843/pubmed\" id=\"9054843\" target=\"_blank\">",
"        9054843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balsano F, Rizzon P, Violi F, et al, &ldquo;Antiplatelet Treatment With Ticlopidine in Unstable Angina. A Controlled Multicenter Clinical Trial. The Studio della Ticlopidina nell'Angina Instabile Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1990, 82(1):17-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/2194694/pubmed\" id=\"2194694\" target=\"_blank\">",
"        2194694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Becquemin JP, &ldquo;Effect of Ticlopidine on the Long-Term Patency of Saphenous-Vein Bypass Grafts in the Legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(24):1726-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9392698/pubmed\" id=\"9392698\" target=\"_blank\">",
"        9392698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berger PB, Bell MR, Hasdai D, et al, &ldquo;Safety and Efficacy of Ticlopidine for Only 2 Weeks After Successful Intracoronary Stent Placement,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(2):248-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9892591/pubmed\" id=\"9892591\" target=\"_blank\">",
"        9892591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bertrand ME, Legrand V, Boland J, et al, &ldquo;Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (Fantastic) Study,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(16):1597-603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9778323/pubmed\" id=\"9778323\" target=\"_blank\">",
"        9778323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grines CL, Bonow RO, Casey DE, et al, &ldquo;AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the Amercian College of Physicians,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(6):813-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/17224480/pubmed\" id=\"17224480\" target=\"_blank\">",
"        17224480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hass WK, Easton JD, Adams HP Jr, et al, &ldquo;A Randomized Trial Comparing Ticlopidine Hydrochloride With Aspirin for the Prevention of Stroke in High-Risk Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1989, 321(8):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/2761587/pubmed\" id=\"2761587\" target=\"_blank\">",
"        2761587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kastrati A, Schuhlen H, Hausleiter J, et al, &ldquo;Restenosis After Coronary Stent Placement and Randomization to a 4-Week Combined Antiplatelet or Anticoagulant Therapy: Six-Month Angiographic Follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 96(2):462-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9244213/pubmed\" id=\"9244213\" target=\"_blank\">",
"        9244213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leon MB, Baim DS, Popma JJ, et al, &ldquo;A Clinical Trial Comparing Three Antithrombotic-Drug Regimens After Coronary-Artery Stenting. Stent Anticoagulation Restenosis Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(23):1665-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9834303/pubmed\" id=\"9834303\" target=\"_blank\">",
"        9834303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rupprecht HJ, Darius H, Borkowski U, et al, &ldquo;Comparison of Antiplatelet Effects of Aspirin, Ticlopidine, or Their Combination After Stent Implantation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 97(11):1046-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9531251/pubmed\" id=\"9531251\" target=\"_blank\">",
"        9531251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;mig A, Neumann FJ, Kastrati A, et al, &ldquo;A Randomized Comparison of Antiplatelet and Anticoagulant Therapy After the Placement of Coronary-Artery Stents,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(17):1084-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/8598866/pubmed\" id=\"8598866\" target=\"_blank\">",
"        8598866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinhubl SR, Lauer MS, Mukherjee DP, et al, &ldquo;The Duration of Pretreatment With Ticlopidine Prior to Stenting Is Associated With the Risk of Procedure-Related Non-Q-Wave Myocardial Infarctions,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1998, 32(5):1366-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9809949/pubmed\" id=\"9809949\" target=\"_blank\">",
"        9809949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Urban P, Macaya C, Rupprecht HJ, et al, &ldquo;Randomized Evaluation of Anticoagulation Versus Antiplatelet Therapy After Coronary Stent Implantation in High-Risk Patients: The Multicenter Aspirin and Ticlopidine Trial After Intracoronary Stenting (MATTIS),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(2):2126-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/27/35255/abstract-text/9815866/pubmed\" id=\"9815866\" target=\"_blank\">",
"        9815866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9996 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35255=[""].join("\n");
var outline_f34_27_35255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709984\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227763\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227804\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227767\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227768\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6759555\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6759556\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227744\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227729\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227747\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227746\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227800\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961827\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227802\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227750\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227733\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227738\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227759\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227740\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13459612\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227772\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227753\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227752\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227742\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227754\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227732\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227749\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9996|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/34/4645?source=related_link\">",
"      Ticlopidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35256="Treatment of resistant hypertension";
var content_f34_27_35256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of resistant hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35256/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35256/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35256/contributors\">",
"     David A Calhoun, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35256/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35256/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/27/35256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant hypertension is defined in the 2008 American Heart Association guideline as blood pressure that remains above goal in spite of concurrent use of three antihypertensive agents of different classes, one of which should be a diuretic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients whose blood pressure is controlled with four or more medications are considered to have resistant hypertension.",
"   </p>",
"   <p>",
"    Patients with resistant hypertension are at high risk for adverse cardiovascular events and are more likely than those with controlled hypertension to have a secondary cause, which is usually at least in part reversible.",
"   </p>",
"   <p>",
"    The treatment and prognosis of resistant hypertension that is not due to secondary causes will be reviewed here. The definition, prevalence, risk factors, and evaluation of resistant hypertension and secondary causes of hypertension, such as renovascular disease and primary aldosteronism, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=see_link\">",
"     \"Definition, risk factors, and evaluation of resistant hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND GOAL BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant hypertension is defined in the 2008 American Heart Association guideline as blood pressure that remains above goal in spite of concurrent use of three antihypertensive agents of different classes, one of which should be a diuretic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients whose blood pressure is controlled with four or more medications are considered to have resistant hypertension.",
"   </p>",
"   <p>",
"    The goal blood pressure is less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in average risk hypertensive patients. There is evidence supporting a lower goal blood pressure in patients with atherosclerotic cardiovascular disease, diabetes mellitus, or chronic kidney disease. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with recommendations from the 2008 American Heart Association guideline on resistant hypertension that both nonpharmacologic and pharmacologic therapies are warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Identify and treat secondary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;An essential component of the treatment of resistant hypertension is identification and treatment of potentially reversible causes of secondary hypertension (",
"    <a class=\"graphic graphic_table graphicRef77787 \" href=\"mobipreview.htm?12/21/12635\">",
"     table 1",
"    </a>",
"    ). The most common are obstructive sleep apnea, primary aldosteronism and renal artery stenosis.",
"   </p>",
"   <p>",
"    The possible presence of secondary rather than essential hypertension is suggested by a number of clinical clues, one of which is resistant hypertension. Thus, secondary hypertension should be considered in all patients with resistant hypertension. The clinical clues suggesting secondary hypertension are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stop medications that raise the blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications can raise the blood pressure and worsen underlying hypertension (",
"    <a class=\"graphic graphic_table graphicRef56767 \" href=\"mobipreview.htm?14/40/14987\">",
"     table 2",
"    </a>",
"    ). Nonsteroidal antiinflammatory drugs are probably most common and, if possible, any such medications should be discontinued or the dose lowered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=see_link\">",
"     \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involving the patient in monitoring his or her own blood pressure at home may improve control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who have resistant hypertension due to real or perceived side effects of many different antihypertensive drugs are often the most difficult to treat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Refer to a hypertension specialist",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a specific secondary cause of hypertension is suspected or if the blood pressure remains elevated in spite of six months of more intensive treatment, referral to a hypertension specialist is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, the American Society of Hypertension (ASH) provides a list of hypertension specialists who are members of ASH. This list can be accessed at:",
"    <a class=\"external\" href=\"file://www.ash-us.org/htn-specialist/htn-specialists-directory.aspx\">",
"     www.ash-us.org/HTN-Specialist/HTN-Specialists-Directory.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Out-of-office BP monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apparently resistant patients should be evaluated by out-of office blood pressure measurements, either by self measurement of blood pressure at home or by ambulatory monitoring. Both home and ambulatory blood pressure measurements help to identify white coat hypertension. Ambulatory measurements are a better predictor than office blood pressure measurements of cardiovascular morbidity (ie, end-organ damage) and mortality in patients with resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapies are usually beneficial in patients with resistant hypertension. The main modalities include a lower salt diet, weight loss in obese and overweight patients, and moderation of alcohol intake. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link&amp;anchor=H10#H10\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Effects of dietary sodium restriction on blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of hypertension in adults\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 24-hour urine collection can be used to estimate sodium intake. The completeness of the collection can be estimated from the rate of urinary creatinine excretion, which is equal to creatinine production in the steady state. Normal values in adults under the age of 50 are 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (177 to 221",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    lean body weight in men and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (133 to 177",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    lean body weight in women. From the ages of 50 to 90, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in men), due primarily to a fall in muscle mass. A diet high in sodium may play an important role in drug resistant hypertension. The goal sodium intake in patients with hypertension is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link&amp;anchor=H15#H15\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Major society recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Achieving lasting dietary changes is difficult and professional guidance and follow-up with a certified dietitian or nutritionist is recommended, if available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following approach applies to patients with resistant hypertension who do not have a reversible secondary cause of hypertension. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Identify and treat secondary hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The pharmacologic treatment of resistant hypertension, by definition, involves combinations of three or more drugs, including a diuretic. The choice of agents should be individualized and may depend upon consideration of prior benefit, history of adverse events, financial limitations, and the presence of concomitant disease processes such as chronic kidney disease or diabetes.",
"   </p>",
"   <p>",
"    Regimens should be simplified and long-acting combination agents used as much as possible in order to reduce the number of prescribed pills and to permit once daily dosing. Treatment adherence worsens as the use of pills, complexity of the dosing regimen, and out-of-pocket costs increase. Medication-related adverse effects should be discussed and side effects addressed with down-titration of or substitution for the offending agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=see_link\">",
"     \"Patient adherence and the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent volume expansion (typically not sufficient to produce edema) contributes to resistant hypertension, even among patients who have been on conventional doses of thiazide diuretics. This was illustrated in a study of 279 patients with resistant hypertension, 85 percent of whom were being treated with a thiazide diuretic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/5\">",
"     5",
"    </a>",
"    ]. Serum brain-type natriuretic peptide and atrial natriuretic peptide levels were significantly higher among patients with resistant hypertension compared to controls, suggesting volume expansion.",
"   </p>",
"   <p>",
"    Effective diuretic use is almost always necessary to achieve blood pressure control in patients with resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/6\">",
"     6",
"    </a>",
"    ]. Diuretics should be titrated until the blood pressure goal or the maximum recommended dose (as described below) has been reached or the patient has signs suggestive of overdiuresis such as fatigue, orthostatic hypotension, or decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the serum creatinine concentration. If overdiuresis is suspected, diuretic therapy needs to be reduced.",
"   </p>",
"   <p>",
"    In those with little renal impairment,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    is preferred to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    for the treatment of resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/7\">",
"     7",
"    </a>",
"    ]. Chlorthalidone has a more potent antihypertensive effect than hydrochlorothiazide due, in part, to its much longer half-life. The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H5#H5\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Chlorthalidone versus hydrochlorothiazide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies that have compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    have evaluated patients with mild to moderate hypertension. Limited data suggest that chlorthalidone also provides comparatively greater benefit in patients with resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally begin",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    at 12.5 mg daily, which requires splitting of the 25 mg pill, with subsequent titration up to 25 mg daily or, rarely, higher. For patients already being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , we stop that drug and substitute chlorthalidone. Monitoring of serum electrolytes is necessary. Hypokalemia is a more common problem in patients with resistant hypertension, due at least in part to higher aldosterone levels, which explains the responsiveness of patients with resistant hypertension to aldosterone antagonists. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Aldosterone antagonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among patients with an estimated glomerular filtration rate of less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per m2, thiazide diuretics are less effective and loop diuretics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    , may be necessary for effective volume control. Furosemide is relatively short acting and usually requires at least twice daily dosing. A loop diuretic with a longer duration of action and more consistent absorption, such as torsemide, may be more effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Treatment of hypertension in chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At a given diuretic dose in stable hypertensive patients, urinary sodium and potassium loss only occur in the first 10 to 14 days of therapy (",
"    <a class=\"graphic graphic_figure graphicRef74940 \" href=\"mobipreview.htm?15/33/15901\">",
"     figure 1",
"    </a>",
"    ). Thereafter, the patient is in a steady state, in which the extracellular fluid volume is reduced but stable, and the serum potassium is stable at a level that is usually lower than baseline, assuming no major changes in diet or other medications that affect potassium balance (eg, angiotensin inhibitors, aldosterone antagonists). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H7#H7\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Monitoring for hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A low dietary salt intake can enhance the efficacy of all antihypertensive medications, and should be recommended, despite diuretic therapy. Since sodium intake and excretion come back into balance with chronic (as opposed to acute) diuretic therapy, a 24-hour urine collection can be used to estimate sodium intake. The completeness of the collection can be estimated from the rate of urinary creatinine excretion, which is equal to creatinine production in the steady state. The normal rate of daily creatinine excretion in adults under the age of 50 is 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    lean body weight (177 to 221",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    in men, and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (133 to 177",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    lean body weight in women. From the ages of 50 to 90, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in men), due primarily to a fall in muscle mass. The goal sodium intake in patients with hypertension is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link&amp;anchor=H15#H15\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Major society recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available aldosterone antagonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , are mineralocorticoid receptor antagonists, while potassium-sparing diuretics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    ) block collecting tubule sodium channels that are normally opened by aldosterone. Spironolactone, eplerenone, and amiloride provide significant antihypertensive benefit when added to existing multiple drug regimens in patients with resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. This effect may reflect, at least in part, significantly higher plasma aldosterone levels in patients with resistant hypertension compared with individuals who have normal blood pressure or controlled hypertension on one or two medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/5\">",
"     5",
"    </a>",
"    ]. However, spironolactone, which has been most widely studied, can also lower the blood pressure in patients with resistant hypertension who have normal plasma and urine aldosterone levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antihypertensive effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    was evaluated in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), which included 1411 patients whose blood pressure was not controlled on three antihypertensive drugs (mean blood pressure",
"    <span class=\"nowrap\">",
"     157/85",
"    </span>",
"    mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/9\">",
"     9",
"    </a>",
"    ]. The mean baseline serum potassium was 4.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the mean serum creatinine was 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (99",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    The addition of spironolactone (median dose 25",
"    <span class=\"nowrap\">",
"     mg/daily)",
"    </span>",
"    as a fourth drug was associated with a mean",
"    <span class=\"nowrap\">",
"     22/10",
"    </span>",
"    mmHg reduction in blood pressure at one-year follow-up. The mean rise in serum potassium was 0.4",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    with hyperkalemia (serum potassium &gt;5.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    occurring in 4 percent. Spironolactone may be more likely to cause hyperkalemia in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    in patients with resistant hypertension has been evaluated in randomized trials. The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      (25 to, if necessary, 50",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was compared with dual angiotensin blockade in an unblinded crossover trial in 42 overweight or obese patients who were treated with an average of four antihypertensive medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/10\">",
"       10",
"      </a>",
"      ]. An angiotensin receptor blocker was added if already taking angiotensin-converting enzyme inhibitors (or vice versa) for 12 weeks; after a four-week washout period, the patients were then treated with 12 weeks of spironolactone. Compared to baseline, spironolactone therapy was associated with a significantly greater fall in 24 hour ambulatory blood pressure",
"      <span class=\"nowrap\">",
"       (21/15",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       7/3",
"      </span>",
"      mmHg) and a significantly higher rate of attaining an office blood pressure less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg (54 versus 26 percent). A second study also concluded that a spironolactone-based therapeutic regimen was superior to a regimen based upon dual angiotensin blockade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      (25 mg per day) was compared with placebo in a double blind parallel trial of 117 patients who were treated with an average of four antihypertensive medications at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/12\">",
"       12",
"      </a>",
"      ]. Compared with placebo, spironolactone therapy significantly decreased the mean daytime and nighttime ambulatory systolic blood pressures (by 5.4 and 8.6 mmHg, respectively). However, there was no significant difference between the treatment groups in the change in diastolic pressure or the frequency of achieving an office systolic pressure of less than 140 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are being treated with aldosterone antagonists should be monitored for the development of hyperkalemia. The risk is increased among patients with chronic kidney disease and among those who are also treated with other drugs that can cause hyperkalemia such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or nonsteroidal antiinflammatory drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CHOICE OF REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following approach applies to patients with resistant hypertension who do not have a reversible secondary cause of hypertension and who do not have a specific indication for a class of drugs (eg, beta blocker or nondihydropyridine calcium channel blocker for rate control in atrial fibrillation). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Identify and treat secondary hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Few studies have evaluated different drug combinations of three or more medications in the treatment of resistant hypertension. Our approach is to sequentially combine agents with different mechanisms of action. The triple combination of an ACE inhibitor or ARB, a long-acting dihydropyridine calcium channel blocker (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ), and a long-acting thiazide diuretic (preferably",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ) is often effective and generally well tolerated. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diuretics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients with uncontrolled hypertension who are already being treated with such a three drug regimen at maximum recommended and tolerated doses, we add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    . We usually begin spironolactone at 12.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (which requires splitting of a 25 mg tablet) before titrating to 25 and, if necessary, 50",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The risk of adverse effects such as gynecomastia, breast tenderness, and erectile dysfunction increases with higher doses. We generally do not increase the spironolactone dose above 50 mg daily in the absence of proven primary aldosteronism. The more specific aldosterone blocker,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , is now generic and does not induce the side effects seen with spironolactone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of primary aldosteronism\", section on 'Aldosterone antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with resistant hypertension are being treated with a three-drug regimen different from the preferred regimen of an angiotensin inhibitor, long-acting dihydropyridine calcium channel blocker, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ; in addition, most who are prescribed four or more antihypertensive drugs are not receiving an aldosterone antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/17\">",
"     17",
"    </a>",
"    ]. Our approach varies with the patient's regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , we switch to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      If the current regimen includes a drug not from the three recommended drug classes, we add the missing preferred drug and assess the response. We do not discontinue any drugs, as long as they are well tolerated, before achieving blood pressure control.",
"     </li>",
"     <li>",
"      If the patient is still hypertensive despite being treated with the three preferred drugs, we add an aldosterone antagonist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient is still hypertensive, additional medications are added sequentially. Possible agents that may be used include vasodilating beta blockers (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/34/32295?source=see_link\">",
"     nebivolol",
"    </a>",
"    ), centrally acting agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/17/32023?source=see_link\">",
"     guanfacine",
"    </a>",
"    ), and direct vasodilators (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    ). If beta blockers are used, a vasodilating beta blocker, such as labetalol, carvedilol or nebivolol, may provide more antihypertensive benefit with fewer side effects compared to traditional beta blockers, particularly when high doses are used (although head-to-head full dose comparisons are lacking) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Centrally acting agents may be effective, but adverse effects are common and outcome data are lacking. Direct vasodilators",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    are reserved for patients who remain hypertensive despite the above approach. Fluid retention and tachycardia are common side effects. Minoxidil also causes hirsutism, which may be a particular problem in women that may require switching to hydralazine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially effective therapies that are being evaluated include catheter-based radiofrequency ablation of the renal sympathetic nerves and electrical stimulation of the carotid sinus baroreceptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Catheter-based radiofrequency ablation of renal sympathetic nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-based radiofrequency ablation of the renal sympathetic nerves may lower the blood pressure in patients with resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. This procedure was tested in the Symplicity-HTN-2 trial of 106 patients with resistant hypertension despite treatment with an average of five antihypertensive medications including a diuretic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/19\">",
"     19",
"    </a>",
"    ]. The patients were randomly assigned to renal sympathetic denervation or maintenance of previous medical therapy. At six months, radiofrequency ablation significantly decreased the office blood pressure from",
"    <span class=\"nowrap\">",
"     178/97",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     143/85",
"    </span>",
"    mmHg compared with no decrease in blood pressure in patients maintained on baseline antihypertensive therapy. In addition, a systolic pressure of less than 140 mmHg was attained significantly more often with radiofrequency ablation (39 versus 6 percent). There was no significant difference between the groups in kidney function. Complications related to radiofrequency ablation included one femoral artery pseudoaneurysm. Whether this technique is superior to other interventions such as aldosterone antagonism is not known.",
"   </p>",
"   <p>",
"    Long-term data regarding efficacy and safety of radiofrequency ablation remain limited. In a cohort study of 153 patients with resistant hypertension treated with catheter-based radiofrequency ablation, medical evaluation was performed in 64 patients at 12 months and 18 patients at 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/23\">",
"     23",
"    </a>",
"    ]. Compared with baseline, blood pressure was reduced by",
"    <span class=\"nowrap\">",
"     23/11",
"    </span>",
"    mmHg at 12 months and",
"    <span class=\"nowrap\">",
"     32/14",
"    </span>",
"    mmHg at 24 months. The average number of antihypertensive medications used was the same at last follow-up as it was at baseline. Renal artery stenosis was diagnosed and stented in one patient six months after radiofrequency ablation.",
"   </p>",
"   <p>",
"    The studies of radiofrequency ablation mentioned above enrolled patients with normal renal function. However, many patients with resistant hypertension have chronic kidney disease. In a pilot study, 15 patients with chronic kidney disease and resistant hypertension underwent radiofrequency ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/24\">",
"     24",
"    </a>",
"    ]. The 15 patients enrolled included 6 women and 11 with type 2 diabetes; the mean age was 61 years, the mean estimated glomerular filtration rate was 31",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m",
"    <sup>",
"     2",
"    </sup>",
"    , and the mean number of antihypertensive medications used at baseline was 5.6. After six months, the mean office blood pressure had fallen from",
"    <span class=\"nowrap\">",
"     174/91",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     145/77",
"    </span>",
"    mmHg, although the mean 24 hour ambulatory blood pressure was not significantly lowered. There was no change estimated glomerular filtration rate or proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Electrical stimulation of carotid sinus baroreceptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical stimulation of the carotid sinus baroreflex system, or baroreflex activation therapy (BAT), may decrease blood pressure in patients with resistant hypertension. Feasibility studies have shown reductions in blood pressure after implantation of a device designed to stimulate the carotid baroreflex system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Rheos Pivotal Trial, 265 patients with resistant hypertension (defined as a mean office blood pressure, based upon five readings, greater than",
"    <span class=\"nowrap\">",
"     160/80",
"    </span>",
"    mmHg and a mean 24-hour ambulatory systolic blood pressure greater than or equal to 135 mmHg despite at least three antihypertensive medications including a diuretic) underwent surgical implantation of a device designed to stimulate the carotid baroreceptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/29\">",
"     29",
"    </a>",
"    ]. One month after surgery, patients were randomly assigned to have BAT turned on immediately or to have BAT turned on six months later. The patients were followed for at least 12 months.",
"   </p>",
"   <p>",
"    The major findings from this trial were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At six months, patients receiving BAT had a nonsignificantly larger decrease in systolic pressure (16 versus 9 mmHg) and a nonsignificantly greater likelihood of having a 10 mmHg or larger decrease in systolic pressure (54 versus 46 percent). In addition, patients receiving BAT were significantly more likely to achieve a goal systolic pressure of 140 mmHg or lower (42 versus 24 percent).",
"     </li>",
"     <li>",
"      At twelve months, the mean reduction in systolic pressure in the BAT group was 25 mmHg; more than 80 percent of these patients had at least a 10 mmHg decrease in systolic pressure.",
"     </li>",
"     <li>",
"      Within one month of surgery, 35 percent of patients had a serious procedure-related adverse event, including nerve injury. In most patients, procedure-related adverse events resolved spontaneously. Seven patients died (3 percent), but none were attributable to the device.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with resistant hypertension are more likely to have target organ damage and are at greater risk of stroke, myocardial infarction, heart failure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic kidney disease compared with patients who have more easily controlled hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/4,30-32\">",
"     4,30-32",
"    </a>",
"    ]. The high cardiovascular risk is attributable in part to long-standing, poorly controlled hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35256/abstract/33\">",
"     33",
"    </a>",
"    ] and to the coexistence of other cardiovascular risk factors, including left ventricular hypertrophy, obesity, diabetes, hyperlipidemia, chronic kidney disease, and obstructive sleep apnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpharmacologic treatment of resistant hypertension includes the identification and reversal of possible contributing factors with measures including weight loss if overweight, regular exercise, a low salt diet, and moderation of alcohol intake. Patients diagnosed with secondary causes of hypertension should be referred as needed to appropriate specialists and, if present, obstructive sleep apnea should be treated. Medications that may be contributing to hypertension should be withdrawn or avoided if possible. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary causes of hypertension should be considered and, if present, treated.",
"     </li>",
"     <li>",
"      The pharmacologic treatment of resistant hypertension involves combinations of three or more drugs. Some patients have a specific indication for a class of drugs (eg, beta blocker or non-dihydropyridine calcium channel blocker for rate control in atrial fibrillation). If there is no such indication, the preferred three-drug regimen consists of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, a long-acting calcium channel blocker such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      , and a long-acting thiazide diuretic, preferably",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      . Among patients with an estimated glomerular filtration rate of less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per m2, a loop diuretic, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      is usually necessary for effective volume control. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with persistent uncontrolled hypertension despite the above three-drug regimen in optimal dosage, we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically begin at 12.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and titrate up to, but not above, 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in the absence of proven primary aldosteronism. Monitoring of serum potassium levels for both hypokalemia and hyperkalemia are necessary if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      and spironolactone are used. For patients who cannot tolerate spironolactone,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      are alternatives. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Aldosterone antagonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients who are still hypertensive, we suggest adding a vasodilating beta blocker (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives include a long-acting centrally acting agent such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/17/32023?source=see_link\">",
"       guanfacine",
"      </a>",
"      or a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      transdermal patch.",
"     </li>",
"     <li>",
"      Among patients who remain resistant, a direct vasodilator such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      for women or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      for men may be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with resistant hypertension are being treated with a three drug regimen different from the preferred regimen of an angiotensin inhibitor, long-acting dihydropyridine calcium channel blocker, and a long-acting thiazide diuretic. Our approach varies with the patient's regimen (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Choice of regimen'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the patient is on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , we switch to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      and then add other drugs, as necessary.",
"     </li>",
"     <li>",
"      If the current regimen includes a drug not from the three recommended drug classes, we add the missing preferred drug and assess the response. We do not discontinue any drugs, as long as they are well tolerated, before achieving blood pressure control.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/1\">",
"      Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/2\">",
"      Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ 2004; 329:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/3\">",
"      Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991; 151:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/4\">",
"      Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/5\">",
"      Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/6\">",
"      Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/7\">",
"      Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension 2006; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/8\">",
"      Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich) 2005; 7:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/9\">",
"      Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/10\">",
"      Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/11\">",
"      Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/12\">",
"      V&aacute;clav&iacute;k J, Sedl&aacute;k R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/13\">",
"      Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/14\">",
"      Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/15\">",
"      Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/16\">",
"      Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/17\">",
"      Hanselin MR, Saseen JJ, Allen RR, et al. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011; 58:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/18\">",
"      Townsend RR, DiPette DJ, Goodman R, et al. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990; 48:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/19\">",
"      Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/20\">",
"      Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/21\">",
"      Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/22\">",
"      Williams B. Resistant hypertension: an unmet treatment need. Lancet 2009; 374:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/23\">",
"      Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/24\">",
"      Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/25\">",
"      Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/26\">",
"      Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006; 44:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/27\">",
"      Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/28\">",
"      Alnima T, Scheffers I, De Leeuw PW, et al. Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens 2012; 30:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/29\">",
"      Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/30\">",
"      Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/31\">",
"      Isaksson H, Ostergren J. Prognosis in therapy-resistant hypertension. J Intern Med 1994; 236:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/32\">",
"      Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35256/abstract/33\">",
"      Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168:2340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3819 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35256=[""].join("\n");
var outline_f34_27_35256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND GOAL BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Identify and treat secondary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stop medications that raise the blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Refer to a hypertension specialist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Out-of-office BP monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NONPHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CHOICE OF REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXPERIMENTAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Catheter-based radiofrequency ablation of renal sympathetic nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Electrical stimulation of carotid sinus baroreceptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3819|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/33/15901\" title=\"figure 1\">",
"      Time course of diuretic action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/21/12635\" title=\"table 1\">",
"      Secondary causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/40/14987\" title=\"table 2\">",
"      Agents that increase BP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=related_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=related_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35257="Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation";
var content_f34_27_35257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Robert Phang, MD, FACC, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     N A Mark Estes, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35257/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/27/35257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conversion of atrial fibrillation (AF) to sinus rhythm is associated with a small incidence of short-term thromboembolic events that may be due to either pre-existing or de novo thrombus formation. Treatment strategies (prolonged anticoagulation or shorter-term anticoagulation with screening transesophageal echocardiography [TEE]) can reduce the incidence of thromboembolization after cardioversion to less than 1 percent during the first month after cardioversion.",
"   </p>",
"   <p>",
"    This topic will discuss issues related to anticoagulation around the time of cardioversion from AF to sinus rhythm. The modalities used to perform cardioversion, anticoagulation in patients with persistent AF, and an overview of the management of AF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90507286\">",
"    <span class=\"h1\">",
"     EXTREMELY HIGH-RISK PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AF and valvular heart disease, especially mitral stenosis and prosthetic heart valves, are at extremely high risk of embolization at all times, not just at the time of cardioversion. The approach to anticoagulation in such patients is discussed in other UpToDate topics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link&amp;anchor=H10#H10\">",
"     \"Medical management and indications for intervention in mitral stenosis\", section on 'Prevention of thromboembolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LEFT ATRIAL THROMBUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolization after the return of synchronous atrial contraction has classically been attributed to the dislodgement of left atrial (LA) thrombi present at the time of cardioversion. However, there have been case reports and series of patients of patients developing de novo LA thrombi after cardioversion, when the screening TEE showed no LA thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link&amp;anchor=H8#H8\">",
"     \"Role of echocardiography in atrial fibrillation\", section on 'Spontaneous echo contrast'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43528?source=see_link\">",
"     \"Mechanisms of thrombogenesis in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The transient atrial contractile dysfunction after cardioversion is known as atrial \"stunning\" and can occur whether sinus rhythm is restored spontaneously, by external or internal DC (electric) cardioversion or by antiarrhythmic medications. The duration of the LA dysfunction appears to be related in part to the duration of AF prior to cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=see_link&amp;anchor=H10#H10\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Atrial stunning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RATIONALE FOR ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with AF have an increased risk of embolization compared to those without. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'Incidence of embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This risk is increased in the immediate post-cardioversion period, whether planned or spontaneous. Patients undergoing cardioversion of AF of more than 48 hours duration represent a high-risk group (compared to AF of shorter duration), with an embolic risk from as low as 1 to as high as 5 percent in the first month in the absence of anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This rate is substantially higher than the rate that would be calculated for the general population of patients with AF, in whom the yearly rate is between 1.3 and 5.1 percent, depending on age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'Incidence of embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most embolic events occur within 10 days of cardioversion, and occur more often in patients who are not effectively anticoagulated in the peri- and post-cardioversion period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peri-cardioversion anticoagulation decreases the frequency of this adverse event. While there is a measurable risk of important bleeding related to this therapy, we believe the benefit outweighs the risk in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105980134\">",
"    <span class=\"h2\">",
"     Before cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of thromboembolism after cardioversion can be diminished to less than one percent (during the four weeks after cardioversion) by the use of a month of therapeutic anticoagulation prior to and extending for one month after cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/5,6,9\">",
"     5,6,9",
"    </a>",
"    ]. This observation was made more than 20 years ago in clinical observations, case series, and retrospective studies. In two reports of patients undergoing cardioversion (79 and 332 patients respectively), none of the patients who were anticoagulated had an embolic event, where the 28 and 179 patients not receiving anticoagulation had embolic rates of 7 and 3.3 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Prospective therapeutic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    data from the ACUTE and RE-LY trial have demonstrated 30-day post-cardioversion clinical thromboembolism rates of 0.5 and 0.6 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Among patients with nonvalvular AF, the efficacy of a month of therapeutic anticoagulation prior to cardioversion appears to be largely related to resolution, rather than organization and adherence, of LA thrombi. A report of 14 patients with 18 atrial thrombi found that resolution of thrombi occurs in 16 (89 percent) after four weeks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and that new thrombi did not form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the routine use of transesophageal echocardiography (TEE) to document the absence of thrombus for patients without previously documented thrombus who have received one month of warfarin does not reduce the incidence of embolic events and is not cost effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'TEE-based approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1380564685\">",
"    <span class=\"h2\">",
"     After cardioversion",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13977439\">",
"    <span class=\"h2\">",
"     Immediate post-conversion anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for one month of therapeutic anticoagulation",
"    <strong>",
"     after",
"    </strong>",
"    cardioversion comes from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In those studies cited above where the risk of embolization after cardioversion was reduced in patients who were started on anticoagulant therapy before cardioversion, virtually all were kept on it for at least three weeks.",
"     </li>",
"     <li>",
"      Many patients have recurrent episodes of AF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/16\">",
"       16",
"      </a>",
"      ]. Up to 90 percent of these episodes are asymptomatic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/17\">",
"       17",
"      </a>",
"      ] and asymptomatic episodes lasting more than 48 hours are not uncommon, occurring in 17 percent of patients in a report using continuous monitoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recovery of atrial mechanical function may be delayed for several weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13977446\">",
"    <span class=\"h2\">",
"     Long-term anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale and indications for chronic anticoagulation after the period of post-conversion anticoagulation are similar to those for the broad population of patients with AF and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90507724\">",
"    <span class=\"h2\">",
"     Patients with AF of less than 48 hours duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion above generally refers to patients with AF of more than 48 hours duration. The risk of embolization after cardioversion among patients with AF of less than 48 hours duration and no anticoagulant protection appears to be lower than that among patients with AF of longer than 48 hours. In the Mayo Clinic study discussed above, there were no embolic events in 32 patients who did not receive anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1380564704\">",
"    <span class=\"h2\">",
"     Spontaneous conversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with AF have spontaneous conversion prior to planned cardioversion. There is no evidence that they are at lower risk of subsequent embolization in the first few weeks after conversion than patients who undergo electrical or chemical cardioversion.",
"   </p>",
"   <p>",
"    In a study of 1041 patients who were anticoagulated prior to and after cardioversion, 16 percent underwent spontaneous cardioversion (prior to electrical cardioversion). The rate of embolism was similar between patients with and without spontaneous cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/19\">",
"     19",
"    </a>",
"    ]. We believe that spontaneous cardioversion should not alter the anticoagulant strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AF OF MORE THAN 48 HOURS DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with guidelines from the 2012 American College of Chest Physicians (ACCP), the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA),",
"    </span>",
"    and the European Society of Cardiology, which strongly recommend that patients without a contraindication to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    who have been in AF for more than 48 hours receive a month of therapeutic warfarin",
"    <strong>",
"     prior to",
"    </strong>",
"    cardioversion with a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Since patients undergoing cardioversion for AF of more than 48 hours duration represent a high-risk group, we recommend that an INR of 2.0 or greater be documented for four consecutive weeks before cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations are based on a large body of observational evidence that anticoagulation reduces the risk of embolization in patients with AF. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Rationale for anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 2012 ACCP and",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines recommend that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy be continued for at least four weeks",
"    <strong>",
"     after",
"    </strong>",
"    cardioversion with a target INR of 2.5 (range 2.0 to 3.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. However, this recommendation only deals with protection from embolic events related to the pericardioversion period. The long-term recommendations for patients with recurrent AF who are at high risk for thromboembolism are similar to those in patients with longstanding persistent AF even when they are in sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines also suggest an alternative approach using",
"    <strong>",
"    </strong>",
"    shorter-term anticoagulation with screening TEE. The TEE-guided approach shortens the precardioversion duration of anticoagulation, but does not change the requisite four weeks of anticoagulation postcardioversion. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'TEE-based approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162042548\">",
"    <span class=\"h2\">",
"     Importance of INR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon observational studies and published guidelines, the recommended goal INR for most patients with chronic AF in whom",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is used is 2.0 to 3.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. This degree of anticoagulation appears to provide the best combination of protection against both embolization and major bleeding (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"mobipreview.htm?42/18/43296\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef87025 \" href=\"mobipreview.htm?3/17/3358\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This degree of anticoagulation is also optimal in the periprocedural period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/6,27\">",
"     6,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1217807677\">",
"    <span class=\"h2\">",
"     Use of non-warfarin oral anticoagulants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13977522\">",
"    <span class=\"h3\">",
"     Dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RE-LY trial compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    110 or 150 mg twice daily to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in over 18,000 patients with nonvalvular AF and found that the lower dose was similar to and the higher dose was superior to warfarin for the prevention of chronic thromboembolism and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a post hoc analysis of 1983 cardioversions (85 percent electric) in 1270 RE-LY participants, there was no significant difference in the rate of thromboembolism and stroke within 30 days in those who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    110 or 150 mg twice daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    leading up to cardioversion using the conventional or expedited TEE approach (0.8, 0.3, and 0.6 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    is a reasonable alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for patients who require anticoagulation prior to and after cardioversion. A more detailed discussion of the use of dabigatran is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13977553\">",
"    <span class=\"h3\">",
"     Rivaroxaban and apixaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the oral direct thrombin inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , the newer oral Factor Xa inhibitor anticoagulants",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    have demonstrated long-term efficacy and safety data for clinical thromboembolism prophylaxis that are equal to or superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H358919860#H358919860\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Rivaroxaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H147982962#H147982962\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Apixaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    use prior to and immediately after cardioversion have not been adequately evaluated. Thus, they are not currently recommended for use prior to or immediately after cardioversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     TEE-based approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section discusses the potential role of a transesophageal echocardiogram (TEE) based approach as an alternative to a month of therapeutic anticoagulation in the management of patients with AF of longer than 48 hours duration. The general role of echocardiography in the patient with AF is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that the TEE based approach be used for patients for whom there is a concern about a one month delay in cardioversion. Such a concern might arise from a preference to not have ongoing symptoms or a possible lower likelihood of successful cardioversion with a longer period of AF. This recommendation for a limited use of the TEE-based approach is based on our concerns about the cost, morbidity, and possibility of worse outcomes with this approach raised by the ACUTE trial presented below.",
"   </p>",
"   <p>",
"    Approximately 13 percent of patients with new onset AF will have evidence for an LA thrombus on TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/11,31,32\">",
"     11,31,32",
"    </a>",
"    ]. The prevalence is increased in high-risk patients with mitral stenosis (33 percent in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/33\">",
"     33",
"    </a>",
"    ], left ventricular systolic dysfunction, enlargement of the LA or LA appendage, or spontaneous echo contrast. Though unsupported by randomized data, we believe that patients with an LA thrombus should be treated with at least a month of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation followed by a TEE to document thrombus resolution prior to cardioversion.",
"   </p>",
"   <p>",
"    Observational studies have suggested that patients with AF can be acutely anticoagulated with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"     /oral",
"    </span>",
"    anticoagulant and proceed directly to cardioversion without prolonged anticoagulation if no atrial thrombus is seen on precardioversion TEE (",
"    <a class=\"graphic graphic_table graphicRef72971 graphicRef54077 \" href=\"mobipreview.htm?4/54/4973\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/31,32,34,35\">",
"     31,32,34,35",
"    </a>",
"    ]. The ACUTE trial compared a TEE-guided strategy with a conventional strategy (including therapeutic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [INR 2.0-3.0] anticoagulation for at least three weeks prior to electrical cardioversion) in 1222 patients with AF of more than two days&rsquo; duration (median duration 13 days) who were undergoing electrical cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/11,36\">",
"     11,36",
"    </a>",
"    ]. Patients assigned to the TEE-guided strategy were anticoagulated with heparin before TEE if inpatients or with oral warfarin for five days (target INR 2.0 to 3.0) before TEE in outpatients. TEE was then followed by cardioversion if no atrial thrombi were identified. With both approaches, warfarin therapy was continued for four weeks after cardioversion. If the initial TEE demonstrated thrombus (which was present in 12 percent), cardioversion was postponed and patients received therapeutic (INR 2-3) anticoagulation for three weeks, at which time a repeat TEE was performed. Patients assigned to conventional strategy received three weeks of therapeutic anticoagulation before cardioversion.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Within the eight weeks after study enrollment, there was no significant difference between the TEE and conventional groups in the incidence of ischemic stroke (0.6 versus 0.3 percent, respectively; relative risk [RR] 1.95, 95% CI 0.36-10.60) or all embolic events, including stroke, transient ischemic attack, and peripheral embolism (0.8 versus 0.5 percent, respectively; RR 1.62, 95% CI 0.39-6.76).",
"     </li>",
"     <li>",
"      There were significantly fewer hemorrhagic events with the TEE strategy (2.9 versus 5.5 percent), but no significant difference in the incidence of major bleeding (0.8 versus 1.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/11,37\">",
"       11,37",
"      </a>",
"      ]; in addition, there was no significant difference in all-cause mortality (2.4 versus 1 percent) or cardiac deaths (1.3 versus 0.7).",
"     </li>",
"     <li>",
"      The TEE strategy led to a shorter mean time to cardioversion (3 versus 31 days) and a greater incidence of successful restoration of sinus rhythm (71 versus 65 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important limitation is that the study was underpowered to demonstrate superiority; it was estimated that approximately 3000 patients would be needed in each group to demonstrate the possible superiority of one approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition we are concerned that the point estimates for the risk ratio for mortality, ischemic stroke and all embolic events are worse with the TEE-guided approach. However, the embolic events in the TEE arm all occurred in patients in AF or with subtherapeutic INR at the time of the embolic events, while embolic events in the conventional arm all occurred while the patient had a therapeutic INR. Thus, the TEE images may have been &ldquo;correct&rdquo; in that there was no thrombus at that time, but thrombus may have developed with AF recurrence or while atrial mechanical function was still depressed.",
"   </p>",
"   <p>",
"    Thromboembolism has been reported after a negative TEE in some patients who were not anticoagulated at the time of and for one month after cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These adverse events may be related to the limited sensitivity of TEE in some cases, but new thrombus formation has been documented during the period between TEE and cardioversion or after cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Thus, we recommend therapeutic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    (not tested in the ACUTE trial and the way to measure therapeutic anticoagulation is uncertain) or if necessary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for all patients undergoing a TEE based approach.",
"   </p>",
"   <p>",
"    The development of impaired LA mechanical function and of new thrombi after cardioversion provide the rationale for a month of therapeutic anticoagulation after cardioversion (INR 2.0 to 3.0), even when the precardioversion TEE shows no thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. There is suggestive evidence that such an approach reduces the incidence of embolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Rationale for anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the results of the ACUTE study discussed above raise concerns about possible worse outcomes in patients treated with this strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/38\">",
"     38",
"    </a>",
"    ], some experts have suggested that the TEE strategy is a reasonable alternative to a conventional approach in some patients, such as those with a strong preference for early cardioversion, those with AF of less than three weeks&rsquo; duration, and those at increased risk of hemorrhagic complications (as the duration of anticoagulation may be shortened).",
"   </p>",
"   <p>",
"    Another potential reason to consider this strategy is that a shorter period of AF may increase the likelihood of successful cardioversion and long-term maintenance of sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701654#H8701654\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'DC cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TEE based approach and the conventional approach with a month of therapeutic oral anticoagulation were felt to be equivalent approaches in guidelines from European Society of Cardiology and the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society gave a strong recommendation to the conventional approach and a weak recommendation to the TEE based approach (this was not changed in the 2011 Focused Update) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. We believe that the evidence for equivalence is weak. The ACUTE Trial may indicate the results with a TEE guided approach to cardioversion results in worse outcomes when compared with a conventional approach.",
"   </p>",
"   <p>",
"    Screening TEE may also be reasonable in patients who require hospitalization, have an increased risk of hemorrhagic complications during prolonged",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, or are not likely to tolerate AF despite adequate rate slowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162043524\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;If chosen, the TEE approach should include the following steps before cardioversion:",
"   </p>",
"   <p>",
"    For inpatients, administer either low molecular weight or unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (bolus and continuous drip goal partial thromboplastin time 1.5 to 2.0 times control) and simultaneously initiate oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.0 to 3.0). As the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    are different than warfarin, the combination of a heparin plus dabigatran may lead to supratherapeutic anticoagulation. Thus, until further evidence is available, we do not recommend overlap of heparin and dabigatran.",
"    <br/>",
"    <br/>",
"    For outpatients (or inpatients), oral warfarin (or dabigatran 150 mg twice daily) can be started five days before TEE with the target INR 2.0 to 3.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/11\">",
"     11",
"    </a>",
"    ]. A minimal pre-cardioversion INR of 2.0 is acceptable, though 2.5 may be preferred. As an alternative to warfarin, a strategy of at least three days of dabigatran (150 mg twice daily) prior to TEE guided cardioversion. The dose of dabigatran may need to be adjusted based on renal function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain a TEE",
"      <strong>",
"       after",
"      </strong>",
"      therapeutic parenteral anticoagulation (based on a PTT or INR) has been achieved (or after three days of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ) to assess for the presence of left or right atrial thrombi.",
"     </li>",
"     <li>",
"      If a thrombus is seen on TEE, the patient should receive a minimum of one month of therapeutic anticoagulation and a",
"      <strong>",
"       repeat",
"      </strong>",
"      TEE to document thrombus resolution prior to attempted cardioversion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/13\">",
"       13",
"      </a>",
"      ]. If thrombus is absent on repeat TEE, cardioversion may be performed. If thrombus is still evident, the rhythm control strategy may be changed to a rate control strategy, especially when AF-related symptoms are controlled, since there is a high risk of thromboembolism if cardioversion is performed. The evidence supporting this latter recommendation is minimal.",
"     </li>",
"     <li>",
"      It is best to be conservative with a month of pre-cardioversion",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ) if an atrial thrombus cannot be fully excluded on TEE.",
"     </li>",
"     <li>",
"      Among patients without TEE evidence for thrombi, continue therapeutic anticoagulation from the time of TEE through cardioversion.",
"     </li>",
"     <li>",
"      Continuous anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (INR 2-3) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      (150 mg twice daily) for at least one month after cardioversion in all eligible patients, regardless of the cardioversion method or apparent maintenance of sinus rhythm. In patients who have not achieved therapeutic anticoagulation with warfarin at the time of cardioversion, unfractionated or low molecular weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      should be continued until the INR is therapeutic. The combination of heparin and dabigatran has not been fully evaluated and we do not recommend this combination pending further study.",
"     </li>",
"     <li>",
"      As no data are available regarding safety of cardioversion using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      75 mg twice daily, it is not recommended in peri-cardioversion. Data are similarly unavailable with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      and these agents are not recommended during the pericardioversion period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     AF OF LESS THAN 48 HOURS DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of certain high-risk patients (eg, mitral valve disease, severe left ventricular dysfunction, prosthetic valves, or history of thromboembolism), the embolic risk appears to be very low if cardioversion (either intended or spontaneous) occurs within 48 hours of the onset of AF, assuming the onset can be determined definitively. It should be noted that a patient&rsquo;s reporting of the time of onset based on symptoms is frequently not reliable for determining the time of onset of AF.",
"   </p>",
"   <p>",
"    However, there is only a small amount of observational evidence that can be used to formulate recommendations regarding the approach to anticoagulation in these patients with AF of short duration. A low risk of embolization was found in a study of 375 consecutive patients with AF of less than 48 hours duration (screening TEE was not performed), in whom conversion to sinus rhythm during the hospitalization occurred in 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/39\">",
"     39",
"    </a>",
"    ]. A clinical thromboembolic event occurred in three (0.8 percent), each of whom converted spontaneously, all elderly women with good left ventricular systolic function. This overall rate of clinical thromboembolism is similar to what would have been expected with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy for one month prior to cardioversion. Similar findings have been noted in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the risk of an embolic event appears to be low in these patients, TEE evidence of left atrial thrombus is not uncommon in patients with AF of short duration. The rate of left atrial thrombus in patients studied with TEE has been between 12 and 14 percent with AF duration of less than 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/1,40\">",
"     1,40",
"    </a>",
"    ]. These values, which did not differ in those with AF of &le;2 days and two to three days&rsquo; duration, are similar to the 12 to 13 percent incidence noted above in TEE studies of patients with new onset AF of more than two days&rsquo; duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/11,32\">",
"     11,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, despite the apparent low risk of embolization, the rationale for the use of pericardioversion",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    comes from these observations of LA thrombus in up to 14 percent of patients with AF of short duration and pericardioversion atrial dysfunction. However, there are no studies comparing heparin to no heparin in patients with AF of short duration.",
"   </p>",
"   <p>",
"    Similarly, there are no studies comparing differing forms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with AF of short duration. Indirect evidence comparing the two heparins comes from a trial of 496 patients with AF of more than 48 hours duration who were randomly assigned to either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) followed by oral anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients were cardioverted after either 21 days of anticoagulation or after a TEE that was negative for thrombus; anticoagulation continued for 28 days after cardioversion. LMWH was noninferior to UFH followed by oral anticoagulation in terms of the combined primary end point of ischemic neurologic events, major hemorrhage, or death by the end of study treatment (2.8 versus 4.8 percent). LMWH also has a safety and efficacy profile similar to UFH when used as a bridge to oral anticoagulation in patients undergoing TEE-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with AF of less than 48 hours duration, many of our experts administer either low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously every 12 hours) or unfractionated heparin (bolus and continuous drip goal partial thromboplastin time 1.5 to 2.0 times control) prior to elective DC cardioversion. Oral anticoagulant is started simultaneously in those patients for the post-cardioversion period. Due to concerns regarding post-cardioversion atrial stunning, some of our experts recommend therapeutic heparin throughout the pericardioversion period and extend its use to 24 hours after cardioversion in those patients who will not be discharged on an anticoagulant OR until therapeutic anticoagulation with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is achieved.",
"   </p>",
"   <p>",
"    For the occasional patient in whom there is certainty that AF has been present for less than 48 hours or for patients at very high bleeding risk, some of our experts recommend cardioversion without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    anticoagulation if normal sinus rhythm can be restored within 48 hours of documented onset. If normal sinus rhythm cannot be re-established within 48 hours onset, anticoagulation can be administered with low molecular weight heparin or unfractionated heparin.",
"   </p>",
"   <p>",
"    Our experts also have differing approaches to the use of oral anticoagulation after cardioversion in patients with AF or less than 48 hours duration. Some prescribe therapeutic oral anticoagulation for at least a month after cardioversion irrespective of the CHADS2 (or CHA2DS2-VASc) score due to concerns regarding a high rate of recurrence of AF. Others do not prescribe post-cardioversion oral anticoagulation for those patients who do not appear to benefit from long-term oral anticoagulation based on CHADS2 criteria. The 2012 American College of Chest Physicians AF guidelines makes a weak recommendation for post-cardioversion anticoagulation in patients with AF less than 48 hours in duration based on less compelling evidence for therapeutic anticoagulation for at least four weeks rather than no anticoagulation, irrespective of baseline stroke risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1380564177\">",
"    <span class=\"h1\">",
"     URGENT CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with AF in whom the ventricular rate is rapid may require urgent cardioversion to prevent adverse clinical and hemodynamic consequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of atrial fibrillation\", section on 'Treatment issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical indications for emergent cardioversion of AF are rare, but in the setting of hemodynamic instability due to rapid AF that is refractory to pharmacologic support, the need for restoration of sinus rhythm may take precedence over the need for protection from thromboembolism. If feasible, the patient should receive precardioversion",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bolus. Performing a TEE in this setting would be reassuring if no thrombus is seen; however, in the urgent setting, postponing cardioversion because of the presence of thrombus may not be an option. Furthermore, a patient who has severe clinical instability due to AF is less likely to have been in AF for more than 48 hours.",
"   </p>",
"   <p>",
"    We agree with the 2012 ACCP guidelines, which recommend that patients undergoing urgent cardioversion receive therapeutic dose parenteral anticoagulation as soon as possible to prevent thrombi from forming due to atrial appendage dysfunction after cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35257/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1238596840\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conversion of atrial fibrillation (AF) to sinus rhythm is associated with a small, but clinically important incidence of clinical thromboembolism, particularly stroke, that may be due to either preexisting or de novo thrombus formation.",
"   </p>",
"   <p>",
"    The following points should be considered when choosing an anticoagulation strategy for a patient in whom cardioversion to sinus rhythm is planned:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AF and significant valvular heart disease, (especially mitral stenosis and prosthetic valves) left ventricular dysfunction, and prior",
"      <span class=\"nowrap\">",
"       stroke/TIA,",
"      </span>",
"      are at extremely high risk of embolization at all times, not just at the time of cardioversion. The approach to anticoagulation in such patients is discussed in other UpToDate topics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the management of chronic mitral regurgitation\", section on 'Anticoagulation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link&amp;anchor=H10#H10\">",
"       \"Medical management and indications for intervention in mitral stenosis\", section on 'Prevention of thromboembolism'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is used as the oral anticoagulant, protection against embolization is dependent upon maintaining a therapeutic International Normalized Ratio (INR). (See",
"      <a class=\"local\" href=\"#H162042548\">",
"       'Importance of INR'",
"      </a>",
"      above.) Similar duration",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      150 mg twice daily may be an effective alternative to warfarin. Data regarding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      are unknown and thus not recommended.",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      anticoagulation is being used, the available evidence suggests that unfractionated and low molecular weight preparations are equally effective and safe. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'AF of less than 48 hours duration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following recommendations apply to all patients with AF, except those at extremely high risk. (see",
"    <a class=\"local\" href=\"#H90507286\">",
"     'Extremely high-risk patients'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with AF that is less than 48 hours in duration, we suggest that a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      150 mg twice daily for eligible patients) be started before cardioversion then proceed to cardioversion within 48 hours of the onset of AF, as opposed to pretreating for a month with therapeutic oral anticoagulation or performing a pre-cardioversion transesophageal echocardiogram (in the absence of high-risk factors) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The duration of heparin after successful cardioversion is discussed above.",
"      <br/>",
"      <br/>",
"      For patients with AF that is less than 48 hours in duration, we suggest that a heparin (or dabigatran 150 mg twice daily for eligible patients) be started before cardioversion then proceed to cardioversion within 48 hours of the onset of AF, as opposed to not treating with a heparin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For patients at very high risk for periprocedural bleeding, such as those who have had recent surgery, or those in whom there is a high degree of certainty regarding the timing of onset, not using heparin is a reasonable option. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'AF of less than 48 hours duration'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Our experts have differing approaches to the use of oral anticoagulation after cardioversion in patients with AF of less than 48 hours. For patients considered to be at low long-term risk of embolization (CHADS2 = 0), some anticoagulate for a month after cardioversion, while others do not use oral anticoagulation during this period. All agree that oral antithrombotic therapy should be used for those patients who are likely to have recurrent AF and have a CHADS2 score of greater than 0.",
"     </li>",
"     <li>",
"      All agree that oral antithrombotic therapy should be used for those patients who have a CHADS2 score of greater than 0.",
"     </li>",
"     <li>",
"      For patients presenting with AF of an unknown duration or longer than 48 hours in duration (see",
"      <a class=\"local\" href=\"#H9\">",
"       'AF of more than 48 hours duration'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend one month of effective (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with INR 2.0-3.0 or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      150 mg twice daily for eligible patients) oral anticoagulation prior to cardioversion, rather than proceeding directly to cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      We suggest one month of effective (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with INR 2.0-3.0 or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      150 mg twice daily for eligible patients) oral anticoagulation prior to cardioversion rather than a transesophageal echocardiogram (TEE) based strategy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      A TEE-based strategy of expedited cardioversion using shorter duration anticoagulation followed by TEE is reasonable for patients with a modest duration of AF (less than a few months but greater than 48 hours) who have a strong preference to not delay cardioversion, or in whom there is a concern about bleeding with prolonged oral anticoagulation, or who require hospitalization, or who are not likely to tolerate AF despite adequate rate slowing. For these patients, the TEE based strategy is a reasonable approach to minimize the duration of AF prior to an attempt to restore sinus rhythm.",
"     </li>",
"     <li>",
"      For patients with a duration of AF of at least 48 hours but not a candidate for any anticoagulation (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ), we suggest a TEE guided approach rather than &ldquo;blind&rdquo; cardioversion. If a thrombus is seen, cardioversion should be deferred with reconsideration of the potential",
"      <span class=\"nowrap\">",
"       risks/benefits",
"      </span>",
"      of anticoagulation.",
"      <br/>",
"      <br/>",
"      The details of the TEE based approach are discussed above. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'TEE-based approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend therapeutic oral anticoagulation (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with INR 2.0-3.0 or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      150 mg twice daily) for at least one month after cardioversion, rather than discontinuing anticoagulation after cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The decision to continue anticoagulation after one month should be based on an evaluation of individual&rsquo;s risk of recurrence of atrial fibrillation and his or her risk of thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/1\">",
"      Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/2\">",
"      Black IW, Hopkins AP, Lee LC, Walsh WF. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients. Am Heart J 1993; 126:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/3\">",
"      Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 1994; 89:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/4\">",
"      Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J 1995; 129:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/5\">",
"      Kinch JW, Davidoff R. Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies. Arch Intern Med 1995; 155:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/6\">",
"      Gentile F, Elhendy A, Khandheria BK, et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc 2002; 77:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/7\">",
"      Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/8\">",
"      Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998; 82:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/9\">",
"      Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992; 326:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/10\">",
"      Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/11\">",
"      Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/12\">",
"      Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/13\">",
"      Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995; 92:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/14\">",
"      Seidl K, Rameken M, Dr&ouml;gem&uuml;ller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol 2002; 39:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/15\">",
"      Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997; 29:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/16\">",
"      Israel CW, Gr&ouml;nefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/17\">",
"      Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/18\">",
"      Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989; 13:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/19\">",
"      Tejan-Sie SA, Murray RD, Black IW, et al. Spontaneous conversion of patients with atrial fibrillation scheduled for electrical cardioversion: an ACUTE trial ancillary study. J Am Coll Cardiol 2003; 42:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/20\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/21\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/22\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/23\">",
"      You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/24\">",
"      Olshansky B. High intensity anticoagulation for cardioversion of atrial arrhythmias? The shocking truth. J Am Coll Cardiol 2002; 40:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/25\">",
"      Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/26\">",
"      Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/27\">",
"      Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002; 40:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/28\">",
"      Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/29\">",
"      Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/30\">",
"      Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/31\">",
"      Manning WJ, Silverman DI, Keighley CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/32\">",
"      Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 2001; 110:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/33\">",
"      Srimannarayana J, Varma RS, Satheesh S, et al. Prevalence of left atrial thrombus in rheumatic mitral stenosis with atrial fibrillation and its response to anticoagulation: a transesophageal echocardiographic study. Indian Heart J 2003; 55:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/34\">",
"      Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/35\">",
"      Manning WJ, Silverman DI, Gordon SP, et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/36\">",
"      Klein AL, Grimm RA, Jasper SE, et al. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. Am Heart J 2006; 151:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/37\">",
"      Klein AL, Murray RD, Grimm RA, et al. Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies. Am J Cardiol 2003; 92:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/38\">",
"      Silverman DI, Manning WJ. Strategies for cardioversion of atrial fibrillation--time for a change? N Engl J Med 2001; 344:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/39\">",
"      Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/40\">",
"      Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/41\">",
"      Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35257/abstract/42\">",
"      Klein AL, Jasper SE, Katz WE, et al. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 2006; 27:2858.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 906 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35257=[""].join("\n");
var outline_f34_27_35257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1238596840\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90507286\">",
"      EXTREMELY HIGH-RISK PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LEFT ATRIAL THROMBUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RATIONALE FOR ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105980134\">",
"      Before cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1380564685\">",
"      After cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13977439\">",
"      Immediate post-conversion anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13977446\">",
"      Long-term anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90507724\">",
"      Patients with AF of less than 48 hours duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1380564704\">",
"      Spontaneous conversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AF OF MORE THAN 48 HOURS DURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H162042548\">",
"      Importance of INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1217807677\">",
"      Use of non-warfarin oral anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13977522\">",
"      - Dabigatran",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13977553\">",
"      - Rivaroxaban and apixaban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TEE-based approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H162043524\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AF OF LESS THAN 48 HOURS DURATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1380564177\">",
"      URGENT CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1238596840\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/906|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/18/43296\" title=\"figure 1\">",
"      Events in AF according to INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/17/3358\" title=\"figure 2\">",
"      Risk of stroke and intracranial bleeding based on INR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/906|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/0/32779\" title=\"table 1A\">",
"      Conventional approach to cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/35/2620\" title=\"table 1B\">",
"      TEE approach to cardioversion of AF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43528?source=related_link\">",
"      Mechanisms of thrombogenesis in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35258="Evaluation of sexual abuse in children and adolescents";
var content_f34_27_35258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of sexual abuse in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Kirsten Bechtel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Berkeley L Bennett, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/27/35258/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/27/35258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health professionals who care for children in a variety of settings, from clinics and office practices to emergency departments, encounter those who may have been sexually abused. As an example, a clinician may become concerned that a child has been sexually abused because of an unusual injury pattern or behavior identified at the time of a scheduled visit. Alternatively, an evaluation in the emergency department may be initiated when a child is injured or discloses an incident to a caregiver. Specific interviewing skills, evidence-collection procedures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specialized examination techniques may be required to perform a thorough evaluation.",
"   </p>",
"   <p>",
"    The epidemiology, evaluation, and differential diagnosis of sexual abuse in children and adolescents will be reviewed here. The management and sequelae of childhood sexual abuse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11510?source=see_link\">",
"     \"Management and sequelae of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual assault is defined as attempted sexual touching of another person without their consent and includes sexual intercourse (rape), sodomy (oral-genital or anal-genital contact), and fondling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A generally accepted definition of sexual abuse is when a child engages in sexual activity for which",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    cannot give consent, is unprepared for developmentally, cannot comprehend,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an activity that violates the law or social taboos of society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/2\">",
"     2",
"    </a>",
"    ]. This includes fondling and all forms of oral-genital, genital, or anal contact with the child (whether the victim is clothed or unclothed), as well as non-touching abuses such as exhibitionism, voyeurism, or involving the child in pornography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Thus, child sexual abuse can include acts that would be considered sexual assault. For purposes of this chapter the term sexual abuse will be used, indicating that the perpetrator is a person of such acts is also responsible for the child's health and welfare.",
"   </p>",
"   <p>",
"    It is important to distinguish between sexual abuse and \"sexual play\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/4\">",
"     4",
"    </a>",
"    ]. Sexual abuse occurs when there is asymmetry in age or development among the participants, with a coercive quality to the event.",
"   </p>",
"   <p>",
"    \"Sexual play\" occurs in the absence of coercion and involves children of the same age (separated by no more than four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/5\">",
"     5",
"    </a>",
"    ]) or developmental level who engage in viewing or touching each other's genitalia because of mutual interest or curiosity. Sexual play is considered normal behavior and does not have the psychological, developmental, or physical consequences of sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to sexual play, many preschool-aged children mimic behaviors of older family members, such as flirting, batting eyelids, and \"walking sexy.\" This behavior also is considered part of normal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Department of Health and Human Services reports that &gt;60,000 children are sexually abused annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/7\">",
"     7",
"    </a>",
"    ]. Each year approximately 1 percent of children experience some form of sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ]. Worldwide, an estimated 25 percent of girls and 9 percent of boys are exposed to any form of sexual abuse during childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of reported sexual abuse grossly underestimates the true prevalence. Comparison of the prevalence of substantiated sexual abuse in developed countries (UK, US, Canada, Australia), as determined by agency reports, with self-reported sexual abuse by parents or victims who reside in these countries, suggests that only one in 10 instances of sexual abuse comes to official attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/8\">",
"     8",
"    </a>",
"    ]. One US survey found that 20 percent of high school students experienced sexual assault, but only 50 percent of these students revealed the incident to someone else [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Reasons that these events go unreported include fear of the medical evaluation, social stigma, and desire for privacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual abuse of children occurs primarily in the preadolescent years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Girls are more likely than boys to be sexually abused; however, boys are less likely to report sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perpetrators of sexual abuse are usually male, and often trusted adult acquaintances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/5,13,15\">",
"     5,13,15",
"    </a>",
"    ]. Statistics from reported cases in the United States indicate that \"father\" and \"other relatives\" were responsible for 21 and 19 percent of sexual abuse victims, respectively; mothers acting alone or with another person accounted for 4 and 8 percent of perpetrators, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/16\">",
"     16",
"    </a>",
"    ]. Perpetrators report that they gained access to children through caretaking (eg, babysitting), that they targeted children using bribes, gifts, and games, and systematically desensitized children through touch, talk about sex, and persuasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Victims of sexual abuse include children from all social, cultural, and economic backgrounds. However, some features related to family structure and parenting have been associated with an increased risk of childhood sexual abuse; the increased risk associated with these features is small, and their absence in no way precludes sexual abuse as a possibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/14\">",
"     14",
"    </a>",
"    ]. These features include poor parent-child relationships, poor relationships between parents, the absence of a protective parent, and the presence of a nonbiologically related male in the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of sexual abuse may present with a variety of medical complaints. They may be brought to medical attention specifically for evaluation of possible sexual abuse, or they may present for routine care or acute evaluation of medical or behavioral concerns that are not obviously related to the abuse. In the latter scenarios, the diagnosis of sexual abuse depends, to some extent, upon the willingness of the evaluating physician to consider it as a possibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the complaints that are possible indicators of sexual abuse are nonspecific (",
"    <a class=\"graphic graphic_table graphicRef65874 \" href=\"mobipreview.htm?7/20/7501\">",
"     table 1",
"    </a>",
"    ). Those that are more specific for inappropriate sexual contact or exposure include rectal or genital bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sexually transmitted infections (STIs) that were not acquired perinatally.",
"   </p>",
"   <p>",
"    Behaviors that may indicate that a child has been sexually abused include perpetration of sexual abuse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sexually explicit acting out, developmentally inappropriate knowledge of sexual activities, or developmentally inappropriate play (such as repeatedly touching an adult's genitals or asking an adult to touch the child's genitals). Such behaviors are learned and are not a normal part of childhood fantasy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,18-20\">",
"     13,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical evaluation of childhood sexual abuse has several immediate goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To identify injuries or other conditions that require treatment",
"     </li>",
"     <li>",
"      To screen for or diagnose sexually transmitted infections",
"     </li>",
"     <li>",
"      To evaluate for, and if possible, reduce the risk of pregnancy",
"     </li>",
"     <li>",
"      To document findings of potential forensic value",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation for possible sexual abuse includes a history and physical examination and may include forensic evidence collection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    screening for sexually transmitted infections. Whenever possible, the evaluation should be performed by an experienced child abuse team, including a child abuse specialist or clinician with similar experience. Consultation with a regional child abuse specialist or assessment center may also be helpful in difficult cases, or in cases that occur in the context of other family problems such as family violence or substance abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sexual abuse evaluations are best performed in a non-emergent setting, such as a child abuse advocacy center, where the history and physical examination can be performed in a calm, quiet environment and proceed at a pace tailored to the victim&rsquo;s needs.",
"   </p>",
"   <p>",
"    Urgent evaluation is necessary under the following circumstances and typically occurs in an emergent setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,13,23\">",
"     3,13,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The alleged abuse occurred within the previous 72 hours",
"     </li>",
"     <li>",
"      There are genital or anal injuries that require treatment",
"     </li>",
"     <li>",
"      There is obvious forensic evidence on the patient&rsquo;s clothes or body that must be collected",
"     </li>",
"     <li>",
"      There is danger of continued abuse or reprisal by the alleged perpetrator",
"     </li>",
"     <li>",
"      The victim has reported homicidal or suicidal ideation or other emergent complaints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all other cases, an evaluation by an experienced child abuse team, if available, and in a setting that is not emergent should be scheduled as soon as possible after the alleged incident or disclosure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. In addition to an evaluation for sexual abuse, it is essential that each child receives a thorough general medical assessment that may identify unmet medical and psychological needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining an unbiased history from a child who may have been sexually abused may be the most important part of the evaluation, particularly since diagnostic physical findings are frequently absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/5,13,20,25\">",
"     5,13,20,25",
"    </a>",
"    ]. A history of sexual abuse that is obtained in the course of medical diagnosis and treatment may be admissible in court as an exception to the laws restricting hearsay testimony. Thus, complete (verbatim, if possible) documentation of questions and answers is critical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/15,26\">",
"     15,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=see_link\">",
"     \"Child abuse: Social and medicolegal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, in the evaluation of nonspecific complaints that are possibly related to sexual abuse, the history should focus on differentiating among possible explanations for the child's symptoms: sexual abuse, physical abuse to the genital area, unintentional injury to the genital area, or other medical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Caregiver history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history regarding concerns about sexual abuse and any accompanying symptoms should be obtained from the parent or caregiver separately from the child, in a calm, unhurried manner. Many parents are understandably worried and appreciate an opportunity to share their concerns privately.",
"   </p>",
"   <p>",
"    The history should be comprehensive and include the child's current and past medical problems, as well as social and family histories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"     13",
"    </a>",
"    ]. The review of systems should identify changes in bowel or bladder habits (such as enuresis or encopresis), sleep disturbances, and behavioral changes and when they were first noted. Sexual abuse often triggers these symptoms.",
"   </p>",
"   <p>",
"    Parents should be asked how the abuse came to light or, if the child has not disclosed abuse, why the parents suspect it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"     28",
"    </a>",
"    ]. For children who have made a disclosure, the content of statements to parents or other caregivers should be documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Patient interview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the history from the child is such an important part of the evaluation, it should be performed by an experienced professional. For patients who have disclosed sexual abuse, the history obtained by the evaluating physician may be abbreviated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"     13",
"    </a>",
"    ]. Investigative interviews should be performed by the appropriate agencies, and if possible, by forensic interviewers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. This minimizes the need for a child to relate painful and distressing information on multiple occasions and also reduces bias that may be introduced by repeated, suggestive, or leading questions.",
"   </p>",
"   <p>",
"    In cases where sexual abuse is suspected, but not yet disclosed, the evaluating physician must obtain additional information from the caregiver. Child Protective Services should intervene to determine the need for a trained forensic interviewer when there is reasonable concern that abuse has occurred.",
"   </p>",
"   <p>",
"    During the evaluation of child sexual abuse cases, the role of each clinician should be clearly defined and based on clinical expertise. As an example, a clinical assistant who is handling laboratory specimens should not ask the child or family about the details of the abuse. In the situation where the clinician must obtain a history of abuse from the child, he or she must remember that this should be an opportunity for the patient to tell the story without guidance or prompting from the parent or examiner.",
"   </p>",
"   <p>",
"    The following section outlines a common approach taken by trained interviewers when questioning a child or adolescent who has been sexually abused.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children",
"      </strong>",
"      &ndash; Children should be interviewed without the parents present, if at all possible. However, when the child is uncomfortable alone with the examiner, it may be more effective to permit the parent to stay. The examiner should explain to the parent the importance of obtaining the history in the child's own words. The presence of a parent can be an opportunity to observe parent-child interaction. Although there is no consensus regarding the necessity of a chaperone for the interview, we suggest that it be conducted with either the parent or a Child Life worker in the room.",
"      <br/>",
"      <br/>",
"      In addition to obtaining the patient history, the clinician should explain the reason for the visit and describe the examination that may follow. As rapport is established, it is important to determine what words the child uses to describe his or her body parts.",
"      <br/>",
"      <br/>",
"      The accuracy of the history may be improved by asking open-ended questions, such as \"Has someone ever touched you in a way you didn't like or that made you feel uncomfortable?\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,15\">",
"       13,15",
"      </a>",
"      ]. To encourage a spontaneous narrative, the examiner should avoid any display of shock or disbelief, and maintain a \"Tell me more.\" or \"And then what happened?\" approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      When an incident is disclosed, the following information must be obtained with a gentle and non-threatening manner, using language that the child can understand [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"       28",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Who was the person who did this?",
"     </li>",
"     <li>",
"      With what part of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      body?",
"     </li>",
"     <li>",
"      What part(s) of the patient's body was (were) touched?",
"     </li>",
"     <li>",
"      How many times was the child touched?",
"     </li>",
"     <li>",
"      When was the last time that it happened?",
"     </li>",
"     <li>",
"      At what location did the abuse occur?",
"     </li>",
"     <li>",
"      Was there any exposure to blood or body fluids?",
"     </li>",
"     <li>",
"      Did the child experience pain to the affected body part?",
"     </li>",
"     <li>",
"      For male assailants, was there ejaculation?",
"     </li>",
"     <li>",
"      Did the child tell anyone about the incident?",
"      <br/>",
"      <br/>",
"      Leading and suggestive questions (such as, \"Mr. X touched your bottom, didn't he?\" or \"Did Mr. X touch your bottom?\") should be avoided. Allowing the child to use a doll or drawing to describe what happened may be helpful in obtaining and clarifying information. The patient may disclose more details during the course of the physical examination.",
"      <br/>",
"      <br/>",
"      At the end of the history, it is important that the child understands that he or she did the right thing in telling what happened, that he or she did nothing wrong, and that he or she is not in trouble [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11510?source=see_link&amp;anchor=H8#H8\">",
"       \"Management and sequelae of sexual abuse in children and adolescents\", section on 'Anticipatory guidance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adolescents",
"      </strong>",
"      &ndash; The adolescent history should occur without the presence of other family members. It is helpful to inform the adolescent that this is an opportunity for",
"      <span class=\"nowrap\">",
"       him/her",
"      </span>",
"      to ask questions as well as share details about the event(s).",
"      <br/>",
"      <br/>",
"      The patient should be told that information disclosed in this setting is, to an extent, confidential. Adolescents may receive confidentiality around some issues (as an example, their sexual activity), but health care providers are mandated to report disclosures about sexual abuse to a child protective services agency. Many adolescents are more willing to share information once they realize that the law grants them some protection of confidentiality. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link\">",
"       \"Confidentiality in adolescent health care\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      At the conclusion of the interview, the examiner should support the adolescent's decision to report the abuse and reassure the adolescent that he or she has done nothing wrong [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the history, the nature and timing of the examination depend to some extent upon the presenting complaint. The examination should be performed by trained and experienced examiners as soon as possible after the alleged incident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,24\">",
"     3,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physical examination of the possibly sexually abused child may be more difficult for the examiner than the child. It is helpful to approach this evaluation as one would any other type of physical complaint. The tone in the room is often set by the examiner; the more comfortable he or she is, the more comfortable the patient and his or her parent(s) will be.",
"   </p>",
"   <p>",
"    The physical examination should not result in additional emotional or physical trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ]. The purpose and noninvasive nature of the examination should be explained to the child and parents before it is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. Many children and adolescents are comforted by knowing that \"adults need to have these examinations too\" and that such examinations can help the child or adolescent know that his or her body is \"okay\".",
"   </p>",
"   <p>",
"    Parents may expect that the physical examination will yield evidence that confirms or excludes abuse. It is important to explain that physical evidence is rarely present in pediatric patients who are evaluated for sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20\">",
"     20",
"    </a>",
"    ]. Even among children who report vaginal or anal penetration, the rate of abnormal physical examination findings is only 5 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20,28\">",
"     20,28",
"    </a>",
"    ]. The examination is important for assessing medical problems that require attention, but other aspects of the evaluation (eg, history, laboratory analysis) may be more helpful in determining whether the child has been abused. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Interpretation of findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    During the examination, a supportive adult who is not suspected of involvement in the abuse should be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ]. Recognizing that the physical examination may be emotionally difficult for the child, permitting the child to decide who he or she would prefer to have in the examination room is one way to empower him or her. Distraction techniques may help the child tolerate the uncomfortable nature of the evaluation. Respect for the child's modesty whenever possible (such as by using drapes) is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"     13",
"    </a>",
"    ]. For children who are extremely anxious or uncooperative, use of a mild sedative, with careful monitoring, may be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The examination should include the mouth, breasts, genitals, inner thighs, perineal region, buttocks, and anus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ]. Good illumination is essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/15,29\">",
"     15,29",
"    </a>",
"    ]. An otoscope light source often provides sufficient illumination for direct visualization of genital structures. Colposcopy offers the advantages of magnification and photographic documentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"     13",
"    </a>",
"    ]. It may be helpful in identifying subtle lacerations or tears, but is not considered essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/21,30\">",
"     21,30",
"    </a>",
"    ]. Signs of trauma should be documented by photographs or detailed drawings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=see_link\">",
"     \"Child abuse: Social and medicolegal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ultraviolet or Wood's lamp may be used for detecting semen within several hours after the abuse. However, urine and oily fluids also fluoresce under the Wood's lamp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/11,31,32\">",
"     11,31,32",
"    </a>",
"    ]. In addition, semen may not reliably fluoresce using a Wood's lamp (360 nm wavelength) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/31\">",
"     31",
"    </a>",
"    ]. Consequently, the Wood's lamp examination is most helpful for identifying suspicious areas for more definitive forensic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/21\">",
"     21",
"    </a>",
"    ]. An alternate UV light source, such as one with a 420 to 450 nm wavelength, may be more useful for identifying semen on the skin. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Forensic evidence collection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oral cavity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the oral cavity should include evaluation for evidence of forced oral penetration such as bruising or petechiae of the hard or soft palate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tears of the frenulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Female genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the female genitalia is depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef62557 \" href=\"mobipreview.htm?26/23/26995\">",
"     figure 1",
"    </a>",
"    ). In all girls, the labia majora, labia minora, introitus, and hymen should be inspected for erythema, lesions, abrasions, or tears. The presence of a vaginal discharge in a prepubertal girl should prompt evaluation for sexually transmitted infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'STI testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The female genitalia are best viewed with the child lying supine (either on the examination table or in the lap of an adult, depending upon the child's comfort) with her hips externally rotated and knees flexed (frog-leg position). This allows examination of the external genitalia, vaginal vestibule, and hymenal structures. The prone knee-chest position (",
"    <a class=\"graphic graphic_figure graphicRef55157 \" href=\"mobipreview.htm?33/5/33887\">",
"     figure 2",
"    </a>",
"    ) is helpful in evaluating the anogenital region. In girls, it permits better visualization of the posterior hymen, vagina, and sometimes cervix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]. The lithotomy position may be helpful in older girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prepubertal girls (Tanner stage 1 or 2 for pubic hair) do not require a speculum examination unless there is active bleeding of unknown etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. When a speculum examination is required, the child should be adequately sedated, and the hymenal findings (eg, hymen configuration, presence of tears, erythema, abrasions) should be clearly documented before insertion of the speculum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A speculum examination may be necessary for pubertal adolescent females. Saline or water should be used instead of petroleum-based lubricants, since petroleum-based lubricants may affect sperm motility and culture results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/9,35\">",
"     9,35",
"    </a>",
"    ]. The vaginal walls as well as the cervix should be visualized to detect any evidence of trauma and to obtain samples from fluid collections. After the speculum examination is completed, a bimanual examination should be performed to assess adnexal and cervical tenderness. A rectal examination may be included as indicated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hymen",
"      </strong>",
"      &ndash; One of the most challenging aspects of the female genitalia examination is evaluation of the hymen. Visualization of the hymen is best achieved by gently grasping the labia minora bilaterally and pulling downward and outward when the patient is lying supine. The redundant folds of the estrogenized adolescent hymen may be more easily visualized using a moistened cotton swap or saline drops to fold out the edges [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The appearance of the hymen changes with age and in response to hormonal influences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/36\">",
"       36",
"      </a>",
"      ]. The prepubertal hymen is characterized as thin, translucent, and sensitive to touch (",
"      <a class=\"graphic graphic_figure graphicRef61605 \" href=\"mobipreview.htm?3/46/3808\">",
"       figure 3",
"      </a>",
"      ). It becomes thickened, elastic, redundant, and accommodating in puberty, as the result of a physiologic increase in estrogen exposure. Common normal variations in the appearance of the hymen include imperforate, microperforate, cribriform, and septate forms (",
"      <a class=\"graphic graphic_figure graphicRef57977 \" href=\"mobipreview.htm?8/20/8514\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The significance of notches or clefts in the hymen depends upon the location and extent of the defect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/37\">",
"       37",
"      </a>",
"      ]. Superficial notches can occur in the absence of abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/6,13,36\">",
"       6,13,36",
"      </a>",
"      ], whereas deep notches (ie, &gt;50 percent of hymenal diameter) are more concerning for abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/6,37,38\">",
"       6,37,38",
"      </a>",
"      ], although this finding is controversial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Interpretation of findings'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Acute lacerations, transections (clefts that extend to the junction of the hymen and the vestibule), and bruising of the hymen are more specific for penetrating sexual trauma, as is the absence of hymenal tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/6,28,37,38\">",
"       6,28,37,38",
"      </a>",
"      ]. However, the absence of these findings is common in girls who have suffered perceived genital penetration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. For example, an observational study of 506 girls age 5 to 17 years, who disclosed penile-genital penetrative abuse, found that most girls did not have definitive physical findings of abuse regardless of the number of reported penetrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/41\">",
"       41",
"      </a>",
"      ]. Specifically, no findings were seen on expert review of photocolposcopy in all of the girls less than 10 years of age (N=74), 87 percent of girls &ge;10 years of age with no history of consensual sex (358 of 410 patients), and 82 percent of girls &ge;10 years of age with a history of consensual sex (18 of 22 patients).",
"      <br/>",
"      <br/>",
"      Attachments or fusions between the labia minora and hymen may represent prior hymenal injury and are suggestive of abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/30\">",
"       30",
"      </a>",
"      ]. In contrast, labial adhesions (agglutination or fusion of the labia minora in the midline) normally occur in children and are not indicators of abuse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link&amp;anchor=H23#H23\">",
"       \"Vulvovaginal complaints in the prepubertal child\", section on 'Labial adhesions'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Measurements of the hymenal orifice vary widely among abused and normal children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20,36,42,43\">",
"       20,36,42,43",
"      </a>",
"      ]. Consequently, the transverse diameter of the hymenal orifice is not a marker for whether or not vaginal penetration occurred. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Interpretation of findings'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Male genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male genitalia may be examined with the patient standing or supine. The anatomy of the male genitalia is depicted in the picture (",
"    <a class=\"graphic graphic_picture graphicRef74328 \" href=\"mobipreview.htm?43/32/44546\">",
"     picture 1",
"    </a>",
"    ). A younger child may be more comfortable being examined in his parent's lap. He should be supine in the frog-legged position, so that the penis, scrotum, perineal area, and anus can be visualized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=see_link&amp;anchor=H3#H3\">",
"     \"The pediatric physical examination: The perineum\", section on 'Males'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The scrotum and penis should be examined for signs of acute or chronic trauma, including erythema, bruises, bite marks, or abrasions.",
"   </p>",
"   <p>",
"    The urethral meatus should be examined for erythema and lacerations. Genital injuries that have been described in retrospective series include lacerations, bruises, and burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Penile and anal injuries are much more common than injuries to the scrotum.",
"   </p>",
"   <p>",
"    Discharge at the urethral meatus may indicate infection. Penile or anal secretions should be obtained via swabs and cultured when discharge is noted. Anal secretions should be examined for evidence of semen if anal penetration within the previous 24 hours is suspected or reported. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'STI testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Forensic evidence collection'",
"    </a>",
"    below.) Lesions suggestive of sexually transmitted infections should be noted (eg, ulcerations, condyloma lata). (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Perianal area",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the anus in both males and females may be accomplished with the patient lying in the lateral recumbent position and grasping his or her knees. The examiner separates the buttocks for approximately 30 seconds, allowing sphincter relaxation and visualization of the anal canal. If penetration is suspected, a stool guaiac test should be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laxity of the anus may represent abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/46\">",
"     46",
"    </a>",
"    ]. It also can be seen with chronic constipation, neurologic disorders, or sedation. Dilation greater than 20 mm is suggestive of abuse if there is no stool in the ampulla [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"     28",
"    </a>",
"    ]. However, consensus regarding the significance of this finding is lacking (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Interpretation of findings'",
"    </a>",
"    below). Irregularity of anal folds after complete dilation is suggestive of abuse as well.",
"   </p>",
"   <p>",
"    Evidence of acute anal trauma may be seen if the child is evaluated soon after the abuse; however, anorectal changes are rarely definitive indicators of abuse. Swelling of the anus with blue discoloration is suggestive of trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/46\">",
"     46",
"    </a>",
"    ] and may be present up to 48 hours after the event. It is important not to confuse this finding with hemorrhoids (",
"    <a class=\"graphic graphic_picture graphicRef75759 graphicRef72916 \" href=\"mobipreview.htm?22/31/23028\">",
"     picture 2A-B",
"    </a>",
"    ). Perianal erythema is suspicious for trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/46\">",
"     46",
"    </a>",
"    ]. It may also be seen in children with encopresis, poor hygiene, pinworms, or Group A streptococcal or staphylococcal infection. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Penetrating injuries causing lacerations of the rectum may heal with scarring, but over time are difficult to detect. Midline anal tags are not indicative of abuse, whereas deformities outside of the midline may indicate chronic trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Forensic evidence collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Material evidence, when it is identified, is invaluable in the investigation of allegations of sexual abuse. Every institution that provides care to victims of alleged sexual abuse must have an organized approach to the collection of forensic evidence. Many states have developed the Sexual Assault Nurse Evaluator (SANE) system, which utilizes specially trained nurse examiners for evidence collection from adults and children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Trained providers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Forensic evidence is typically collected using kits that are specified by state or hospital protocol. The instructions for obtaining and labeling specimens must be followed carefully. In addition, the kit must be sealed, stored, and transferred to law enforcement authorities in a manner that maintains an unbroken chain of evidence. The forensic examination for victims of sexual assault is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Forensic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines on evidence collection reflect data and conclusions from adult studies that may not be directly applicable to children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/47\">",
"     47",
"    </a>",
"    ]. Several retrospective series have demonstrated that the yield for forensic examinations in children is low and that the majority of forensic evidence is found on clothing and linens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Semen is identified from body swabs more commonly in older children and rarely identified in any children more than 24 hours after an alleged assault. Some experts suggest that the interests of prepubertal children would best be served by deferring the forensic examination to centers with expertise in sexual abuse evaluation in cases where the abuse event occurred more than 24 hours prior and no obvious injury or infection is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, protocols regarding when evidence must be collected vary from state to state.",
"   </p>",
"   <p>",
"    The decision to collect forensic evidence from children who may have been sexually abused should take into consideration state protocols, the probability that the examination will yield evidence, and the potential emotional impact of the collection procedure on the child. Whenever possible, the decision to perform a forensic examination should be made by individuals with training and experience in child sexual abuse.",
"   </p>",
"   <p>",
"    Careful documentation of the decision making process regarding evidence collection is essential. Reasons for not collecting evidence or modifying the type of evidence that is collected must be documented. Information should be included regarding the emotional needs of the child and details of the abuse that are likely to decrease the yield of evidence (such as the use of condoms, lubricant, or showering or bathing prior to the examination).",
"   </p>",
"   <p>",
"    For prepubertal children and adolescents who are evaluated within 24 hours of the alleged abuse, forensic evidence should generally be collected in any of the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is reasonable concern that sexual abuse has occurred.",
"     </li>",
"     <li>",
"      The child has a genital injury as the result of alleged sexual abuse.",
"     </li>",
"     <li>",
"      Clothing or linen associated with the abuse is available.",
"     </li>",
"     <li>",
"      There are other concerning clinical features.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children who are evaluated more than 24 hours after the incident, state protocols should be followed, recognizing that the yield in evidence collection often decreases after 24 hours. The clinician must also consider that evidence may be identified that was unanticipated by the child's history or general physical examination and that there are reported instances of collection of identifiable DNA samples beyond 24 hours in young children under 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/48,53,54\">",
"     48,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although limited data suggest that the yield of evidentiary exams after 24 hours is also low for adolescents, patients in this age group are usually managed according to adult protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Forensic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence collection may be modified (as allowed by local protocols) to eliminate procedures that are unlikely to yield evidence based on details of the alleged abuse. Clothing and linen are very important sources for semen and other DNA identification and should be collected whenever they are available. Aspects of the examination itself that should be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DNA evidence may be identified from sources other than semen. Consequently, the clinician should consider the details of the alleged abuse when deciding which parts of the rape kit to complete. As an example, fingernail scrapings should be obtained when a victim describes grabbing the assailant or pulling his hair.",
"     </li>",
"     <li>",
"      Swabs to confirm the presence of semen should be collected from areas of fluorescence identified with an ultraviolet light source. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation and management of adult sexual assault victims\", section on 'Forensic evaluation'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A speculum examination is not indicated to obtain evidence from prepubertal girls. For those who are postpubertal, collection of semen from vaginal fluid or cervical mucus can be done using swabs or a pipette facilitated by a speculum examination. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Female genitalia'",
"      </a>",
"      above.) Motile sperm may be found in the vagina for eight hours and in the cervical mucus for two to three days after intercourse. Nonmotile sperm may persist in the vagina and rectum for 24 hours and in the cervical mucus for 17 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/11,55\">",
"       11,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Every effort must be made to collect forensic evidence without traumatizing the child. Some children may require sedation for the procedure, particularly in the unlikely event that a speculum examination is necessary. Evidence can be collected in the operating room for those patients with injuries who require evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment under general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     STI testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of a sexually transmitted infection (STI) in a prepubertal child or an adolescent who has not become sexually active may be evidence that the child has been sexually abused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/56\">",
"     56",
"    </a>",
"    ]. The prevalence of STIs in pediatric victims of sexual abuse is approximately 5 to 8 percent. However, the prevalence varies according to physical findings, geographic location, and infectious agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/57-61\">",
"     57-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among children undergoing evaluation for sexual abuse, positive tests for an STI are found in up to 25 percent of girls with vaginal discharge and 6.5 percent of girls with normal or nonspecific physical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/61\">",
"     61",
"    </a>",
"    ]. Thus, most sexually abused girls with STIs have normal or nonspecific findings on physical examination. The prevalence of STIs in boys with normal examination findings appears to be extremely low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/57,61,62\">",
"     57,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to test for STIs (which is often made on a case by case basis) is discussed below. Prophylaxis for STIs, including HIV, is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11510?source=see_link&amp;anchor=H3#H3\">",
"     \"Management and sequelae of sexual abuse in children and adolescents\", section on 'STI prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prepubertal victims",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experts recommend STI testing in the prepubertal child in the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20,33,61,63-67\">",
"     20,33,61,63-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High likelihood of sexual abuse based on interview [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The presence of signs or symptoms consistent with STIs (eg, genital discharge) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/33,64,65\">",
"       33,64,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An STI in the patient's sibling or another child in the patient's intimate environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The suspected perpetrator has an STI or is at high risk for having an STI",
"     </li>",
"     <li>",
"      The parents request testing",
"     </li>",
"     <li>",
"      There is evidence of anal or genital penetration (eg, acute tears) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evidence of ejaculation is present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, screening for HIV should be performed for the same indications and in conjunction with other STI screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/21\">",
"     21",
"    </a>",
"    ]. However, before HIV screening is performed, the possibility of vertical transmission (if the child is found to be positive) and its implications must be discussed with the child's mother.",
"   </p>",
"   <p>",
"    It is important to consider the incubation period of potential pathogens when testing for STIs after an acute event. Testing for gonorrhea, chlamydia, trichomonas, and bacterial vaginosis should be performed two weeks after the incident for patients who did not receive prophylactic therapy at the initial evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/15\">",
"     15",
"    </a>",
"    ]. Serologic testing for human immunodeficiency virus (HIV) should be performed at baseline and 6, 12, and 24 weeks after the incident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/15,56\">",
"     15,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appropriate culture method must be used, if and when STI testing is performed. In the United States, culture in addition to nonculture methods (eg, nucleic acid amplification tests (NAAT)) are preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/61,68,69\">",
"     61,68,69",
"    </a>",
"    ]. In one study of 485 children undergoing evaluation of sexual abuse, the use of urine NAAT significantly increased the detection of chlamydia and gonorrhea infection in prepubertal children undergoing evaluation for sexual abuse (4.5 percent positive by NAAT versus 3.3 percent positive by culture) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/70\">",
"     70",
"    </a>",
"    ]. Nonculture methods are still not accepted as forensic evidence in some United States jurisdictions.",
"   </p>",
"   <p>",
"    However, in Canada, nonculture methods are being used in the evaluation of sexually abused children and are accepted as forensic evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/71\">",
"     71",
"    </a>",
"    ]. Given that urine NAAT may be more accurate than culture and is less invasive, it may be the preferred method of detection in children with normal or nonspecific findings who live in legal jurisdictions that accept such methods as a forensic standard. Confirmation tests of positive NAAT&rsquo;s should be done with a second FDA-approved NAAT that targets a different DNA sequence from the initial test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending upon the suspected pathogen, the following specimens may be obtained as guided by the description of the events and the child's symptoms and physical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neisseria gonorrhoeae: Rectal, throat, and urethral or vaginal cultures (cervical specimens should not be collected from prepubertal girls) and NAAT",
"     </li>",
"     <li>",
"      Chlamydia trachomatis: Rectal or vaginal cultures (cervical specimens should not be collected from prepubertal girls) and urine NAAT",
"     </li>",
"     <li>",
"      Syphilis: Darkfield microscopy",
"     </li>",
"     <li>",
"      HIV: Serologic testing of abuser (if possible); serologic testing of child at time of abuse and 6, 12, and 24 weeks later",
"     </li>",
"     <li>",
"      Hepatitis B virus: Serum hepatitis B surface antigen testing of alleged abuser (if possible); hepatitis B surface antibody testing of the child to document response to vaccine, if the child received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"     </li>",
"     <li>",
"      Herpes simplex virus: Culture of suspicious lesion. Routine serology for HSV infections is not warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bacterial vaginosis: Wet mount, pH, and potassium hydroxide testing of vaginal discharge or Gram stain",
"     </li>",
"     <li>",
"      Human papillomavirus: Biopsy of lesion",
"     </li>",
"     <li>",
"      Trichomonas vaginalis: Wet mount and culture of vaginal discharge",
"     </li>",
"     <li>",
"      Pediculosis pubis: Identification of eggs, nymphs, and lice with naked eye or using a hand lens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The significance of the identification of a sexually transmitted agent in a child as evidence of possible child sexual abuse varies by pathogen. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Interpretation of findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Postpubertal victims",
"    </span>",
"    &nbsp;&mdash;&nbsp;For adolescents who have been sexually active, testing for sexually transmitted infection (STI) is controversial. Evidence of infection is generally not necessary for prosecution and positive tests may be used by the defense as discrediting evidence of promiscuity. In addition, prophylactic treatment is typically prescribed regardless of culture results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/56,63\">",
"     56,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts recommend that all postpubertal patients be screened for STIs, including HIV, because the prevalence of preexisting asymptomatic infection is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/63\">",
"     63",
"    </a>",
"    ]. Others suggest that the decision to test a victim of sexual abuse for STIs be made on an individual basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other forms of child abuse, the interpretation of findings in children with suspected sexual abuse depends upon the constellation of historical, physical, and laboratory findings. Isolated examination or laboratory findings are rarely diagnostic, but become more concerning when combined with a disclosure of sexual abuse, specific behavioral changes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the lack of another plausible explanation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history is often the most important part of the evaluation. The provision by the child of a spontaneous, clear, consistent, and detailed description of sexual molestation is specific for sexual abuse and should be reported to Child Protective Services (CPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/33,73\">",
"     33,73",
"    </a>",
"    ]. CPS should also be consulted to evaluate situations where there is reasonable concern that abuse has occurred, but the initial history is inconclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Normal physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal physical examination does not preclude the possibility that a child has been sexually abused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/34\">",
"     34",
"    </a>",
"    ]. The lack of physical findings may be inherent in the nature of the abuse (eg, fondling of the breast or genitals, oral-genital contact, exposure to pornographic material) or may be the result of the intrinsic elasticity and rapid healing of the anogenital tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/74-78\">",
"     74-78",
"    </a>",
"    ]. Furthermore, in retrospective series, there were no differences in the rates of healing of hymenal and other genital injuries between children with inflicted injuries and those with accidental mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the event that there are no physical findings consistent with abuse, the report should contain a statement such as \"Normal or nonspecific findings are to be expected in a child who describes this type of molestation,\" or \"A normal examination neither rules out nor supports an allegation of sexual abuse\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Abnormal physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal physical examination findings are present in the minority of children who are evaluated for possible sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20,38\">",
"     20,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Nonspecific findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in cases of possible sexual abuse may identify nonspecific findings that are associated with other medical conditions or are normal variants of anogenital structures (",
"    <a class=\"graphic graphic_table graphicRef78867 graphicRef57033 \" href=\"mobipreview.htm?4/41/4766\">",
"     table 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58224 \" href=\"mobipreview.htm?3/17/3356\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28,36,42,79-87\">",
"     28,36,42,79-87",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link\">",
"     \"Vulvovaginal complaints in the prepubertal child\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of a disclosure of sexual abuse, these nonspecific findings do not necessarily raise concern for sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"     28",
"    </a>",
"    ]. The physician should refer the child to a child abuse specialist (usually at an academic medical center, children's hospital, or child advocacy center) for further evaluation before a report of suspected abuse is made whenever there is a question regarding the significance of physical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Suspicious findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain anogenital findings have been noted in children with documented sexual abuse. However, data regarding the specificity of these findings for sexual abuse is insufficient or contradictory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28,73\">",
"     28,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suspicious findings include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,5,28,34,42,46,79,80,88-94\">",
"     3,5,28,34,42,46,79,80,88-94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genital or anorectal injury that requires surgical care is concerning. One observational study of 44 girls found that 25 percent of such injuries were caused by sexual abuse and the other injuries were associated with straddle or impalement mechanisms or motor vehicle collisions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/95\">",
"       95",
"      </a>",
"      ]. Sexually abused children had no plausible mechanism by history to explain the severity of findings.",
"     </li>",
"     <li>",
"      Deep notches or clefts (&gt;50 percent of the width of the hymenal rim) in the",
"      <span class=\"nowrap\">",
"       posterior/inferior",
"      </span>",
"      rim of the hymen (below the line drawn through 3 o'clock to 9 o'clock, with the patient supine) may be caused by previous blunt force or penetrating trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/5,34,88\">",
"       5,34,88",
"      </a>",
"      ]. In one case control study, deep notches were described in none of the controls, but in only",
"      <span class=\"nowrap\">",
"       2/192",
"      </span>",
"      girls with a history of penetration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/38\">",
"       38",
"      </a>",
"      ]. However, deep notches may be an artifact of examination technique and it is difficult to distinguish between superficial and deep notches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A thin posterior hymenal rim may also be indicative of penetrating trauma, but accurate measurement of the hymenal rim is difficult [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/5,28\">",
"       5,28",
"      </a>",
"      ]. Studies have demonstrated inconsistent results. The finding was absent in several studies of girls chosen who were not abused [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/42,79,80\">",
"       42,79,80",
"      </a>",
"      ]. However, in a series of similar girls who also had not been abused, 22 percent had a posterior rim estimated to be &lt;1 to 2 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A wide hymenal orifice may be a normal finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/42\">",
"       42",
"      </a>",
"      ]. In a large cohort of girls 3 to 12 years of age being evaluated for sexual abuse, transverse diameter of the hymenal ring did not correlate with sexual abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lesions that appear to be genital warts may be skin tags, nongenital warts, or genital warts acquired by perinatal or nonsexual transmission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,90,91\">",
"       3,90,91",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'STIs'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Vesicular lesions or ulcers in the anogenital area may be caused by STIs (such as syphilis or HSV) as well as other viruses (including Epstein-Barr virus), Behcet's disease, Crohn's disease, and others (",
"      <a class=\"graphic graphic_table graphicRef78867 graphicRef57033 \" href=\"mobipreview.htm?4/41/4766\">",
"       table 2A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,90,91\">",
"       3,90,91",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'STIs'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Marked, immediate anal dilation to a diameter of 2 cm or more, in the absence of other predisposing factors such as chronic constipation, sedation, anesthesia, or neuromuscular conditions may be indicative of sexual abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/46,82,92\">",
"       46,82,92",
"      </a>",
"      ]. However, there is no clear consensus among experts regarding the significance of this finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history is critical in determining the overall significance of suspicious or indeterminant findings. In the absence of a history of abuse, children with these findings require further investigation (eg, diagnostic studies or careful questioning of the child). Consultation with a child abuse specialist may be helpful. Reporting to Child Protective Services (CPS) should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28,93\">",
"     28,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Specific findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination findings that are diagnostic of genital trauma, and in the absence of a clear, timely, plausible history of accidental injury should be reported to CPS, are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef64069 \" href=\"mobipreview.htm?9/32/9740\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings that are diagnostic for sexual abuse include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy in the absence of consensual intercourse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Identification of sperm, semen, semen-specific antigens (eg, prostate-specific protein p30), or enzymes (eg, acid phosphatase) in or on a child's body [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     STIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The significance of the identification of a sexually transmissible pathogen in the evaluation for childhood sexual abuse varies according to the pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/56\">",
"     56",
"    </a>",
"    ]. STIs that are specific for sexual contact in prepubertal children and should be reported to CPS include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,28,56,90,93,94\">",
"     3,28,56,90,93,94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postnatally acquired gonorrhea",
"     </li>",
"     <li>",
"      Postnatally acquired syphilis",
"     </li>",
"     <li>",
"      Human immunodeficiency virus infection that is not acquired perinatally or iatrogenically",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    STIs that are less specific for childhood sexual abuse, either because there are other modes of acquisition or because perinatal infection may remain asymptomatic, but nonetheless should be reported to CPS, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,94\">",
"     3,94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Herpes simplex virus",
"     </li>",
"     <li>",
"      Genital warts",
"     </li>",
"     <li>",
"      Chlamydia infection",
"     </li>",
"     <li>",
"      Trichomonas vaginalis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited observational evidence suggests that children can acquire herpes simplex virus (HSV) through nonabusive contact (such as diaper changing or autoinoculation) or through sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/96\">",
"     96",
"    </a>",
"    ]. Sexual transmission may be more likely for children &ge;5 years of age, for those with only genital lesions, and when HSV type 2 is isolated from lesions. Genital herpes caused by HSV type 1 can be acquired through sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/97\">",
"     97",
"    </a>",
"    ]. Consequently, the type of HSV isolated from a genital lesion may not be sufficient to establish whether or not the infection was transmitted through abusive contact. Nevertheless, new herpetic lesions in children who are beyond infancy and have independent toilet habits are suspicious for abuse and should be reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genital warts (condyloma acuminata) are caused by human papillomavirus (HPV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/98\">",
"     98",
"    </a>",
"    ]. The virus may be transmitted both sexually and nonsexually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/99\">",
"     99",
"    </a>",
"    ]. In young children, these lesions can develop as the result of sexual contact or via nonabusive contact with common warts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/100\">",
"     100",
"    </a>",
"    ]. Infants may acquire HPV perinatally from infected mothers. In a prospective study of vertical transmission of HPV, the maximum likelihood of transmission was only 2.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/101\">",
"     101",
"    </a>",
"    ]. Perinatally acquired condyloma acuminata may present any time before 20 months of age. Examination of the mother via colposcopy may be helpful in determining the etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/100\">",
"     100",
"    </a>",
"    ]. Sexual abuse should be considered in children who develop genital warts after the age of approximately two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,21,90\">",
"     3,21,90",
"    </a>",
"    ]. A study designed to delineate the clinical characteristics of pediatric patients with anogenital warts concluded that the modes of transmission of anogenital warts in children cannot be identified either by the clinical appearance of the lesions or by human papillomavirus typing, thus highlighting the importance of the clinical history and exam along with the social context of the family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chlamydial infection of the vagina, urethra, or rectum that occurs after infancy is suggestive of abuse, although infection acquired at birth can remain asymptomatic until as late as three years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/103\">",
"     103",
"    </a>",
"    ]. Sexual contact is likely if chlamydia is cultured from anal or genital tissues of a child who is older than three years via cell culture or comparable method approved by the CDC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,28,90\">",
"     3,28,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trichomonas vaginalis can occur in newborns, but is rare in the prepubertal child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Sexual contact is likely in a child older than one year of age if trichomonal organisms are identified (by an experienced technician or clinician) in vaginal secretions by wet mount examination or culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3,28,90\">",
"     3,28,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatitis B infection, bacterial vaginosis, scabies, and pediculosis pubis may be transmitted sexually; however, transmission occurs by other modes. The decision to involve CPS when these organisms are detected depends upon the complaint or level of suspicion of abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Misdiagnosis of sexual abuse can be traumatic for everyone involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, the differential diagnosis of sexual abuse must be carefully considered in all children, particularly those who present with nonspecific genitourinary complaints or behavioral disturbances and do not volunteer a history of abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of child sexual abuse includes other types of genital injury, infection, dermatologic conditions, congenital conditions affecting the perineum, and other conditions affecting the urethra or anus (",
"    <a class=\"graphic graphic_table graphicRef78867 graphicRef57033 \" href=\"mobipreview.htm?4/41/4766\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unintentional injuries of the perineum include straddle injuries, zipper entrapment, hair tourniquet, and seat belt or motor vehicle accident injury to the genitalia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,27,106\">",
"     13,27,106",
"    </a>",
"    ]. The history in these unintentional injuries is usually readily available.",
"   </p>",
"   <p>",
"    Straddle injuries typically involve the anterior structures, such as the clitoris, clitoral hood, mons pubis, and labial structures, and even posterior fourchette. Penetrating sexual abuse usually results in injury to the hymen and other more posteriorly located structures such as the posterior fourchette and fossa navicularis (",
"    <a class=\"graphic graphic_figure graphicRef62557 \" href=\"mobipreview.htm?26/23/26995\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"     13",
"    </a>",
"    ]. However, accidental penetrating straddle injuries have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35669?source=see_link\">",
"     \"Straddle injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other nonsexual mechanisms of injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zipper entrapment injuries and hair tourniquet injuries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30100?source=see_link\">",
"       \"Management of zipper injuries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/47/13044?source=see_link\">",
"       \"Hair entrapment removal techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vaginal foreign bodies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link&amp;anchor=H13#H13\">",
"       \"Vulvovaginal complaints in the prepubertal child\", section on 'Foreign body'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In girls of African or Middle Eastern descent, female circumcision in infancy or childhood can cause bleeding and unusual genital adhesions and scars [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/108\">",
"       108",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34133?source=see_link\">",
"       \"Female genital cutting (circumcision)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infestations that cause inflammation and erythema of the perineum include streptococcal vaginitis, candidal infections, varicella, pinworms, and perianal cellulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,27,109,110\">",
"     13,27,109,110",
"    </a>",
"    ]. Autoinoculation of common warts or molluscum contagiosum can mimic warts caused by human papilloma virus (condyloma acuminatum) (",
"    <a class=\"graphic graphic_picture graphicRef56924 \" href=\"mobipreview.htm?11/7/11376\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55494 \" href=\"mobipreview.htm?17/24/17794\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link&amp;anchor=H2#H2\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Nonspecific vulvovaginitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Skin conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following dermatologic conditions may cause ulcers, erythema, friability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding of the perineum and should be considered in the differential diagnosis of sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,27,73,111\">",
"     13,27,73,111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonspecific vulvovaginitis (poor hygiene, bubble bath)",
"     </li>",
"     <li>",
"      Seborrheic, atopic, or contact dermatitis (including diaper dermatitis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=see_link\">",
"       \"Overview of diaper dermatitis in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lichen sclerosus, lichen simplex chronicus, or lichen planus (",
"      <a class=\"graphic graphic_picture graphicRef55275 \" href=\"mobipreview.htm?6/33/6687\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69453 \" href=\"mobipreview.htm?19/11/19634\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62561 graphicRef60224 \" href=\"mobipreview.htm?17/27/17849\">",
"       picture 7A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psoriasis (",
"      <a class=\"graphic graphic_picture graphicRef56110 \" href=\"mobipreview.htm?32/48/33540\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bullous pemphigoid",
"     </li>",
"     <li>",
"      Behcet's disease (",
"      <a class=\"graphic graphic_picture graphicRef81014 \" href=\"mobipreview.htm?31/47/32497\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Perineal hemangiomas (of the labia, hymen, perihymenal area, or urethra)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mongolian spots can look like bruises (",
"    <a class=\"graphic graphic_picture graphicRef77805 \" href=\"mobipreview.htm?29/11/29875\">",
"     picture 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link\">",
"     \"Vulvovaginal complaints in the prepubertal child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Anal conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal conditions that may be associated with perianal bleeding or bruising and should be considered in the differential diagnosis of sexual abuse include hemorrhoids (",
"    <a class=\"graphic graphic_picture graphicRef75759 graphicRef72916 \" href=\"mobipreview.htm?22/31/23028\">",
"     picture 2A-B",
"    </a>",
"    ), Crohn's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/112\">",
"     112",
"    </a>",
"    ], rectal prolapse (which can be caused by medical conditions as well as sexual abuse) (",
"    <a class=\"graphic graphic_picture graphicRef75568 \" href=\"mobipreview.htm?6/0/6159\">",
"     picture 11",
"    </a>",
"    ), hemolytic uremic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/113\">",
"     113",
"    </a>",
"    ], and rectal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13,27\">",
"     13,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/48/32519?source=see_link\">",
"     \"Overview of rectal prolapse in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perianal erythema may also be seen as a result of encopresis, poor hygiene, pinworm infection, and Group A streptococcal or staphylococcal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44182?source=see_link\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laxity of the anus may represent abuse, but also can be seen with chronic constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/46,92\">",
"     46,92",
"    </a>",
"    ], neurologic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/27\">",
"     27",
"    </a>",
"    ], and diastasis ani (a normal variant in which there is a slight opening of the visible portion of the anus when the buttocks are spread) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/27/35258/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Urethral conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral conditions to be considered in the differential diagnosis of sexual abuse include urethral prolapse, caruncle, sarcoma botryoides, and ureterocele.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial or complete prolapse of the distal urethra may occur in preadolescent girls. Urethral prolapse appears as an edematous, violaceous, nontender, doughnut-shaped mass surrounding the urethral meatus; bleeding may be the presenting complaint. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link&amp;anchor=H19#H19\">",
"       \"Vulvovaginal complaints in the prepubertal child\", section on 'Urethral prolapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoma botryoides is a unique form of embryonal rhabdomyosarcoma that arises within the wall of the bladder or vagina and is seen almost exclusively in infants. It presents as soft nodules that fill and sometimes protrude from the vagina, resembling a bunch of grapes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An ureterocele is a cystic dilatation of the terminal ureter within the bladder",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the urethra; a prolapsed ectopic ureterocele may protrude through the urethral meatus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41093?source=see_link\">",
"       \"Ureterocele\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A caruncle is a small, red, papillary growth, highly vascular, sometimes found in the urinary meatus in females; it is sensitive to friction and characterized by pain on urination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some communities have a child advocacy center that provides expertise in the evaluation and treatment of sexual abuse victims and the prosecution of sexual abuse perpetrators. These centers may provide social services, law enforcement agencies, legal services, and medical evaluation, and may be a resource for consultation. Local advocacy centers can be identified on the National Children's Alliance website (",
"    <a class=\"external\" href=\"file://www.nca-online.org/\">",
"     www.nca-online.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional resources that may be helpful in the evaluation and management of suspected child abuse are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef57326 graphicRef69110 \" href=\"mobipreview.htm?12/7/12414\">",
"     table 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who may have been victims of sexual abuse should receive a thorough evaluation that includes careful questioning and a complete physical examination. In some situations, evidence-collection procedures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specialized examination techniques may be required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A generally accepted definition of sexual abuse is when a child engages in sexual activity for which",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      cannot give consent, is unprepared for developmentally, cannot comprehend,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an activity that violates the law or social taboos of society. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexual abuse occurs primarily in preadolescent children, more often in girls. Perpetrators are usually males who are known to the victims. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the complaints that are possible indicators of sexual abuse are nonspecific (",
"      <a class=\"graphic graphic_table graphicRef65874 \" href=\"mobipreview.htm?7/20/7501\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The evaluation of children who may have been sexually abused requires careful questioning and a complete physical examination. Such evaluations are best performed in a non-emergent setting, such as a child abuse assessment center, where the history and physical examination can be performed in a calm, quiet environment and proceed at a pace tailored to the victim&rsquo;s needs. Victims who present within 72 hours of the incident, have obvious forensic evidence on their clothes or bodies, have continued risk of harm from the perpetrator, have genital or anal injuries, or other emergent complaints (eg, suicidal ideation) should receive an urgent evaluation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Forensic evidence (usually as a rape kit) should generally be collected from children who are evaluated within 24 hours of the incident in the following situations (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Forensic evidence collection'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There is reasonable concern that a sexual abuse has occurred.",
"     </li>",
"     <li>",
"      The child has a genital injury as the result of alleged sexual abuse.",
"     </li>",
"     <li>",
"      Clothing or linen associated with the abuse is available.",
"     </li>",
"     <li>",
"      There are other concerning clinical features.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For prepubertal children who are evaluated more than 24 hours after the incident, state protocols should be followed recognizing that the yield in evidence collection often decreases after 24 hours. The management of adolescents should generally be according to adult protocols. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Forensic evidence collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that prepubertal girls who are likely to have been sexually abused based on history or physical examination be tested for sexually transmitted infections. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'STI testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adolescent girls who have been sexually abused, we suggest that testing for STI be made on a case by case basis, but that these patients should receive antibiotic prophylaxis regardless of whether testing is completed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Postpubertal victims'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated examination or laboratory findings are rarely diagnostic, but when combined with a disclosure of sexual abuse, specific behavioral changes,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the lack of another plausible explanation, may be consistent with sexual abuse. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Interpretation of findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of child sexual abuse includes other types of genital injury, infection, dermatologic conditions, congenital conditions affecting the perineum, and other conditions affecting the urethra or anus (",
"      <a class=\"graphic graphic_table graphicRef78867 graphicRef57033 \" href=\"mobipreview.htm?4/41/4766\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sexual assault. The National Center for Victims of Crime. Washington, DC. www.ncvc.org/ncvc/main.aspx?dbName=DocumentViewer&amp;DocumentID=32369#1 (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/2\">",
"      Kempe CH. Sexual abuse, another hidden pediatric problem: the 1977 C. Anderson Aldrich lecture. Pediatrics 1978; 62:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/3\">",
"      Kellogg N, American Academy of Pediatrics Committee on Child Abuse and Neglect. The evaluation of sexual abuse in children. Pediatrics 2005; 116:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/4\">",
"      Practice parameters for the forensic evaluation of children and adolescents who may have been physically or sexually abused. AACAP Official Action. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997; 36:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/5\">",
"      Johnson CF. Child sexual abuse. Lancet 2004; 364:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/6\">",
"      Kini N, Lazoritz S. Evaluation for possible physical or sexual abuse. Pediatr Clin North Am 1998; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     Administration for Children &amp; Families. Child Maltreatment 2010. Annual Report. US Government Printing Office; Department of Health and Human Services, Washington, DC 2010. Available from file://www.acf.hhs.gov/programs/cb/pubs/cm10/cm10.pdf (Accessed on April 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/8\">",
"      Gilbert R, Widom CS, Browne K, et al. Burden and consequences of child maltreatment in high-income countries. Lancet 2009; 373:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/9\">",
"      Bechtel K, Podrazik M. Evaluation of the adolescent rape victim. Pediatr Clin North Am 1999; 46:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/10\">",
"      Greydanus DE, Shaw RD, Kennedy EL. Examination of sexually abused adolescents. Semin Adolesc Med 1987; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/11\">",
"      Poirier MP. Care of the female adolescent rape victim. Pediatr Emerg Care 2002; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/12\">",
"      Moody CW. Male child sexual abuse. J Pediatr Health Care 1999; 13:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/13\">",
"      Hymel KP, Jenny C. Child sexual abuse. Pediatr Rev 1996; 17:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/14\">",
"      Finkelhor D. Epidemiological factors in the clinical identification of child sexual abuse. Child Abuse Negl 1993; 17:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/15\">",
"      Lahoti SL, McClain N, Girardet R, et al. Evaluating the child for sexual abuse. Am Fam Physician 2001; 63:883.",
"     </a>",
"    </li>",
"    <li>",
"     Administration on Children, Youth, and Families: 11 years of reporting: child maltreatment 2000. US Government Printing Office; US Department of Health and Human Services, Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/17\">",
"      Elliott M, Browne K, Kilcoyne J. Child sexual abuse prevention: what offenders tell us. Child Abuse Negl 1995; 19:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/18\">",
"      Friedrich WN, Fisher JL, Dittner CA, et al. Child Sexual Behavior Inventory: normative, psychiatric, and sexual abuse comparisons. Child Maltreat 2001; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/19\">",
"      Friedrich WN, Fisher J, Broughton D, et al. Normative sexual behavior in children: a contemporary sample. Pediatrics 1998; 101:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/20\">",
"      Heger A, Ticson L, Velasquez O, Bernier R. Children referred for possible sexual abuse: medical findings in 2384 children. Child Abuse Negl 2002; 26:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/21\">",
"      Atabaki S, Paradise JE. The medical evaluation of the sexually abused child: lessons from a decade of research. Pediatrics 1999; 104:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/22\">",
"      Girardet R, Giacobbe L, Bolton K, et al. Unmet health care needs among children evaluated for sexual assault. Arch Pediatr Adolesc Med 2006; 160:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/23\">",
"      Floyed RL, Hirsh DA, Greenbaum VJ, Simon HK. Development of a screening tool for pediatric sexual assault may reduce emergency-department visits. Pediatrics 2011; 128:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/24\">",
"      Lamb ME. The investigation of child sexual abuse: an interdisciplinary consensus statement. Child Abuse Negl 1994; 18:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/25\">",
"      De Jong AR, Rose M. Legal proof of child sexual abuse in the absence of physical evidence. Pediatrics 1991; 88:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/26\">",
"      Hanes M, McAuliff T. Preparation for child abuse litigation: perspectives of the prosecutor and the pediatrician. Pediatr Ann 1997; 26:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/27\">",
"      Bays J, Jenny C. Genital and anal conditions confused with child sexual abuse trauma. Am J Dis Child 1990; 144:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/28\">",
"      Adams JA. Medical evaluation of suspected child sexual abuse. J Pediatr Adolesc Gynecol 2004; 17:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/29\">",
"      Bays J, Chadwick D. Medical diagnosis of the sexually abused child. Child Abuse Negl 1993; 17:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/30\">",
"      Muram D, Elias S. Child sexual abuse--genital tract findings in prepubertal girls. II. Comparison of colposcopic and unaided examinations. Am J Obstet Gynecol 1989; 160:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/31\">",
"      Santucci KA, Nelson DG, McQuillen KK, et al. Wood's lamp utility in the identification of semen. Pediatrics 1999; 104:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/32\">",
"      Gabby T, Winkleby MA, Boyce WT, et al. Sexual abuse of children. The detection of semen on skin. Am J Dis Child 1992; 146:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/33\">",
"      Adams JA. Evaluating children for possible sexual abuse. Am Fam Physician 2001; 63:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/34\">",
"      Berkoff MC, Zolotor AJ, Makoroff KL, et al. Has this prepubertal girl been sexually abused? JAMA 2008; 300:2779.",
"     </a>",
"    </li>",
"    <li>",
"     Osterhoudt KC, Burns Ewald M, Shannon M, Henretig FM. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.951.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/36\">",
"      Berenson AB. A longitudinal study of hymenal morphology in the first 3 years of life. Pediatrics 1995; 95:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/37\">",
"      Berenson AB. Normal anogenital anatomy. Child Abuse Negl 1998; 22:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/38\">",
"      Berenson AB, Chacko MR, Wiemann CM, et al. A case-control study of anatomic changes resulting from sexual abuse. Am J Obstet Gynecol 2000; 182:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/39\">",
"      Kellogg ND, Menard SW, Santos A. Genital anatomy in pregnant adolescents: \"normal\" does not mean \"nothing happened\". Pediatrics 2004; 113:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/40\">",
"      Adams JA, Botash AS, Kellogg N. Differences in hymenal morphology between adolescent girls with and without a history of consensual sexual intercourse. Arch Pediatr Adolesc Med 2004; 158:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/41\">",
"      Anderst J, Kellogg N, Jung I. Reports of repetitive penile-genital penetration often have no definitive evidence of penetration. Pediatrics 2009; 124:e403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/42\">",
"      Myhre AK, Berntzen K, Bratlid D. Genital anatomy in non-abused preschool girls. Acta Paediatr 2003; 92:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/43\">",
"      Goff CW, Burke KR, Rickenback C, Buebendorf DP. Vaginal opening measurement in prepubertal girls. Am J Dis Child 1989; 143:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/44\">",
"      Hobbs CJ, Osman J. Genital injuries in boys and abuse. Arch Dis Child 2007; 92:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/45\">",
"      Kadish HA, Schunk JE, Britton H. Pediatric male rectal and genital trauma: accidental and nonaccidental injuries. Pediatr Emerg Care 1998; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/46\">",
"      Hobbs CJ, Wynne JM. Sexual abuse of English boys and girls: the importance of anal examination. Child Abuse Negl 1989; 13:195.",
"     </a>",
"    </li>",
"    <li>",
"     A national protocol for sexual assault medical forensic evaluations adults/adolescents. US Department of Justice, Office of Violence Against Women. September 2004, NCJ 206554. Available at www.ncjrs.org/pdffiles1/ovw/206554.pdf (Accessed December 13, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/48\">",
"      Christian CW, Lavelle JM, De Jong AR, et al. Forensic evidence findings in prepubertal victims of sexual assault. Pediatrics 2000; 106:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/49\">",
"      Palusci VJ, Cox EO, Shatz EM, Schultze JM. Urgent medical assessment after child sexual abuse. Child Abuse Negl 2006; 30:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/50\">",
"      Young KL, Jones JG, Worthington T, et al. Forensic laboratory evidence in sexually abused children and adolescents. Arch Pediatr Adolesc Med 2006; 160:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/51\">",
"      Adams JA. Guidelines for medical care of children evaluated for suspected sexual abuse: an update for 2008. Curr Opin Obstet Gynecol 2008; 20:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/52\">",
"      Dubowitz H. Healing of hymenal injuries: implications for child health care professionals. Pediatrics 2007; 119:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/53\">",
"      Thackeray JD, Hornor G, Benzinger EA, Scribano PV. Forensic evidence collection and DNA identification in acute child sexual assault. Pediatrics 2011; 128:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/54\">",
"      Girardet R, Bolton K, Lahoti S, et al. Collection of forensic evidence from pediatric victims of sexual assault. Pediatrics 2011; 128:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/55\">",
"      Hampton HL. Care of the woman who has been raped. N Engl J Med 1995; 332:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/56\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/57\">",
"      Siegel RM, Schubert CJ, Myers PA, Shapiro RA. The prevalence of sexually transmitted diseases in children and adolescents evaluated for sexual abuse in Cincinnati: rationale for limited STD testing in prepubertal girls. Pediatrics 1995; 96:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/58\">",
"      Robinson AJ, Watkeys JE, Ridgway GL. Sexually transmitted organisms in sexually abused children. Arch Dis Child 1998; 79:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/59\">",
"      Ingram DL, Everett VD, Lyna PR, et al. Epidemiology of adult sexually transmitted disease agents in children being evaluated for sexual abuse. Pediatr Infect Dis J 1992; 11:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/60\">",
"      de Villiers FP, Prentice MA, Bergh AM, Miller SD. Sexually transmitted disease surveillance in a child abuse clinic. S Afr Med J 1992; 81:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/61\">",
"      Girardet RG, Lahoti S, Howard LA, et al. Epidemiology of sexually transmitted infections in suspected child victims of sexual assault. Pediatrics 2009; 124:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/62\">",
"      Simmons KJ, Hicks DJ. Child sexual abuse examination: is there a need for routine screening for N gonorrhoeae and C trachomatis? J Pediatr Adolesc Gynecol 2005; 18:343.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Sexually transmitted diseases in adolescents and children. In: Red Book 2006: The Report of the Committee on Infectious Diseases, 27th ed, Pickering, LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2006. p.166.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/64\">",
"      Argent AC, Lachman PI, Hanslo D, Bass D. Sexually transmitted diseases in children and evidence of sexual abuse. Child Abuse Negl 1995; 19:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/65\">",
"      Ingram DM, Miller WC, Schoenbach VJ, et al. Risk assessment for gonococcal and chlamydial infections in young children undergoing evaluation for sexual abuse. Pediatrics 2001; 107:E73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/66\">",
"      Ingram DL, Everett VD, Flick LA, et al. Vaginal gonococcal cultures in sexual abuse evaluations: evaluation of selective criteria for preteenaged girls. Pediatrics 1997; 99:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/67\">",
"      Muram D, Speck PM, Gold SS. Genital abnormalities in female siblings and friends of child victims of sexual abuse. Child Abuse Negl 1991; 15:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/68\">",
"      Hammerschlag MR, Ajl S, Laraque D. Inappropriate use of nonculture tests for the detection of Chlamydia trachomatis in suspected victims of child sexual abuse: A continuing problem. Pediatrics 1999; 104:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/69\">",
"      Hammerschlag MR. Appropriate use of nonculture tests for the detection of sexually transmitted diseases in children and adolescents. Semin Pediatr Infect Dis 2003; 14:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/70\">",
"      Black CM, Driebe EM, Howard LA, et al. Multicenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated for sexual abuse. Pediatr Infect Dis J 2009; 28:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/71\">",
"      Hammerschlag MR. The transmissibility of sexually transmitted diseases in sexually abused children. Child Abuse Negl 1998; 22:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/72\">",
"      Ramos S, Lukefahr JL, Morrow RA, et al. Prevalence of herpes simplex virus types 1 and 2 among children and adolescents attending a sexual abuse clinic. Pediatr Infect Dis J 2006; 25:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/73\">",
"      Adams JA. Evolution of a classification scale: medical evaluation of suspected child sexual abuse. Child Maltreat 2001; 6:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/74\">",
"      McCann J, Voris J. Perianal injuries resulting from sexual abuse: a longitudinal study. Pediatrics 1993; 91:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/75\">",
"      Heppenstall-Heger A, McConnell G, Ticson L, et al. Healing patterns in anogenital injuries: a longitudinal study of injuries associated with sexual abuse, accidental injuries, or genital surgery in the preadolescent child. Pediatrics 2003; 112:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/76\">",
"      McCann J, Miyamoto S, Boyle C, Rogers K. Healing of hymenal injuries in prepubertal and adolescent girls: a descriptive study. Pediatrics 2007; 119:e1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/77\">",
"      McCann J, Miyamoto S, Boyle C, Rogers K. Healing of nonhymenal genital injuries in prepubertal and adolescent girls: a descriptive study. Pediatrics 2007; 120:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/78\">",
"      Pillai M. Genital findings in prepubertal girls: what can be concluded from an examination? J Pediatr Adolesc Gynecol 2008; 21:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/79\">",
"      Berenson AB, Heger AH, Hayes JM, et al. Appearance of the hymen in prepubertal girls. Pediatrics 1992; 89:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/80\">",
"      McCann J, Wells R, Simon M, Voris J. Genital findings in prepubertal girls selected for nonabuse: a descriptive study. Pediatrics 1990; 86:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/81\">",
"      Berenson AB, Somma-Garcia A, Barnett S. Perianal findings in infants 18 months of age or younger. Pediatrics 1993; 91:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/82\">",
"      McCann J, Voris J, Simon M, Wells R. Perianal findings in prepubertal children selected for nonabuse: a descriptive study. Child Abuse Negl 1989; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/83\">",
"      Berenson AB. Appearance of the hymen at birth and one year of age: a longitudinal study. Pediatrics 1993; 91:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/84\">",
"      Berenson A, Heger A, Andrews S. Appearance of the hymen in newborns. Pediatrics 1991; 87:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/85\">",
"      Myhre AK, Bemtzen K, Bratlid D. Perianal anatomy in non-abused preschool children. Acta Paediatr 2001; 90:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/86\">",
"      Gardner JJ. Descriptive study of genital variation in healthy, nonabused premenarchal girls. J Pediatr 1992; 120:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/87\">",
"      Heger AH, Ticson L, Guerra L, et al. Appearance of the genitalia in girls selected for nonabuse: review of hymenal morphology and nonspecific findings. J Pediatr Adolesc Gynecol 2002; 15:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/88\">",
"      Hobbs CJ, Wynne JM, Thomas AJ. Colposcopic genital findings in prepubertal girls assessed for sexual abuse. Arch Dis Child 1995; 73:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/89\">",
"      Ingram DM, Everett VD, Ingram DL. The relationship between the transverse hymenal orifice diameter by the separation technique and other possible markers of sexual abuse. Child Abuse Negl 2001; 25:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/90\">",
"      Hammerschlag MR. Sexually transmitted diseases in sexually abused children: medical and legal implications. Sex Transm Infect 1998; 74:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/91\">",
"      Siegfried EC, Frasier LD. Anogenital skin diseases of childhood. Pediatr Ann 1997; 26:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/92\">",
"      Clayden GS. Reflex anal dilatation associated with severe chronic constipation in children. Arch Dis Child 1988; 63:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/93\">",
"      Saperia J, Lakhanpaul M, Kemp A, et al. When to suspect child maltreatment: summary of NICE guidance. BMJ 2009; 339:b2689.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. When to suspect child maltreatment. July 2009. Available at file://www.nice.org.uk/CG89 (Accessed on September 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/95\">",
"      Jones JG, Worthington T. Genital and anal injuries requiring surgical repair in females less than 21 years of age. J Pediatr Adolesc Gynecol 2008; 21:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/96\">",
"      Reading R, Rannan-Eliya Y. Evidence for sexual transmission of genital herpes in children. Arch Dis Child 2007; 92:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/97\">",
"      Wald A. Genital HSV-1 infections. Sex Transm Infect 2006; 82:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/98\">",
"      De Jong AR, Weiss JC, Brent RL. Condyloma acuminata in children. Am J Dis Child 1982; 136:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/99\">",
"      Tay SK, Ho TH, Lim-Tan SK. Is genital human papillomavirus infection always sexually transmitted? Aust N Z J Obstet Gynaecol 1990; 30:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/100\">",
"      Hyden PW, Gallagher TA. Child abuse intervention in the emergency room. Pediatr Clin North Am 1992; 39:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/101\">",
"      Watts DH, Koutsky LA, Holmes KK, et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 1998; 178:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/102\">",
"      Marcoux D, Nadeau K, McCuaig C, et al. Pediatric anogenital warts: a 7-year review of children referred to a tertiary-care hospital in Montreal, Canada. Pediatr Dermatol 2006; 23:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/103\">",
"      Bell TA, Stamm WE, Wang SP, et al. Chronic Chlamydia trachomatis infections in infants. JAMA 1992; 267:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/104\">",
"      Ross JD, Scott GR, Busuttil A. Trichomonas vaginalis infection in pre-pubertal girls. Med Sci Law 1993; 33:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/105\">",
"      Jones JG, Yamauchi T, Lambert B. Trichomonas vaginalis infestation in sexually abused girls. Am J Dis Child 1985; 139:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/106\">",
"      Baker RB. Seat belt injury masquerading as sexual abuse. Pediatrics 1986; 77:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/107\">",
"      Dowd MD, Fitzmaurice L, Knapp JF, Mooney D. The interpretation of urogenital findings in children with straddle injuries. J Pediatr Surg 1994; 29:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/108\">",
"      Diejomaoh FM, Faal MK. Adhesion of the labia minora complicating circumcision in the neonatal period in a Nigerian community. Trop Geogr Med 1981; 33:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/109\">",
"      Boyd M, Jordan SW. Unusual presentation of varicella suggestive of sexual abuse. Am J Dis Child 1987; 141:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/110\">",
"      Spear RM, Rothbaum RJ, Keating JP, et al. Perianal streptococcal cellulitis. J Pediatr 1985; 107:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/111\">",
"      Williams TS, Callen JP, Owen LG. Vulvar disorders in the prepubertal female. Pediatr Ann 1986; 15:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/112\">",
"      Hey F, Buchan PC, Littlewood JM, Hall RI. Differential diagnosis in child sexual abuse. Lancet 1987; 1:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/27/35258/abstract/113\">",
"      Vickers D, Morris K, Coulthard MG, Eastham EJ. Anal signs in haemolytic uraemic syndrome. Lancet 1988; 1:998.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6605 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.137.129.113-48EA216BE4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35258=[""].join("\n");
var outline_f34_27_35258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Caregiver history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Patient interview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oral cavity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Female genitalia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Male genitalia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Perianal area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Forensic evidence collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      STI testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prepubertal victims",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Postpubertal victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INTERPRETATION OF FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Normal physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Abnormal physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Nonspecific findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Suspicious findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Specific findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - STIs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Skin conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Anal conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Urethral conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6605|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/23/26995\" title=\"figure 1\">",
"      Anatomy female genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/5/33887\" title=\"figure 2\">",
"      Knee chest examination position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/46/3808\" title=\"figure 3\">",
"      Normal hymens in prepubertal girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/20/8514\" title=\"figure 4\">",
"      Hymen anatomic variations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6605|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/32/44546\" title=\"picture 1\">",
"      Anatomy male genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/27/36272\" title=\"picture 2A\">",
"      Prolapsed internal hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/30/14831\" title=\"picture 2B\">",
"      Thrombosed external hemorrhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/7/11376\" title=\"picture 3\">",
"      Verruca vulgaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/24/17794\" title=\"picture 4\">",
"      Anal condyloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/33/6687\" title=\"picture 5\">",
"      Lichen sclerosus child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/11/19634\" title=\"picture 6\">",
"      Lichen simplex chronicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/51/13110\" title=\"picture 7A\">",
"      Hypertrophic lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/37/40530\" title=\"picture 7B\">",
"      Erosive lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/48/33540\" title=\"picture 8\">",
"      Vulvar psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/47/32497\" title=\"picture 9\">",
"      Vasculitic ulcers in Behcets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/11/29875\" title=\"picture 10\">",
"      Mongolian spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/0/6159\" title=\"picture 11\">",
"      Complete rectal prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/20/7501\" title=\"table 1\">",
"      Clinical findings associated with sexual abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/42/4781\" title=\"table 2A\">",
"      Differential diagnosis of physical findings sexual abuse 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/36/34380\" title=\"table 2B\">",
"      Differential diagnosis of physical findings sexual abuse 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/17/3356\" title=\"table 3\">",
"      Normal anogenital variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/32/9740\" title=\"table 4\">",
"      Specific anogential findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/20/4429\" title=\"table 5A\">",
"      Child abuse neglect resources A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/25/1437\" title=\"table 5B\">",
"      Child abuse neglect resources B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44182?source=related_link\">",
"      Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34133?source=related_link\">",
"      Female genital cutting (circumcision)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/47/13044?source=related_link\">",
"      Hair entrapment removal techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11510?source=related_link\">",
"      Management and sequelae of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30100?source=related_link\">",
"      Management of zipper injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/48/32519?source=related_link\">",
"      Overview of rectal prolapse in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35669?source=related_link\">",
"      Straddle injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41093?source=related_link\">",
"      Ureterocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_27_35259="Echinacea quality criteria";
var content_f34_27_35259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of Echinacea products meeting specified quality criteria*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Product name (manufacturer or distributor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gaia Herbs Echinacea Supreme&reg; (Gaia Herbs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GNC Herbal Plus Standardized Echinacea Extract&reg; (GNC Corp.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rite Aid Echinacea&reg; (Rite Aid Corp.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solgar Echinacea Herb Extract&reg; (Solgar Vitamin and Herb)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin World&reg; Echinacea (Vitamin World, Inc.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Full report available at",
"    <a href=\"file://www.consumerlabs.com\" target=\"_blank\">",
"     www.consumerlabs.com",
"    </a>",
"    .",
"    <div class=\"footnotes\">",
"     * To pass testing, products had to meet all of the following criteria:",
"     <br>",
"      <ol>",
"       <li>",
"        Absence of E. coli, Salmonella spp., Staphylococcus aureus, and Pseudomonas aeruginosa.",
"       </li>",
"       <li>",
"        Less than 10(5) aerobic bacteria, 10(3) yeast/mold, and 10(3) other coliform bacteria per gram.",
"       </li>",
"       <li>",
"        Meets the State of California's Prop 65 limits for lead in supplements.",
"       </li>",
"       <li>",
"        Contains &lt;0.3 mcg/gram (parts per million) of cadmium for dried herb or &lt;0.1 mcg/gram for extracts.",
"       </li>",
"       <li>",
"        Contains &lt;10 mcg of arsenic per daily serving.",
"       </li>",
"       <li>",
"        Concentration of any detectable chlorinated pesticide residue(s) must be less than the individual limit(s) listed by the USP.",
"       </li>",
"       <li>",
"        Meets recommended USP parameters for disintegration for dietary supplements.",
"       </li>",
"       <li>",
"        Meets all FDA labeling requirements.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35259=[""].join("\n");
var outline_f34_27_35259=null;
var title_f34_27_35260="Influenza symptoms PI";
var content_f34_27_35260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Is it a cold or the flu?",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cold",
"       </td>",
"       <td class=\"subtitle1\">",
"        Flu",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Usual; high (100&deg;F to 102&deg;F; occasionally higher, especially in young children); lasts 3 to 4 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Headache",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        General aches, pains",
"       </td>",
"       <td>",
"        Slight",
"       </td>",
"       <td>",
"        Usual; often severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fatigue, weakness",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Usual; can last up to 2 to 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extreme exhaustion",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"       <td>",
"        Usual; at the beginning of the illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stuffy nose",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sneezing",
"       </td>",
"       <td>",
"        Usual",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sore throat",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Chest discomfort, cough",
"       </td>",
"       <td>",
"        Mild to moderate; hacking cough",
"       </td>",
"       <td>",
"        Common; can become severe",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Antihistamines",
"        </p>",
"        <p>",
"         Decongestant",
"        </p>",
"        Pain/fever reliever (eg, ibuprofen/Motrin&reg;), naproxen/Aleve&reg;, acetaminophen/Tylenol&reg;",
"       </td>",
"       <td>",
"        <p>",
"         Antiviral medicines - see your doctor",
"        </p>",
"        Pain/fever reliever (eg, ibuprofen/Motrin&reg;), naproxen/Aleve&reg;, acetaminophen/Tylenol&reg;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Prevention",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Wash your hands often",
"        </p>",
"        Avoid close contact with anyone with a cold",
"       </td>",
"       <td>",
"        <p>",
"         Annual vaccination; antiviral medicine - see your doctor",
"        </p>",
"        <p>",
"         Wash your hands often",
"        </p>",
"        Avoid close contact with anyone who has the flu",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Complications",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Sinus congestion",
"        </p>",
"        <p>",
"         Middle ear infection",
"        </p>",
"        <p>",
"         Asthma",
"        </p>",
"        Bronchitis",
"       </td>",
"       <td>",
"        Bronchitis, pneumonia; can be life threatening",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Institutes of Health. (file://www.niaid.nih.gov/publications/cold/sick.pdf).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35260=[""].join("\n");
var outline_f34_27_35260=null;
var title_f34_27_35261="Mortality diabetes in HF";
var content_f34_27_35261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cumulative mortality from all causes in patients with heart failure with and without diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of diabetes on HF mortality. In the DIAMOND-CHF trial of 5491 patients with heart failure (HF), 900 (16 percent) had diabetes mellitus. Mortality for patients with diabetes was significantly higher than for those without diabetes (31 versus 23 percent at one year, adjusted risk ratio 1.5, 95% CI 1.3 to 1.6).",
"    <div class=\"footnotes\">",
"     +DM: diabetic patients; -DM: non-diabetic patients.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43:771. Copyright &copy; 2004 American College of Cardiology Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35261=[""].join("\n");
var outline_f34_27_35261=null;
var title_f34_27_35262="Placement of cryoprobe";
var content_f34_27_35262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometrial cryoablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Probe placement on the left side of uterus with ice ball formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35262=[""].join("\n");
var outline_f34_27_35262=null;
var title_f34_27_35263="Complete breech presentation";
var content_f34_27_35263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Complete breech presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 478px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHeAgcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqK5uIrWFpbiRI4l5LMcAUBuS0VxepeOoV3Jptu0p7SSfKv5dT+lcze+JtWu/vXbxg/wAMPyD9Of1rGVeKOuGDqS1eh6yzqv3mA+ppomiJ4kQ/8CFeJXM01yQ1zNLK3QF3LEfnTY4+OP0qPrHkbLL+8vwPcqK8Yt9QvrUnybu4jB9JDg/hWhb+KdZg4F15gHaRQf1qliF1RMsBNbM9XorjdI8cW8xEepwm3bp5ifMpPuOo/WuttriG6iEtvKksZ6MjZFaxmpbHJUpTpv3kS0UUVRmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUyWRYYnkkO1EBZj6AUAUta1W30m1864OWPCIOrGvL9Z1e81ictcuRDnKRL91f8frT/EOsvq1+8zBhEvESH+Ef41QjXAGetcVSpzOy2PYw2HVJcz3ECYHbOO1KsfIPpS5P8qkjHAx9fpWR1DSgC+tOCrkD/JqQqCeKTGOtMRG0Y696jKdeCKs9zn86CpGelAXKbKcetTWN9c6fMJrOZo277Tw31HenlRyMVA8fB20bDdmrM9I8M+KItUIt7kCG7xwM8P9Pf2rpa8OUtGwZSVZeQQeRXeeEvFfnMtlqkn7w8RzH+L2b3966ada+kjzcTg+X36e3Y7Wiiiug88KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuP+IGpyQwR2EJx5y75D3254H44P5V2FeS+J7l7rXrxySVD7APRV4x+dY1pWideDp89S76GYBjnAqVRgc9TSNynXinRruYjvmuM9cAoPSnonGR+FO24Q4645pyjAHOKZNxuMHjrSHqCMH69qVhkjI5p8kTZBXkdaAI85z+opwODjPSgDcfQ+lIw2kZ60ADDIPNRv0Ixkj9aex6Y6UyQ/JwKQEMo4yO1VnJU9PpVtQSx6800w5LZGR1oKTPRvAutHU9PME7ZubfAJPVl7H+ldNXjmh3cml6rDcxkhQ2HHqvcV7DG6yRq6EFWGQR3FdlGfNGzPIxdH2c7rZjqKKK2OQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAiu5RBazTEZEaFz+AzXjU0nmOzuTvY7mPrk5r1rxEduhagf+mD/yNeQrt3AMck9a5cQ9Uj0sAtGx6jjBPA7/AIVMgPP+1nmokHy4IqZWXBOeM4rnO9k64PJ4zQiMxb5ehzT40L7Txir0SBQB6VSVzNsjEKlRxTvL9KsqmafsAq7E8xntCM5xzUSw5Hzdc8GtRogahaPFKw1IzjbYbI6U2WDINX2WmFaVikygsfzcjHGKVl44qyy1GRSsUmUJVwa9I8D3pu9DRHOXgJjP06j9Dj8K89mWup+HE2J72DPVVcfhkf1FaUXaRhjI81JvsdzRRRXYeMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ/iDJ0O+AGT5L/AMq8eX73PSvbLqIXFtLC3SRCp/EYrxYDa2wj51yPxHauXELVHp4B6SRICQ3T0qXAAyOT2/Oo1AH1NTxcjkZrnO1l60AMSnHNXEFV7ddqgdquRrWiM5MlQVJ5ecUIMCn5FWjFsaVAqNwCamOCOtRHGaBpld0xULLVt8GoXqWi0yo4qFhVtsVC4FJmiZTmFbnw/ONcmHrA3/oS1izCt34fR51e5k7LDt/Nh/hTp/EicQ/3Ujv6KKK7TwwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryPxJZvY+I7uIKxEjmVABnIbn+ZI/CvXK8q8eXVyviOeCFgHcoqs3RV2A/wA8/nWFde6d2Av7RryMdmZG+dHQk4+YYrUsgPLG4fN3rCgu5orkQSyidSeeMY+tbkTBTiuVHqSjY0FHpViNsAVVjOVqVa0Rg0WGkxTGfPSq8zbQTms6W9YZCKTQ3YFC5s+ZxzTTIK543l0TxHgfWkN5cj+AfiaXMilTZvtLzUbNms6C4aRctwfrUry/u8g0XDksTSOo71CZF9ay5d91L8jPtHocCpUssDJXJ9yTSuXy2LkjArxXV/DyEC2vJ8H55An5DP8A7NXCzosaMcYP1r0vwPbmDw1alhhpcyn3yeP0xWlFXkc2MfLSt3N6iiius8gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK86+KdhIktrqcS/KBskI9s4/Qn8hXotV7+0hv7OW2uV3RSDBH9R71E480bG1Cr7KakfPlvcIt3cM56Mcfh/8AWrprGYTQI6tuBHX1qrr3hc6bqMkE0O+NsmORTtJX1HY/Tt9Kh0DTpdOhkjeVni3ZQMMbfauGzTsz33KM48yZ0ls2TirY6VmQNgitBG3CrRzyRFMN2RVZYUDHJq/szVa5tTJwsjx+64z+tDQJ9BpjjA4GapXUkaj5kIH1FEumZHzXdyf+BAfyFZ9zbW1oCwBkkPQyMXP4Z6VLNI2uTW0ga42pyDVrWAbey3A84qjpob7QrMOSa1dbjEliR7c0LYctJIxLG+MIUFZGXHVIy38q0TqeRiO1unPvGV/niue0d50XCMGZTtK/Sugt5Lhxh0IpIqcdSpeSSyxgyRmPP8JIJ/SvX/D8sc2iWDw42eSgHtgYI/MV5NqCkIc9a9I8A5/4Re1yc/M+PpuNb0H7zRw49Xpp+Z0NFFFdR5IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVl69rVvo1sJJsvI3CRg8t/gPek2krsqMXJ8sdyxqttZ3Vk8eorGbfGSXONvuD2+teN3cNrD4hvIbC+kureEgpk9MjOPfHIz7Vf1jV7zWJy9zIdgOVjXhV/CsC9heCZL2BS0kYw6j+NO4rjq1FLZHs4XDyor3nv0NyGQ961bRt4Fc7bzpPEk0LbkYZBrVsZtuKhM3nHQ3I1pZI/So4JlyDU8kgxWhyu9zMvLYsDliPpWBqKpaQvJjJHTPrXSXEgIrmtfIki8vGS3GKiR0Ur3JrK5hheAyEY6k1p6ne25tW2sGBHauah0hZFDySy5A6mUgCnNaQrmN7gMmPXr+VSm7Gjgm73KmnME1IhSMsoLAdjXXRsoXmuRNv8AZ7yN4gFQcEAVurcZjzREdRX2DUpRg88Dmt/wb4ytbXSba1vIHhjG7bMp3AgsTkjqOvbNcLrVwzBbdDmWc7R7Duf8+tbVvZKbZEA4AxVRm4u6M6tKE48sz2Cyu4L2BZrWVJYm6MhyKsV47o+o3Xh2982AloGP7yEnhh/Q+9es6dew6hZQ3Vs26KQZHqPY+9ddOop+p4+Jwzou61RZooorQ5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKup3sWn2Mt1OfkjGcDqT2AryTUr641a/e4uGyzHhR0UdgK6j4k6gS9vp8R6DzHx69AP5/nWBotkX+ZhXLVk5S5Uetg6ap0/aPdjLe1+XJFNuLfAOB+Fb0sAQYrLu2CkismrHTGfMzj52l0i5eVI2kspDmRF5KH+8Pb1FbVpcJNCs1u4eNuQRUDFNQupIlfMacEA/eP1rMufD9zpt19p0y6eKNjmSIjcuPXFQbuz0Z1MV0R1qyLwEYrBinkOMhJBjqnH6f8A16lEyk8Eg+hqrkOCNWWUt0qhPCXbftLFR0HepIp8DBFWI5FbjNG4l7pyl/f3jyeSsBhHYSNgH34zVCRdURy73VmY/wC4FbP55/pXYXlmJwQVDA9jWcmhrvyVbHualpm0ZxsUtK+2zANMIhCPcnP0rQlkSGNmZgqKCST0FWGRYVxxxxXL6q9xqd4bSyjMkEJ/ekHALf3SfajYV+Zl7RIjf3rX0uQnSJT2X/PNdfEyKoGRXGJBqVuiIhtw5+6gJJ/lW7aabL5O+9lLP9eB9BQiZpdzRvIllQ4q/wCANVex1c6fM/8Ao1x9wHs//wBfp+Vc3b3nk3EkJ3vGoB3YJ2+2addEq8dxAeVIZSOxFXGVndGc6XPFwfU9voqppV4moadb3UZG2VA30Pcfgat13p3Pn2mnZhRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPJPEM32zxJePnIEhQfReP6Vt6VGEhFcvA/m3juf42Lfma6u0+WIfSuKLu7nuVVyxUUR3r4JxXJ61c5ZYhkhjl8dl711Gog7CRXIW0iNqdyJvusdqk9wB0/X9amZdFaXLQst8aSWjBXQdOxHpWjYXAuYzDOhVxwQaoLBNYOGtyZLc9B3X/wCtW1ZIJGDlQGNJIqb0uZr6YbactHgxN1X+orE8TabLJF5lnI0VxGMxsp6/7J9q76SEMnvWNqNuNp9qcok06t3qef6f4guFgX7Zbu2OC8f9RWpb65ZOQVuVQ+kmV/nVMyfYdWnhlULHI25Mjg564rQNtaXA+aJD+FZo6XYux67aqBm4hP0cUy58TWSqQJlJ9F+b+VVF0qxU5+zp+VTfYrZMEQoMe1PUnliY99rE94ywWUUiPKdolkGMe4FdNo2mJZ2KQwDAA6nqT3J9zWVaKkusEqAFiTj6nj/Gu20+EGMHFOKuyas+VGVa2IgdpHJeRurEdvQVHfNNO4gg+XI5bHAFdLJEjJjHNZVwnlEletW42MY1OZ3M2dILCy2d8ck9T7ms22kfY8U0ZTdlkz6VoRWrTTG4vD8qnKJ2+v1qheXRk1CEquIA23f7+lQzePY9E+GV2ZNJuLRj81vJkfRuf5g12VeafDucxeIp4R92aE8e4IP+Nel12UXeJ4mMhy1X56hRRRWpyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSN900tFAHi9gP3orqrY/uwK5m3Tyr14z/A5X8jXSW5+UVwwPdrajrtd0RriJYkS6mtrgEK7F42H58e4rupeUNc3q1mlwjK4PXII6g+1E0FCVtCDT3ngzHIwkj7OO/1rbt3GARXFPdyafn7U/7oH/Wen1FbllqURgV94ZSMhlOQamMjWpBvU6TzflyTVC4YSNisttZhIIQsw/2QTSQ6hDI2N2D703K5nGk1qWL3S4ruDZNErr7iubutJu7Bs2xaaAfwH7y/412dpOrqBuyKtSW6SrlcUctxqq4uzOBtr5W4Y4I4IPUVNcXSrHktWxrGhRXJLFSkvZ14P4+tc1Po13A/7395CD8zR9cfSoaaN4yjIl8OeZLfTzbT5bKAG7ZBPFdvZTbVxWLp01q0CJblQFGAvTFXgcVUdDKp7xriVWPWqV4Rmq/mle9Qy3KDlmyapszjCzIr2J5gEL7IerkdcVkqVvb5I7cbbW39Ohb0qvqeqteSm0s5AqniSQHoPQe9aulxW9rarHEynA7Go3Oi3KtTS8IZi8X2eOjb1P8A3ya9YryXwtk+K7Ej++f/AEE161XVQ+E8nMP4i9Aooorc4AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqOragthACq75n4jT1PqfYUpSUVdjinJ2Reori5vtV02+8upOeiK21R+AqNrYfw3Ev/fZrhePjfRHUsI+rO4orhlS7j/1N7cD/ALaGrEd7qsfS6LD0dQf6ZprHQ6oTwsujOxorl01vUY/9bBBKP9nKn+tXIPEcBOLmCaE+uNw/Tn9K2jiqUupnLD1F0Nyiq1rfWt1xbzo5/ug8/l1qzW6aeqMmmtzx+8Hl65ern7s7j/x41uWrZQVh6qca9fZ/5+JP/QjWtYvlBXEtz3Jq8Uy6/Ss28Tqa0m+7WfcMNrZ7U5EQOK8UxCS2ni7upA+tM8MeH0sbRJLsu80gDeWSdq/hWikYvdVLuMxQ8/U9q1k+d81kkdjlZWHQ28knAHFOn04smJY1ce4zWtYBQBmrczIVrVR0OV1WnocebaS3ObaRkI/hY5B/wrR0vVPNJjcFJVOGU1NeRckgVh6kvkTRXS8FTtb3B6VHwmytUWp1+UmXmq09qCOKoWl3gA54rRS4DDrmrumYOLi9DEvdNjdt5Taw/jTg1U33VrwG8+P0PDD/ABrpXZWByKz7uOMKWbAA5qWjWM76M52+1tIIXkY4ZeNhHJNULO01HW18y6kMFs3RV4LCtBLQardb5FH2SNuMj7x9BXQxJ0CgADgAVCVzZyUFpuYtv4YsVQAo7H13Gny6BHEv7iSaM/72R+tdfZQoE5HNJeRoRwK05FY5/bu9jmfCMd3aeK9OFwweFpCN/THynFezV5PMgVvp0r0Dwteve6UjTMWljJjYnv6H8q1oO3unHjouVqnyNiiiori4ht03TyKg/wBo9a6G7bnm2uS0Vjz62u7baW7zf7TfIv8Aj+lVJNS1CToYYh/srk/rXPPF0o9TaOHm+h0dFcm73kn+tv5/+AEJ/LFVXtlLZe4nc+rSsf61i8fDojRYV9WdtRXEraRZyrEH1zU0YvLX5rW6kH+yx3L+RoWPjfVDeFfRnYUVk6Nq32x2guUEd0ozgdHHqP8ACtau2E1Nc0TmlFxdmFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcpdS/bNZncnKQ/ulH06/rmurrjdNB865Vvvea2fzrhx0moJLqdWFWrZRv7rMhCnocVVW5PrUuuwmGbzADsbr7GskSYNeYkegjWS6Yd6sRXeetZKPmpFbFFgsbiThhUoKP1ArFjlI71bimz3pWJsXHtY35AFSR3moWePJl81B/BL8369aiSbFTrIGHNVGcoO8WTKKlo0cLqsrS6vdSsnls8hcrnOMnNXrGfaBTfFMHlamJFHyyqD+I4/wqpbNxXdCXMuY67JwRutcDbWJrF55MD4PJq1v+TJPFYeTeaqAeYovnP8AT9apsKcEncuWVube2VG/1jfM59z2q7EMAVEh3Ek9KjF0rMQhyASPxFBTuzZt5MYGavKm4ZrFt3Jwa17eTKirizmqRsV7teDWLqEPnW8idyOPrXQXS5BNZUg+YilJF02Y1lMWgQk845q/FKR3rJmkjtb2SB227jvTPcH/AOvmrMcpFQmdDVzWS4OOayb+eTUboWcBKoOZHHYU2+vDFABEMyudqj3q1pVsLaDDHMz/ADSN6n/CjfQlLl94uQRLHGscYAVRgAVetoueajto9xrUig4Bq4ownOwRsFqC7fg1JJhSRWdeTYJGapuxEVdlC6kbNdb4LvobXTbl7qQIu8Yz1Jx2HU1xdw25hXTeHrdPshlkUFi2B9KxdX2XvIuvBSp8rN6bWLm64tI/IjP/AC0flj9B0H61VEaq5klZpJD1dzk0kkwUYGKqyTE9646ladX4mYQpxj8KLbTKOlQPc+9U3l96rvITWdjSxckuuOtVmuST1qq7moWfjrTsOxckvSg61o6PdNciQHoveuXldpJVjj5ZjgCuu0q0FpaBf4jyx9TQ1YTHRjZrFi68N5mPwPFdfXK2S+brlsnZMufwH+OK6qvUwKfs36nn4r4kFFFFdpzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXI3q/YddnB4jlPmKfr1/XNddWL4psmubAzQrmeDLADqV7j+tc2Kp+0p6bo2oT5Z69SpPCs8RV1DKeorldS0uS2YtGpeL26iuh0e8W4tlJPI4NX3hVwa8hLsehzcrszgo3wKsxuCKu69p4hVp4R0+8B3rIifoR0NG5oncvCpUbB4qsjZFSKaAL0UtWEk96zkODVhGpWEM1+D7VYb1GXiO4fTv/n2rmoWwa69Gz15Fc1qlp9kuTt/1b8r/AIVvQn9k2pS+yQ3s4itWJPaodMgMNoGcfvJjvP07Cqt5m7uYLYdzlvp3rXzuk9hwK6TV6Kw2Ubbdj0rJsP8AVZ9WY/qa170f6O1Y9g2LbB6qxB/PP9aGOGxuWrcYrVtTxWHZyZxWtbviqizGojQkGUrJuFw9aauCtVLxM8iqZlDRnJ+LrH7RbRTrwUbBI7A1nI8mnwgvIHiAyc11l1EJ7WWFujqRXBypcajqMWnYKhGw/wCHU1lLRnbS1WvQ6PS4/tji9KkRYxGD3Pc/0rZhQ7qdDGkUSRRjCIAoHtVm3TLCqSMpzuXbNMYrQJwlVoV2inSyhVrVaHHL3mVLqTGaxLyQsTg1cvZ8k81kSSFnwKzkzqpxsSwqXcd67G2XyLOKLoQvP1rn9CtTJOGYfKvzGugkbOa5K8tokVXd2IpHqu70+Q1Wc1zmYjtUZNONRt0pjI5GqtM5yFUZY8AetPlbapNaPh+x81/tEo6/dFMHoWtA0vyl86YZlb17VtXLrDGSxwBVjCRpxWRMJNU1COztzgD5pH7KKfI27LdmPNfV7Gn4WiaR7m9kXG/93H9B1/X+VdDUdtClvBHDEMIgwBUle3Sp+zgonnVJ88nIKKKK0ICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmtT0CSO4a60kqrMcvAxwGPse30qg2pS2zBLy3khYcHcMfl612lIyhlKsAVPBB71yVcHGbutGdEMQ4q0tThNQ1COeFkiw7MOgrnjE0KBW6iupudPXStVK7B9lmyY29D3WqGt24WQEDhhXmSg4ScWd8JKSTRjxNxVmNuxqpgq2KmXipLLIOKmjbNVQakjPNAF5TzWJ46uWt/DskkZxIJE2n0Of8M1sqeBXLfEUmTSrWBc7pLgfiAp/xpw+JFU1eSKXh3fLbG9nH72QbR9K24Rxk1StIBBbxQr0RQK0E4AruRvN3G3A3QsPasK1GHuY/cOPx4/pW+fmBFc/dE2uoI7cIfkb6H/IoZVPsW7R9rYNbVu3ANYW0rJWrZPkYJoRM0asTYqSQblqqjVZRgVrRHO1YoTLhjWJJClnrP2gKMXK7SfQj/GuhuF5zWXqUHn2rgffX51+o/zioaNoSLS9auWvDVnadKLi3SQHqK0YzimiJ9i7vxVG8n4PNLJOADWTeXIJIBpuRMIakFzMWJ5psCgAu3CjkmmIpkfNVNauDhbKA/vH++R2HpUHUl0R2+hPHLpEM8Q4lBYn8cVYkNY3hGTy7NrQnlPnX8ev6/zrXk61w1E1J3OSatJkLmq0hqd6rOOakQ0mmMeKDTX4FMZTvMlML1NbthqkNtbqkvyMB0IxWfaW5muU3fdU5Nb2lWC6tqB3oBaQYLf7Z7D6VUIOpJRRE5KKuyWH7dqar9ihKQv/AMtpOFx6jua6LStNh02ApFlnc5eRurGrqqFUKoAUDAA7UtetRw8aWq3PMqVpT06BRRRXQZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFTVbJb+yeFjhvvI391h0Ncw1ubmLbJxLGSpB7Guyrn9ciNvqEM8Ywk/wAj/wC8Bwfy/lXDjaV4866HVhqlnynF3URjmZWGCDTFNb2t2ZeHzkHzqM/UVz6Hd0/KvNPQTuSgVLHRGM9anSMdqAHRk1j+JoPOm00n7qSsx/AZrfihqnr8QSGFj1yQKqn8SKg/eRjwjL5q1Ve2HBNQPJPPM0dsyoE4Z2GefQCu42auy6Op96z9ZtfOhJA5xzTXup7SXFwVlhGAzhcFfqPT3rTBWSMEcqRRuPWLuYFhc+bGYpP9dHwfcetXreUo2KranYtE/n2/DCm2k4uUyBtkX7y+lTsaO0ldHQQyblBq5Ce1Y1lIQcGtOJ+lWmc84lp03LVGRcE1oIQy1XuE5JqmRFmLpp+y309q33T+8T6GtMyYrL1ZfK8u6X70Rwf90/5FTtOGjDA9RULQ2a5tR11LxistvnkxU8su44FMlkjs4Gnm7dB3J9KTKirDbu6XT7fcfmkbhF9aq6ZZyMWup+ZHOaZp0EmpXJurgfLnCr2A9K6XywsIAGABQlccpcunUr6TN9n1CInox2H8a6aUc1x8hKShh1BzXaSjcoYdxmuXELVMwqrZlJhUTirBWmMmaxMyky80hHrVxoeKi8ovKsaKWJPI9qAJrbEVu0hHGOtdpoNn9i02NGGJX/eP9T2/DgfhXOSQb57KEgBDKgZfUZGa7OvQwMFrM4sVLaIUUUV6JxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVQ1q1a7sHWP/AFyHfH7kdvxGRV+iplFSTTHFuLujlrOUXlryCDjBBrH1PThA6yRDvhhWzqQbTL5mYf6NMxZGHQE8kH9aqXl0kseFOSeleHUi4S5WepCV9VsZq25A4q1BAeM1bjgIUHGQecVYRABWVy2yKOPFZfihQbGMjqH/AKGtiZhGhNcnrmoq7iFj948VdP4kVD4kzIvLj7Pa5DBSxC59MnrUFrDvJewnkRjyS7AhjSzmVruPyIy7RqWIGOM8A8/jRbeTcPiJmiuhzluNx9xXcdmyL+nKjiW3uVImPLFud3/1qrxu2mXBglB+ysf3b/3fY1ciX7SInlQrPGcZ6f5FWprTzoWWRQysOQaqxm5JPUhO2RccEGsa+sCkvm252SDoR3qdxLp/EjF7fOA/dfr/AI1JPcARF3I2gZzSepUbrYhs7jzcqw2zJ95f61pwS1jrYSeUbvLJdN8wHoP7pq3ZzCaNZANpzhl/un0oQ5JPY2oZanYhhWarVahk4watM55R6kF3EHjZWGVIwRWBAWhd7aUnK/dJ7jsa6hxvFZGp6eZyskZCzJypPQ+xqWjWnLoysTHBG00zYQVkL5uqXfmSgrCv3V9B/jT5kuLy6KTjy1j/AIPT3rVtY0QAAYAqdzb4depo2MSxxBVAAFWGPBzUMOdvFPcMFOas5nuZl396uytXD20P+4P5Vxtz1rT0LUxLhM9OK5sQtEFVaI6Jos0LF7VYgw6g1MEArkMLmXeERJ/tHoKtaVa+TF5kv325JqO+VftUG/7mf1q7cSItscntxVITegumkXWuRqvKwqZD6eg/nXT1geEbXZbzXbdZ2wvsq5H881v17GFhyU15nnYiV5+gUUUV0mIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGJ4uVW0uMN085f61jSWkNvAjRqc8ZNa/iwg29tGSADLuP0AP+NZ8Oo2EuIRcR7x/DmvJxmtSx34e6posIQUBXpS47in+WoX5MY9qQDmuNxsbXKN+cxHFY+k+Ek11pL66uZYlSQpGsYHOOpOfeuhuYdynio9Cvk0ySW2uQRBI5dJAMhSeoP5da6MNyqdpk1HLk9zc811SGS11V4GZY5FBU7sgEgnjI/H9KmjYTSiC+iMMv8AA69voa6r4i6KZnj1axIZTjcyHIB7H6GuXs74TxiO5UF1PfqDXVKPLKx30qntaakjasEIADtuYDk+tajKPL4Hasi2lGQQa0opgQM8iriYzTvcyNRErMYoFG5uMt0ArItNO23uwys8MOCQem/rgew6/lXSXrBFZ+9UbGFkiG777Hc31NQ1qawnaJZjhDLyKx3gNrqLoP8AVzDP/Ah/9b+VdHENq81la0nmIHj4kQ7lPvTa0FCWtiG2kBkaNuoGRVsHHSslXEwE0R2SLwynqD6Gr8EpdRuADd6SZUkaFu4JANWpI1deBmqELAGtG3cY61aMZaaozb3TUmUbgQw+6w4IrHmims2/eqXi/wCeijp9R/WuxCiQc1DcQoV6ZpOI4VWtGc7bXQ2hlYMp6EHNSS3W4VLeaZE77gWjf+8hxn69j+NU59OuokLo6SKOzDB/Mf4VOpqnFlvQrEarq8Fs+fLYkvj+6OTWtrHhWPRb63urGdjbyt5bRScsDgkEH04pngjU9P0152vhJHduMJhdwK+gI7k+uOla13NPq18k8sZigiBEUZOTz1Y+9TVlTVPXc5Krm61lpFEtmMRirVJFHhQKk2151mJsp38Ing2fxZ4PpWfc6bOsZ/0klPTHNb21VGWIAHes671CwfdCbhQ54xmrURKXY6Dw/j+xrPHZAK0KzPDf/IHhXOdhZf1Nade7Sd4J+R5tTSTCiiirICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4f4jSu7QQRsV2RszY/2jj/2WvLprfyGDqSG9Qa9T8WRebqVwD2jTH05rgtYs2CZXpXj1pXqyPVoq1NHUeBtaa7ja1uWJkToT3FdhtBrx/wANzNbazBg4ydpr2GLlQfaotrYmemo1lyMVTntg/atIimlaJU7kxnYwmgniSRIXIjcEMn8JB9R0ri9X0iaGTegww6NjqPQ16gY1NVrmxjnjKuOKX7yK0ZtTrqDPMbW5eMgSqVI4Oa2IJw6gqa0tR0fy24A9jjrVFLFQD+55+uKaxDj8SOpyjNXQyYmQjcaljlRPvMAfSmPaneildoJ/vE1t2lnbrEAABVrEOTtFESaS1MmS4Xbxux67TWfdzAxk5BHtXWPbwlDgcVyepW4XUo0xlGbBHrVRqyclGXUlTSTa6GJK21jMrmMqOSOcj0x3p+n6os8oRo2ST2GQf8K6OS1hkj2LEuB3o0OxhAkJUZ3kE1rWXsldDp4nnumiCNnPWNx/wE1NHMUPOR9RitoxxxEA8r/KieKFo8rgg1zutOOugc6fQpwXS4wTiop71EbAbPsOaiisVlnYIwwpxgjNaCafF0Zxn2FH1ptaIGopmVJO0+VRSrHoTTTa3bpsml+XvsGK2vKgh+V0U+hqW1hM8mxCMdeT2rGVWctLlcySM7TtKjAEcSfMfvHH611UcIFPgiWKNUGOBjNSgCnGn3OWpV5hqrSlcU8AAU2Rgqsx6AZrTlSRjc4vx3rT2cS2lscSuOT6CvO40kkl3EszZyTW34om+2a3Ng5CYX+tNs7X7oA5NTsjpSPR/htfPPps1tMSZImDAnuCP/rV2NcH4KiNtqyAf8tImB/Q13lephZc1NHnYmNqjCiiiugwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5LxKv/E8x2a2X8wzVyN7HlmVq7fxPFjULSXs6NGfqMEf1rk9SUCTjvXjYlWqs9XDu8EcpPH9lvoZewkB/WvWrCUSW0TA5yorzPVYN0J4ro/B2uLNAtpOcTJwM96zv1KnG6Oz3UjNmot9IzVTmYco5pNo5NZ1zfzOWWyt5bhx18tSQPqar6xcvmOGL/WSsFH411thaR2VrHBEOFHJ/vHuTWlCk6zeuiFUkqSWmpxIv7x5fKu4BD/suCDT57eRV3j5l9R2rs76ygvYTHcRhh2PdT6g9q5eaOXS7tbecl4X/ANVL6+x96WIwsqautUaUcQpaW1MS4Vn77XHINR79QHAaPHriugnso5RlcKT6dKoS2U8X3RuHtzXDqjsU4szHkv0XcZgcdttVNRlE32SRfvM2D7VqXCS+UwI28elY80ZS3hx/z2rWg/3i9QnbkZtxRhYPfFUbWfyLW6YdVc1pRxyNEuEY5HpVKCxZ4LnzTgGXoOvavRxi/dr1OLDySk7mZ5t9Kw/egd+lTKl6f+W35Culs9OthGP3f6mpxYW687T+deVZnb7WJh2RMC4YHcep65NZuvawI/3UeVl6Z6HNdJMGluVs7CIee/UgfdHqT6V0miaLb6XESv7y4f78rDk+w9BXTh8LKrr0MKuJjT1tqed6V4V1vVobe5kmWCCXnLs29QDjO33xkc+ldVHod1oqNJFP9qg6uCuGUeo5ORXX0EAggjIPavR+p0+WxxSxlST8jnoJhIoI71PmshkbTtUktG/1R+eI/wCye34dK0Q2cYrzXeDcZG7Sauibfx7VzXivX4bO1aKJw0zcBQai8Y67/Z8PkW/M78fT3rgArzymSRi7tyWNO7ZcIdSeyhMjl5DuZjkn1NdBp8OWHFZ9nFtAre0xQXyegqJM22Oj8MQ7tVkbHEMOPxY/4A11dYnhOErYSXLD5riQsP8AdHA/kT+NbdevhYctJHlYiXNUYUUUV0GIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZ4htzPpjsg/eQnzk/DqPyyK4y8VZPnXoeRXoxGRzXF6lZfYrt4cYiOWj919Pw6flXn46ntNHbhJ/ZZzVzBuQntWHOj2lwk8J2uhyPf2rr5oxg4rB1aEbCa4Is7tzubC4+0WcM399QalkkCrkmsvQw0WkWivwdgpNVuSAsceS78ACo62M7ak+kRnUfECPjMVv85Pv2/X+VdpWboGnjTtPRGH75/mkPv6fhWlXt4al7OFnuedXqc8tNgqtqNnHf2jwTDg8q3dT2IqzRWzSaszJNp3RyNk0imSC4GJoW2t/jVqn6ygTWo3XgyRfN+B60yvBrQ9nNxPThLmipDJR+7asi+UC1hx183+tbL/dNY14f3H+7KP6UUnaaHL4Wa/PlKPaslP8AVTj/AKa1peZ+7HPGKykI2XGenm16eO/hr1OPC/Ga1qMRinTttjJ9BTbU5jFOuBujI9RivIO7qWvCVrts3vJBmW5YnPoo4A/rW9WZ4bdX0iBVPMeY2HoQf/1Vp179FJU1Y8yq25u4UUUVoZmH4rtDJZLdRD99bHdx3Xv/AI/hVDT7gTRq2e1dUwDAggEHgg1xBj/s3VJ7boituT/dPI/w/CvNxtKzVRHbhp3TgcD4mke48QThuikAfzqW0hAQVreKdLK3v22EZicfMR2rPhQha5G9DtiW7dMsAK3LeAhYreIZmuG2D29T+FZ+mRgZeThR3Ndp4a01kLX90uJXGIkP8Cf4mqo0nVnboZ1qipxubkESQQRxRjCRqFUewqSiivbPJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqOr2IvrUoCFlU7o29D/gavUUpRUlZjTcXdHms8dwWcRDeVJVk6MhHUGo4tHnunV7zEUCnJXqW9q1vG9g0GoQ31sWjMw2uVOPmHT8x/Ks62uZJVAlyJB1968SrD2cnE9aE+eKkjTeQEKE4UcCp/DVqt5qkt1IMpb/KgP971/Cs8vjpXReDI9uks5+9JKxP4cf0q8JBSqa9DPES5absbtFFFeyeYFFFY2sapsLWtmd054dh0j/8Ar1FSpGnHmkVCDm7Iz7qYXesTSLzHEPKU+uDyfzJqQkAc1Wi2W0IA7VUnusqXZtqDv/hXhTk5ycn1PUjGySRbuLgL8o5Y9AKzrs5hES5eZ3GFXk/Srmm6bd6gBIgFvbt0kYZZh7Cuj0/SLSxbfGheb/npIct/9b8K6KGFnJqT0RlUrRgrbs5hLhdm0q24fw4OaqhHRJEnRomkPmIHGNwzXoNV72yt76Ly7qISL2z1H0PavRxFL2seVHHRqezldnH2lyPu9COxrQDB1qDVdEuLCNp7Atcwry0D8uB6qe/0qjZ3qTRB4iSvcHqteRVpSpu0j0YyjNXiaOmXf9m6mVkP+jXJAJ/uP2P49K6yuLkCXERR+Qau6VrTWjLa6m37rpHcHt7N/jXZhMQkvZy+RzYii5e9E6eikUhgCpBB5BFLXpHEFch40Xy9Rsph/wAtEaM/gQR/M119cb8QpQJdKiU/OZHfHsAB/WufFK9Jm+Hf7xGfFeDy2jlUFMc5rPktbFY2n3PGnXGaeVDAg9+tMu7bzQgP3BzivHPTRpeEootUviBG32aABzu/iPYfTv8AhXoFcr4BjC2t7IBjMoT8h/8AXrqq9fCwUaafc8zEybm12CiiiukwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDL8S2v2rRrhQMsg8xfqvP8ALIriYQpVW716SwDKQRkHgivNLiNraeW3PWNyn5GvOx0NVI7sHLRxLqrv6Vb0XWU0mZ7a8yLeRtyuBnYe+R6VQsyeM1dKRufnQE/SuGnUdOXNE6ZwU1ys6yHULOZA8V1Ay+ocVFNq9jEDm5R2H8MZ3n9K5oadA/OxfyqxFbRQj5VFdbx8raI5fqse5Leald3xKQK1tb9zn52/w/Cq6olvHhce5qSSQKvoBWdNM07BIwcE4GOrfSuSdSdV3kzphBRVkJNMZH4yVzgAdWPoK2tH0LLLc6kgLjmOE8qnufU1Z0PR/shE9zgz4+VR0jH+PvW1XoYbCqPvT3OStiL+7ABxRRRXecgUUUUAFc7rmhF5jfaaqrcf8tIugl/+v/OuioqKlONRcsi4TcHdHnwkIYgAqQcFTwVPoauRlLiPZIAfrWzr+jfas3NoAtyB8y9pB/j71zUEmGwchhwQeDXjV6LpOz2PSp1FUV0X7ZLywz/Z85WP/nk43J+Xb8KuLr9/HxNp8ch/vRy7f0IP86q29xng1aypGaUMRUhomKVOMt0KfEd1yE0ps9szAD+VYN3Z3upX5vdSlVSBtSNOiD0rZdwOlZOr6i1vJbwpsTzd376QEomBnn3POOR0p1MRUqK0mEKUYO8UZ91eWttKsYYSMH2yBTkxjGdzD06D8asTkKpJPArJuLo3MkMkFg/nMoFwGGzhgRhs8kZGc47VoaVZy6vcwaeHZkjRTcTD0HX8TWcIubsjWTUVdnYeC4imhq5GPOkaQfTOB/Kt6mxRpFEkcahUQBVUdgO1Or3oR5YqPY8icuaTYUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcV4wsJLW6OoRKWt5MCXH8DdM/Q/zrtabIiyIySKGRhgg8gisqtJVY8rNKVR05XR5zDKrAMh4rSt2DDmnaj4RlikaTSpRtJz5Uhxj6H/ABqrBpmtxNtazLe+9f55ryZ4apF2seiqsJK6Zqq6qtV571I15IqaDRNRmA8+SGBT1xl2/wAP1rXsNDtLRxIwM8w/jk5x9B0FVTwdSW+hnKvCPmYlppt3qTByPJt/7zjk/Qf410VhptvZfNGu6THMjcn/AOt+FXaK9KlhoUttzkqVpT06BRRRW5iFFFFABRRRQAUUUUAFYeu6KLvdcWgC3XcZwH/+v71uUVE4Ka5ZFQm4O6POxcNHK0UqNHMnDIwwauRXIZeuK6vU9MtdSj2XMeWH3XXhl+hrkb/w/qlm5Noq3kPbBCuPqD1/CvLq4OUdY6o76eIjPfRkWrSSHT5zAW8wLn5PvY7498ZxWUfsyFbBS72dynnQMmW2EEE8845KsCe+farDnVYjtbS7vPtGSP0qfSvD9/fTs8lqthG335GXDn6CsI0JydkjV1IxV2ynFa3F1c/ZrMtcXcuPMlYYCgdzjgAc/n6mvQdC0mDR7IQQZZz80kh6u3r/APWqbTNOt9NtxDapgfxMfvMfUnvVuvVw+HVJXe5wVq7qaLYKKKK6TAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both hips and both knees are flexed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_27_35263=[""].join("\n");
var outline_f34_27_35263=null;
